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 Allergic contact dermatitis (ACD) is a common T-cell-mediated inflammation resulting 
from repeated contact with allergens (e.g. nickel or poison ivy).  Current treatments typically 
involve topical corticosteroids, which non-specifically and transiently suppress inflammation, 
but fail to address the underlying allergen-specific immune dysfunction.  Here, we present two 
novel approaches that teach the immune system to tolerate contact allergens by inducing 
suppressive regulatory T cells (Tregs).  Specifically, we leveraged biomimetic delivery systems 
to modulate the skin draining lymph node (DLN) microenvironment with microparticles (MPs) 
that release TReg-Inducing (TRI) factors, or the skin microenvironment with microneedle arrays 
(MNAs) that deliver vitamin D3 analog (MC903) to cultivate Treg-inducing tolerogenic 
dendritic cells (DCs).   
We previously demonstrated that TGF-β1, rapamycin, and IL-2 (TRI) promote Treg 
differentiation in vitro; however, original TGF-β1 MPs exhibited an unexpected two-week delay 
in release, inconsistent with existing models of controlled release.  Suspecting electrostatic 
interactions between cationic TGF-β1 and negatively charged PLGA MPs were responsible, we 
characterized the influence of charge on release from PLGA MPs.  Release assays revealed 
inverse correlations between positive charge on encapsulated agents and release rates, and effects 
of polymer charge density.  These results helped us to rationally reformulate TRI MPs using less 
charged PEG-PLGA to achieve faster release. 
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In acute murine models of ACD, new TRI MP formulations were injected near sites of 
allergen exposure to condition the skin DLN.  By expanding allergen-specific Tregs and 
reducing pro-inflammatory effector T cells (Teff), TRI MPs inhibited hypersensitivity responses 
to subsequent allergen exposure in an allergen-specific manner, effectively preventing or 
reversing ongoing ACD.  Much like TRI MP therapy, intradermal delivery of allergen and 
MC903 with MNAs also prevented sensitization and inhibited subsequent hypersensitivity 
responses in naïve and allergic mice by expanding Tregs and reducing Teff.  Notably, treatment 
of human skin explants with MC903 MNA promoted tolerogenic cutaneous microenvironments 
and caused preferential migration of more tolerogenic DCs, previously shown to support Treg-
induction.  Collectively, these results suggest that simultaneous introduction of antigen and 
modulation of local skin or skin DLN with MC903 MNA or TRI MP can induce antigen-specific 
tolerance, with broad therapeutic applications for other inflammatory disorders, autoimmune 
diseases, or transplant rejection. 
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COMMON ABBREVIATIONS 
ACD – allergic contact dermatitis 
APC – antigen-presenting cell 
DC – dendritic cell 
DLN – draining lymph node 
DNCB – 2,4-dinitrochlorobenzene 
DNFB – 2,4-dinitrofluorobenzene 
DTH – delayed-type hypersensitivity 
IL-2 – interleukin-2 
LC – Langerhans cell 
MHC – major histocompatibility complex 
MNA – microneedle array 
MP – microparticle  
OVA – ovalbumin  
PEG – poly(ethylene glycol) 
PLGA – poly(lactic-co-glycolic acid) 
Tc1 – type 1 cytotoxic T cell (CD8+ T-bet+) 
TCR – T-cell receptor 
Teff – effector T cell 
TGF-β1 – transforming growth factor-β1 
Th1 – type 1 helper T cell (CD4+ T-bet+) 
Th2 – type 2 helper T cell (CD4+ GATA-3+) 
Treg – regulatory T cell (CD4+ FoxP3+) 
Tr1 – type 1 regulatory T cell (CD4+ IL-10+) 
TRI MP – Treg-inducing microparticles    




1.0  INTRODUCTION 
Aberrant inflammation leading to tissue destruction is responsible for autoimmunity, transplant 
allograft rejection, and many inflammatory diseases, such as allergic contact dermatitis.  These 
conditions are all characterized by a breakdown in immunological homeostasis, or the balance 
between pro-inflammatory (effector) and anti-inflammatory (regulatory) arms of the immune 
system.  This chapter discusses allergic contact dermatitis and current treatments, key underlying 
immunological mechanisms, and some recent experimental approaches to restore homeostasis by 
enhancing naturally suppressive regulatory T cell populations.  Finally, we introduce two novel 
biomimetic delivery approaches to modify the skin microenvironment, expand allergen-specific 
Tregs, and treat allergic contact dermatitis.   
1.1 ALLERGIC CONTACT DERMATITIS 
1.1.1 Clinical Presentation, Prevalence, and Costs 
Allergic contact dermatitis (ACD) is one of the most prevalent skin diseases, affecting 
approximately 15-20 percent of the general population [1].  ACD typically presents as an 
intensely pruritic rash at the site of contact with one of more than 4,350 potential chemical 
allergens, including fragrances, metals (e.g. nickel), urushiol oil (poison ivy), topical antibiotics 
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(e.g. neomycin), and industrial chemicals [2].  Erythematous lesions and weeping blisters appear 
in acute cases of ACD, while chronic exposure to contact allergens can result in dry, scaly, 
thickened skin with painful fissures.  Chronic ACD, in particular, can have a significant 
detrimental impact on psychosocial and emotional well being of those afflicted [3, 4].  Direct 
medical costs associated with ACD have been reported in excess of $1.6 billion annually in the 
U.S., not including costs of over-the-counter remedies [5].  As one of the leading work-related 
illnesses, ACD is also responsible for an estimated $500 million in indirect costs, associated with 
lost workdays and reduced productivity due to work restrictions [5]. 
1.1.2 Current Treatments and Limitations 
Whenever possible, identifying and avoiding contact with offending allergens is the best way to 
manage ACD.  In the event of incidental contact with an allergen, topical corticosteroids and/or 
topical calcineurin inhibitors are typically used to suppress the resulting inflammatory response 
in the skin [6].  Corticosteroids exhibit broad anti-inflammatory effects on innate and adaptive 
immune cells (especially neutrophils and macrophages [7]), as well as keratinocytes; however, 
adverse effects may be associated with prolonged use of moderate to high potency 
corticosteroids, which is often required for treatment of ACD.  Application site side effects 
include skin atrophy (thinning), telangiectasia (spider veins), photosensitivity, discoloration, and 
striae [8].  When corticosteroid treatment is unsuccessful or contraindicated, as on sensitive skin 
of the face and intertriginous regions, topical calcineurin inhibitors, such as tacrolimus or 
pimecrolimus, may be prescribed.  These agents target adaptive immune responses by inhibiting 
T cell activation, and have fewer local side effects [6], but still fail to reverse the underlying 
allergen-specific T-cell-mediated immune dysfunction or prevent future allergic reactions.  
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Additionally, both topical corticosteroids and calcineurin inhibitors can further impair skin 
barrier function and suppress protective antimicrobial immunity, thereby increasing 
susceptibility to future allergen exposure, as well as viral and bacterial infections of the skin [9, 
10].  For more extensive, severe cases of ACD, systemic antihistamines, corticosteroids, and/or 
immunosuppressive agents may be required; however, long-term global suppression of the 
immune system by such agents can leave individuals susceptible to opportunistic infections and 
increase the risk of cancer [11, 12].  Even with the aforementioned treatments, persistent contact 
dermatitis occurs in 33-81 percent of individuals [13].  Thus, novel therapeutic approaches to 
modulate immune responses to contact allergens may improve the treatment of ACD. 
1.2 NATURAL REGULATORS OF INFLAMMATION: TREGS 
In contrast to current immunosuppressive therapies, our bodies use sophisticated, highly 
regulated, and highly targeted mechanisms to modulate inflammatory responses.  Indeed, the 
immune system relies on a delicate balance of pro-inflammatory effector cells to protect us from 
disease-causing pathogens, and anti-inflammatory suppressor cells to prevent excessive or 
misdirected immune responses that can cause severe tissue damage.  Regulatory T cells (Tregs) 
are subsets of lymphocytes used by the body to suppress and “regulate” immune responses 
against self and foreign antigens through various contact-dependent and contact-independent 
mechanisms [14].  CD4+ FoxP3+ Tregs, which are produced in the thymus or induced de novo 
from naïve T cells in the periphery, constitute approximately 5-15 percent of peripheral CD4+ T 
cells in naïve mice and healthy humans [15].  Tr1 cells (CD4+ FoxP3- IL-10+) are a similar yet 
distinct population of suppressive T cells that are exclusively induced in the periphery and also 
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contribute to immune tolerance [16, 17].  Notably, extensive research indicates that deficiencies 
in Treg function and quantity leads to augmented immune responses toward self and non-self 
antigens (e.g. commensal bacteria, allografts, and allergens), causing autoimmunity, chronic 
inflammatory diseases, and allograft rejection [18].  Numerous studies have also shown that 
increasing the prevalence and/or function of Tregs can ameliorate the destructive inflammation 
and re-establish immune tolerance and homeostasis [19]. 
1.2.1 Mechanisms of Treg-Mediated Suppression  
Tregs employ several contact-dependent and contact-independent mechanisms to suppress 
immune responses (reviewed extensively in [14] and [20]).  Tregs can directly suppress, or kill, 
effector T cells by secreting inhibitory cytokines (e.g. TGF-β1, IL-10, and IL-35) or cytotoxic 
proteins (e.g. granzymes and perforin), respectively.  Additionally, Tregs can make the local 
microenvironment less favorable for effector T cell survival and function by sequestering the T-
cell mitogen IL-2 via elevated surface expression of high affinity IL-2Rα (CD25) [14].  
Conversion of pro-inflammatory extracellular ATP to anti-inflammatory adenosine via two 
ectoenzymes (CD73 and CD39) expressed on the surface of Tregs is another mechanism 
specifically reported to be important for suppression of ACD [21].  Tregs can also mediate 
suppression by contact-dependent mechanisms involving APCs.  For example, high levels of 
CTLA-4 expressed on the surface of Tregs acts as a potent negative co-stimulatory signal for 
APCs (via CD80 and CD86) [14].  Finally, in addition to suppressing effector T cells and APCs, 
Tregs have been shown to directly inhibit other pro-inflammatory innate immune cells, such as 
natural killer (NK) cells [22] and neutrophils [23], either directly or indirectly through modifying 
tissue microenvironments.  
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1.2.2 T-cell Differentiation Requires Integration of Signals from Antigen-Presenting Cells 
Antigen-presenting cells (APCs), such as dendritic cells (DCs), can activate naïve T cells and 
induce differentiation of either effector or regulatory T cells, depending on integration of three 
types of signals, summarized in Figure 1-1.  Differentiation of naïve CD4+ T cells into one of 
several different types of helper T cells or regulatory T cells depends on a combination of the 
strength of antigen recognition (signal 1), the presence and nature of co-stimulation (signal 2), 
and the specific cytokines secreted (signal 3).  In particular, T-cell responses are influenced by 
the avidity of the TCR / peptide-MHC interaction, which depends on both the density of peptide-
MHC molecules on the surface of the APC and the affinity of the TCR for a specific peptide-
MHC complex [24, 25].  Additionally, the presence or absence of positive and negative co-
stimulatory ligands on the APC (summarized in Figure 1-1) can also influence T-cell responses, 
leading to differentiation and development of memory T cells, or alternative outcomes such as T-
cell deletion or anergy [26-28].  Finally, specific cytokines secreted by the APC, or provided in a 
paracrine fashion by nearby cells, dictate what type of pro-inflammatory helper T cell (e.g. Th1, 
Th2, etc.) or anti-inflammatory suppressor T cell (e.g. Treg or Tr1) a naïve CD4+ T cell will 
become [17, 29-31].  Different types of CD4+ T cells and the cytokines responsible for their 
differentiation are summarized in Figure 1-2.  Finally, differentiation of CD8+ T cells into 
various effector phenotypes, such as IFN-γ-producing Tc1 cells, involves similar mechanisms 




Figure 1-1. T-cell activation and differentiation involves integration of three types of signals from an APC. 
Antigen recognition (signal 1) occurs when a peptide antigen is presented to the T-cell receptor (TCR) by the major 
histocompatibility complex (MHC) on the surface of the APC.  Co-stimulation (signal 2) is provided by interactions 
between surface-bound receptor/ligand pairs on the T cell and APC.  The table lists several receptor/ligand pairs that 
provide positive co-stimulatory or negative co-stimulatory (co-inhibitory) signals to the T cell [33, 34].  Finally, 




Figure 1-2. T-cell differentiation is influenced by cytokines secreted by APCs or local cells.  T-cell development 
in the thymus leads to mature populations of single positive CD4+ or CD8+ (not shown) T cells.  Following 
selection, two distinct populations of CD4+ T cells emerge: FoxP3+ thymic tTreg and FoxP3- conventional naïve T 
cells.  In the periphery, naïve T cells can differentiate into various types of regulatory or effector T cells in response 
to the indicated cytokines.  These T-cell subsets often express distinct master transcription factors (e.g. FoxP3, T-
bet, etc.) and have different functions in immunity and tolerance, many of which are mediated by secreted cytokines 
[17, 29-31].     
1.2.3 Tolerogenic Dendritic Cells (DCs) Promote Treg Differentiation 
Tolerogenic DCs are a heterogeneous population of DCs with generally anti-inflammatory or 
suppressive functions that promote immune tolerance.  Tolerogenic DCs may occur naturally in 
response to cues from various tissue microenvironments [35], or may be generated ex vivo by 
various pharmacological treatments (e.g. IL-10, vitamin D3, or rapamycin) [36-38].  While pro-
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inflammatory or immunogenic DCs tend to express high levels of MHC (signal 1) and positive 
co-stimulatory proteins (signal 2), tolerogenic DCs typically express lower levels of MHC and 
positive co-stimulatory molecules, but higher levels of negative co-stimulatory receptors (see 
Figure 1-1) [39].  Furthermore, whereas immunogenic DCs secrete various cytokines to induce 
differentiation of pro-inflammatory effector T cells (see Figure 1-2), tolerogenic DCs secrete 
anti-inflammatory cytokines and other soluble mediators (e.g. IL-10, IL-10, TGF-β1, IDO, and 
retinoic acid), which promote differentiation of suppressive Tregs or Tr1 cells [40-43].  
1.2.4 Role of Tregs in ACD 
Unlike immediate, anaphylactic (type I) allergic reactions to foods and bee venom, ACD 
represents a classic type IV cell-mediated delayed-type hypersensitivity (DTH) response.  In 
ACD, T-cell responses are primed upon first exposure to a contact allergen (sensitization phase), 
and primed effector T cells are responsible for destructive skin inflammation upon subsequent 
exposure to the allergen (elicitation phase).  These specific mechanisms are reviewed extensively 
in [44] and [45].  While IFN-γ producing cytotoxic CD8+ T cells (Tc1) and helper CD4+ T cells 
(Th1) are predominant effectors of inflammation in DTH responses [45], prior studies have 
identified pivotal roles of Tregs in the resolution of ACD [45-47].  In the context of ACD, 
endogenous Tregs have been shown to both control sensitization and resolve inflammation in 
later stages of the elicitation phase [45, 48, 49].  Notably, depletion of Tregs has been shown to 
exacerbate and prolong ACD-associated inflammation [48, 50, 51], while systemic infusion of 
Tregs expanded ex vivo significantly reduces skin inflammation [52].  Accordingly, it has been 
proposed that enriching Treg populations in the body could lead to improvements in treatment 
strategies for ACD. 
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1.3 EXISTING STRATEGIES TO EXPAND TREGS 
To date, the primary method for expanding Treg populations involves isolation from peripheral 
blood and ex vivo expansion.  Drawbacks with such an approach include difficulty isolating pure 
populations of Tregs, as well as the requirements for GMP facilities and multiple clinic visits for 
isolation and reinfusion [53-55].  Furthermore, ex vivo Treg activation and expansion using 
microspheres coated with T cell-activating ligands yields less efficient Treg expansion than co-
culture with genetically modified APCs, which is considerably more complex, expensive, and 
time-consuming [53-55].  In addition to infusion of ex vivo expanded Tregs, which faces a 
number of barriers to clinical translation [53-55], several novel strategies have been investigated 
recently (reviewed in [56] and [57]).   
 Approaches to selectively expand endogenous Tregs in vivo include systemic 
administration of cytokines (e.g. IL-2 [58]), monoclonal antibodies targeting T-cell surface 
proteins (e.g. anti-CD4 [59, 60], anti-CD28 [61, 62], anti-TNFR25 [63]), or combinations of 
factors (e.g. IL-2 plus rapamycin [64] or IL-2/anti-IL-2 complexes [65-68]).  Despite promising 
therapeutic results in various animal models of inflammatory diseases, clinical translation has 
proven to be difficult.  Systemically administered, soluble IL-2 expanded Tregs in some patients 
with graft-versus-host disease (GVHD) [58]; however, Treg specificity is a concern since 
activated effector T cells also express IL-2 receptors.  In fact, systemic IL-2 is also used 
clinically to enhance pro-inflammatory anti-tumor immune responses, and vascular leakage 
syndrome is a potentially life-threatening side effect of systemic IL-2 [69].  In a phase 1 clinical 
trial, agonistic anti-CD28 caused cytokine storm and catastrophic systemic organ failure in six 
healthy volunteers [62].  Finally, by expanding existing polyclonal Tregs, these methods are 
unable to induce Tregs with novel antigen-specificity from the larger pool of naïve T cells.  In 
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other words, if allergen-specific Tregs did not already exist, these methods could not generate 
allergen-specific Tregs from allergen-specific naïve T cells (a broader repertoire).    
In addition to expansion of polyclonal Tregs, antigen-specific Treg populations have been 
expanded by systemic administration of nanoparticles coated with specific antigens (e.g. peptide-
MHCII [70], peptide plus ITE [71], or peptide alone [72]).  Similarly, nanoparticles containing 
peptide or protein antigens and immunomodulatory agents (e.g. antigen plus rapamycin [73]) 
have been shown to promote development of tolerogenic DCs that induce Tregs.  A recent study 
also demonstrated antigen-specific tolerance in rodent and non-human primate models, following 
co-administration of unencapsulated therapeutic proteins and rapamycin nanoparticles via 
intravenous or subcutaneous routes [74].  Most of the aforementioned nanoparticle formulations 
were injected systemically; however, microparticles containing rapamycin and peptide antigen 
have also been injected directly into lymph nodes to reprogram the microenvironment in which 
T-cell polarization occurs [75].  While none of these particle-based treatments have advanced 
beyond pre-clinical stages yet, allergen-specific immunotherapy (SIT) has been used in the clinic 
for more than a century to desensitize patients with type I hypersensitivities by generating 
allergen-specific Tregs [76].  Unfortunately, allergen-SIT requires long-term treatment over a 
period of months to years, with repeated subcutaneous or oral administration of low doses of 
protein allergens [76].  Notably, each of the aforementioned methods to generate antigen-specific 
Tregs uses known protein or peptide antigens, which may not be available in the case of hapten-
mediated ACD, since a heterogeneous repertoire of hapten-protein conjugates (neoantigens) 
forms in situ.  Thus, novel methods to enhance antigen-specific Tregs, especially for treatment of 
ACD, are warranted. 
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1.4 BIOMIMETIC DELIVERY MODIFIES THE SKIN MICROENVIRONMENT TO 
PROMOTE ALLERGEN-SPECIFIC TREGS 
Upon cutaneous antigen exposure, skin-resident dendritic cells (DCs) take up antigen, mature, 
and migrate to skin draining lymph nodes (DLN) to present antigen to T cells.  Information 
encoded in the local microenvironments, where these processes occur, ultimately dictates 
whether T cells will become destructive, pro-inflammatory effector T cells (Teff), or tissue-
protective Tregs.  Typically, innate inflammatory responses to allergens in the skin drive 
sensitization and Teff-mediated hypersensitivity by inducing maturation and migration of 
inflammatory DCs (Figure 1-3A) [44].  In contrast, allergen exposure in the absence of pro-
inflammatory “danger” signals [77-80], or in the context of tolerogenic signals [81-86], can 
induce differentiation of tolerogenic DCs and/or Tregs.  Accordingly, we hypothesized that using 
biomimetic delivery systems to engineer the microenvironments in which allergen is processed 
by DCs, or presented to T cells could lead to allergen-specific tolerance.  To test this hypothesis, 
we developed two complementary approaches to (1) engineer the skin DLN microenvironment 
with biodegradable microparticles (MPs) that locally sustain release of TReg-Inducing (“TRI”) 
factors (Figure 1-3B), and (2) engineer the skin microenvironment with microneedle arrays 
(MNAs) that deliver a vitamin D3 analog (MC903) into the skin to cultivate Treg-inducing 
tolerogenic DCs (Figure 1-3C).  These two approaches to allergen-specific Treg induction are 
examples of biomimetic delivery, as they provide natural (or mimetic) signals to cells in the body 
with appropriate temporal and spatial context to orchestrate specific cellular responses [87].  In 
particular, the first approach uses TRI MPs to mimic the secretion of Treg-inducing factors 
(TGF-β1 and IL-2) by tolerogenic DCs (or other local cells) during antigen presentation to T 
cells [40, 88, 89].  Similarly, the second approach involves flooding the skin microenvironment 
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with an analog of the natural immunosuppressive 1,25-dihydroxyvitamin D3, which is 
synthesized in the skin in response to ultraviolet light [83] and helps to maintain immunological 
homeostasis and peripheral tolerance to benign foreign and self antigens [90, 91].  
The induction and expansion of allergen-specific Treg populations in vivo represents a 
shift from the current paradigm of ACD treatment with non-specific topical immunosuppressive 
agents.  In contrast, the two strategies proposed herein harness the body’s natural regulators of 
immune responses (Tregs) for specific suppression of aberrant inflammation.  These novel 
approaches “re-educate” the immune system by conveying immunological context to direct 
tissue-protective tolerogenic responses to contact allergens, rather than destructive pro-
inflammatory ones.  Unlike typical anti-inflammatory agents used to quell allergic responses, 
local modulation of skin and skin DLN milieus during allergen exposure and processing induces 
Treg-mediated allergen-specific tolerance, which leaves the immune system otherwise intact to 
detect and neutralize pathogens and malignancies.  Efforts by other groups to promote specific 
immune tolerance—either by expanding Tregs or tolerogenic DCs—have often used infusion of 
cells manipulated ex vivo, or systemic administration of biologic agents that promote activation 
and proliferation of existing Tregs (as described in Chapter 1.3).  In contrast, our biomimetic 
approaches use “off-the-shelf” acellular delivery systems—described in more detail in the next 
sections—to directly or indirectly promote local induction of allergen-specific Tregs from larger 




Figure 1-3. Immune responses to contact allergens depend on microenvironment of the skin and/or skin DLN.  
(A) Allergens typically promote innate inflammation (red), which triggers migration of pro-inflammatory DCs to 
skin DLN and differentiation of effector T cells (Teff).  (B) TRI MPs injected subcutaneously condition the skin 
DLN microenvironment to promote Treg differentiation.  (C) MC903 MNAs condition the skin microenvironment 
to provide tolerogenic context (blue) for DCs that take up allergen, migrate to DLN, and induce Treg differentiation.  
1.4.1 Engineering the Microenvironment of Antigen Presentation (Skin DLN) 
During antigen presentation, specific cytokines secreted by DCs provide immunological context 
that influences T-cell differentiation (as summarized in Chapter 1.2.2).  For example, tolerogenic 
DCs induce Treg differentiation from naïve CD4+ T cells by secreting factors such as TGF-β1 
and IL-2 [88].  Drawing inspiration from this natural mechanism used by the immune system, 
our group previously proposed that local delivery of exogenous TGF-β1 and IL-2 to naïve T cells 
during antigen presentation by non-tolerogenic DCs would promote Treg induction.  Since TGF-
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β1 and IL-2 alone may not prevent effector T cell (Teff) differentiation in a pro-inflammatory 
milieu (e.g. in skin DLN after allergen exposure), rapamycin (a natural macrolide) was included 
because of its ability to preferentially suppress generation and proliferation of Teff, while 
enhancing Treg differentiation [92].  Notably, our group previously demonstrated that this 
combination of TReg-Inducing (“TRI”) factors efficiently generates functionally suppressive 
Tregs from naïve CD4+ T cells activated in culture with artificial APCs (anti-CD3/CD28 coated 
microbeads [87]) [93, 94].  Furthermore, these TRI factors were also previously encapsulated in 
biodegradable polymeric MPs to provide sustained release for potential in vivo applications (e.g. 
to induce allergen-specific Tregs and treat ACD) [93].   
1.4.2 Engineering the Microenvironment of Antigen Uptake (Skin) 
While the approach above attempts to mimic some of the Treg-inducing function of natural 
tolerogenic DCs, in vivo modulation of cutaneous DCs toward tolerogenic phenotypes represents 
a complementary indirect approach to expand allergen-specific Treg populations.  During 
cutaneous exposure to foreign antigen, cytokines and other factors secreted by keratinocytes and 
immune cells in the skin provide immunological context that orchestrates maturation and 
differentiation of resident DCs, which ultimately control T-cell differentiation (as described in 
Chapter 1.2.2).  Thus, introduction of allergens through a skin microenvironment modified to 
provide tolerogenic context may lead to generation of ACD-suppressing lymphocyte 
populations, including both classical FoxP3+ Tregs and FoxP3- IL-10+ Tr1 cells [95]. 
Modulation of the skin microenvironment was previously reported with ultraviolet 
(UVB) irradiation, which locally generates several immunosuppressive factors, including 1,25-
dihydroxyvitamin D3 [83, 84].  Notably, application of proteins or haptens to UVB-irradiated 
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skin, or skin pre-treated with topical 1,25-dihydroxyvitamin D3, or synthetic analogs (e.g. 
MC903), enhanced induction of antigen-specific Tregs and inhibited subsequent delayed-type 
hypersensitivity (DTH) responses [81, 82, 84-86].  Unfortunately, the complexity of these 
extensive tolerance induction protocols may limit their translational potential.  In particular, 
epicutaneous allergen application typically follows 3-4 days of treatments with 1,25-
dihydroxyvitamin D3, or MC903, and optimal introduction of protein allergens requires barrier 
layer disruption (e.g. tape-stripping) and occlusive dressings [84, 86].  Each of these components 
of the treatment regimen introduces potential sources of error, including inconsistent areas of 
application, variable per area dosing, and excessive or sub-optimal barrier disruption.  
Dissolvable MNA technology, previously developed by our lab, addresses these limitations by 
enabling convenient, efficient, and reproducible delivery of multiple proteins and/or drugs into 
the epidermal and dermal layers of the skin [96-98].  In Chapter 4, we will describe generation of 
allergen tolerance with MNAs that engineer the skin microenvironment by providing tolerogenic 
context (MC903) for allergen introduction (Figure 1-3C). 
1.5 LIMITATIONS OF PRIOR TRI MP FORMULATIONS 
Mathematical models previously developed by our group allow rational design of biodegradable 
polymer-based delivery systems to achieve desired release kinetics.  In such models, matrix 
geometry, polymer chemistry, and agent molecular weight dictate the rate of polymer matrix 
erosion and the degree of erosion needed for egress of encapsulated agents [99-102].  However, 
because these models neglect electrostatic interactions between encapsulated agents and 
negatively charged degrading polymer matrices, their utility is limited to neutral or negatively 
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charged agents.  While two of the three TRI factors (rapamycin and IL-2) fit this criterion, the 
third (TGF-β1) has considerable positive charge, making its release from PLGA MPs more 
difficult to control and predict.  In fact, the original TGF-β1 MPs exhibited an unexpected initial 
lag phase of more than two weeks [93].  In the prior in vitro study, this limitation was addressed 
by pre-incubating TGF-β1 MPs 18-22 days before adding them to T cell cultures [93]; however, 
the need to pre-incubate particles before use limits their translational potential.  Thus, to extend 
our rational design capabilities to positively charged factors and gain insight into ways to achieve 
faster release of positively charged agents, like TGF-β1, we systematically characterized the 
influence of electrostatic interactions on kinetics of release from different polymeric matrices.  
These studies are described in the next chapter. 
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2.0  AGENT-MATRIX ELECTROSTATIC INTERACTIONS: 
INFLUENCE ON RELEASE KINETICS* 
2.1 INTRODUCTION 
The global market for peptide and protein drugs is projected to reach $179 billion by 2018 [103], 
and combined sales of 25 FDA-approved peptide therapeutics (<50 amino acids) exceeded $14 
billion in 2011 [104]. Still, the overwhelming potential of therapeutic peptides and proteins has 
been limited, in part, by short half-life (minutes to hours) and insufficient bioavailability when 
administered orally. As a result, frequent injections may be needed to deliver sufficient levels of 
bioactive peptides or proteins, which could exacerbate issues with patient compliance. 
Controlled release systems, like the TRI MPs presented in this thesis, have the potential to 
dramatically prolong bioavailability of rapidly cleared drugs (e.g. peptides and proteins) and 
maintain therapeutic levels for weeks to months with less frequent dosing. In turn, improved 
patient compliance and therapeutic efficacy could save the U.S. healthcare system upwards of 
$100 billion each year [105]—more than the total annual direct costs for treating cancer [106].  
A major challenge for developing controlled release formulations is tuning release 
kinetics to achieve the desired dosing schedule for a given therapeutic agent. As one of the most 
                                                 
* This chapter is adapted from Balmert SC, Zmolek AC, Glowacki AJ, Knab TD, Rothstein SN, Wokpetah JM, 
Fedorchak MV, and Little SR. Positive charge of “sticky” peptides and proteins impedes release from 
negatively charged PLGA matrices. Journal of Materials Chemistry B (2015) 3:4723-34, with permission from 
the Royal Society of Chemistry.  
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common types of controlled release systems, biodegradable polymer matrices are often 
fabricated as microspheres or microparticles given the ease of loading and minimally invasive 
implantation through a needle and syringe. These matrices can be fabricated to be practically any 
size using many common polymers that are commercially available in a variety of molecular 
weights. In the past twenty-five years, numerous studies have identified key physical properties 
of such delivery systems that determine their release behavior (reviewed in [99] and [107]). 
Mathematical models developed by our group and others have enabled predictions of release 
kinetics based on such factors as matrix geometry, polymer chemistry, and drug/agent molecular 
weight [101, 102]. Although drug-polymer interactions have been cited as factors affecting 
release from poly(lactic-co-glycolic acid) (PLGA) microparticles [108], the effects of such 
interactions on release kinetics have not yet been extensively studied or characterized. 
For the past few decades, synthetic biodegradable polymers, such as polyesters (e.g. 
PLGA), poly(ortho esters), and polyanhydrides, have been used extensively for drug delivery. 
PLGA is an especially attractive biomaterial for controlled release systems because of its tunable 
degradation rate, proven biocompatibility, and outstanding history of FDA approval [109]. This 
includes at least nine microparticle drug delivery formulations currently on the market [110]. 
Importantly, progressive hydrolytic degradation of polyesters, poly(ortho esters), and 
polyanhydrides produces increasingly shorter polymer chains with carboxylic acid end groups. In 
aqueous solution, these carboxylic acid groups dissociate into carboxylate anions, conferring 
negative charge on the polymers. As a result of this negative charge, which increases over time 
due to polymer degradation, ionic interactions between PLGA matrices and positively charged 
(cationic) peptides have been observed [111-113]. A recent study even demonstrated that 
cationic peptides could be adsorbed to the surface of low molecular weight PLGA microparticles 
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or thin films for extended delivery via subsequent desorption [114]. Additionally, several groups 
have demonstrated that positively charged peptides can become acylated in PLGA matrices [115-
117]. Acylation reactions between nucleophilic (high pKa) primary amines in peptides (e.g. 
lysine residues and N-termini) and PLGA ester bonds form new covalent bonds between 
peptides and PLGA oligomers, resulting in peptide-PLGA adducts [115]. Peptide sorption to 
PLGA (as by electrostatic interactions) is also believed to be a precursor to peptide acylation 
[111]. Since many therapeutic proteins, peptides, and small molecule drugs contain positively 
charged functional groups, better characterization and understanding of the effects of 
electrostatic interactions and/or acylation reactions between these agents and negatively charged 
polymers on release kinetics could improve tools for predicting release and designing controlled 
release systems. 
We hypothesized that positively charged peptides (and larger biomolecules) would 
exhibit a variable degree of “stickiness” to a polymer matrix with negative charge, thereby 
reducing their diffusion through the polymer matrix and impeding release from microparticles. 
We further hypothesized that greater positive charge on a peptide would lead to slower release, 
due to electrostatic interactions and/or acylation. Herein, we demonstrate that release of peptides 
from PLGA microparticles is, in fact, inversely correlated with the peptides’ net positive charge, 
which may increase with a decrease in pH of the surrounding microenvironment. We also show 
that pH of the intraparticle microenvironment, which decreases over time, depends greatly on 
PLGA initial molecular weight and end-group chemistry. Notably, in some cases, peptide charge 
may even switch from negative to positive with the drop in pH in degrading PLGA 
microparticles. Together, these observations allow us to explain previously unintuitive trends in 
early release behavior for some peptides that release faster from slower degrading (higher initial 
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intraparticle pH) polymers. Finally, we show that trends identified for charged peptides extend to 
larger biomolecules, suggesting the results of these studies are relevant to rationale design of 
controlled release systems for delivery of a broad range of therapeutic proteins, growth factors, 
cytokines, and oligonucleotides. 
2.2 MATERIALS AND METHODS 
2.2.1 Peptide and Biomolecule Selection and Net Charge Predictions 
Seven peptides, with similar molecular weights and varying positive charge, fluorescently 
labeled with 5-carboxytetramethyl-rhodamine (5-TAMRA) or HiLyte Fluor 488 (HF488), were 
obtained from AnaSpec (Fremont, CA) (see Table 2-1). Recombinant murine CCL22 and CCL21 
were obtained from R&D Systems (Minneapolis, MN). Ovalbumin labeled with Texas Red was 
obtained from Life Technologies (Grand Island, NY). STAT3 cyclic decoy oligodeoxynucleotide 
(ODN) [118] was generously provided by Malabika Sen and Jennifer Grandis (University of 
Pittsburgh). 
Net charge (Z) of peptides and proteins, which is based on the protonation state of amino 










where Ni and pKai represent the number and pKa values of the N-terminus (9.69) and side chains 
of cationic amino acid residues: arginine (12.48), lysine (10.53), and histidine (6.00) [119]. Nj 
and pKaj represent the number and pKa values of the C-terminus (2.34) and side chains of 
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anionic residues: aspartic acid (3.86), glutamic acid (4.25), cysteine (8.33), and tyrosine (10.07) 
[119]. Charge was normalized to the total mass of the peptide or protein. To determine peptide 
charge as a function of time, we input interpolations of measured intraparticle pH (i.e. pH as a 
function of time) into the equation above, which represents charge as a function of pH.  The 
interpolations were generated using the piecewise cubic Hermite interpolating polynomial 
(PCHIP) function in MATLAB (v7.12, The MathWorks, Inc., Natick, MA). Charge predictions 
for the cyclic oligonucleotide were calculated with the Marvin v14.8 “protonation” plug-in 
(ChemAxon LLC, Cambridge, MA). 
 
Table 2-1. Peptides used for release studies 
Peptide Name Fluorescent Label & Amino Acid Sequence MW (kDa) ID*  
CDK7tide 5-TAMRA-YSPTSPSYSPTSPSYSPTSPS 2.59 +0.0 
Erktide 5-TAMRA-IPTTPITTTYFFFK 2.09 +0.5 
CHK1tide 5-TAMRA-ALKLVRYPSFVITAK 2.12 +1.4 
Neurogranin 28-43 5-TAMRA-AAKIQASFRGHMARKK 2.21 +2.7 
PCKε peptide substrate 5-TAMRA-ERMRPRKRQGSVRRRV 2.48 +3.1 
Casein kinase 1 substrate 5-TAMRA-RRKDLHDDEEDEAMSITA 2.54 CK1sub 
Beta-amyloid 1-17 HF488-DAEFRHDSGYEVHHQKL 2.42 BA17 
 
* Identifier used in figures: net charge per mass (kDa-1) at pH 4 for pH-independent peptides, 
or abbreviated name for pH-dependent peptides. 
2.2.2 Microparticle Fabrication 
Four poly(D,L-lactic-co-glycolic acid) (PLGA) polymers, with 50:50 lactide:glycolide 
composition and different molecular weights and end groups, were purchased from Sigma 
Aldrich (St. Louis, MO; supplier of Evonik RESOMER RG502H, RG504H, and RG502 
polymers) and Lakeshore Biomaterials (Birmingham, AL; supplier of Evonik 5050 DLG1A).  
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Poly(vinyl alcohol) (PVA, 98 mol% hydrolyzed, Mw = 25,000 g mol-1) was purchased from 
PolySciences (Warrington, PA). 
Microparticles containing one of the eight fluorescently labeled peptides, rmCCL22, or 
rmCCL21, were fabricated using a double emulsion-evaporation technique, as described 
previously [120, 121]. Briefly, microparticles were prepared by mixing 200 μL of an aqueous 
solution containing the respective agent (125 μg of fluorescently labeled peptide, 5 μg of 
rmCCL22 or rmCCL21, 200 μg of ovalbumin, or 1 mg of STAT3 cyclic decoy ODN) with 200 
mg of 50:50 PLGA (DLG1A, RG502H, RG502, or RG504H) dissolved in 4 mL of 
dichloromethane. This mixture was sonicated (Vibra-Cell VC750; Sonics, Newton, CT) at 25% 
amplitude for 10 sec to form the first emulsion (water-in-oil, w/o), and then poured into a 2% 
PVA solution (60 mL) being homogenized (L4RT-A; Silverson, East Longmeadow, MA) at 
3000 rpm. Following 1 min of homogenization, the resulting double emulsion (w/o/w) was 
added to a 1% PVA solution (80 mL) and stirred for 3 h to allow the dichloromethane to 
evaporate. Freshly formed microparticles were centrifuged (300 g for 5 min at 4 1C) and washed 
4 times with deionized water (DIW). The microparticles were then re-suspended in DIW (5mL), 
flash-frozen with liquid nitrogen, and lyophilized (Benchtop 2K Freeze Dryer; VirTis, Gardiner, 
NY; operating at 80 mTorr). 
2.2.3 Microparticle Characterization 
Scanning electron micrographs of microparticle surface morphology were obtained using a 
scanning electron microscope (JSM-6330F; JEOL, Peabody, MA).  Size distributions of 
microparticles were determined using volume impedance measurements on a Beckman Coulter 
Counter (Multisizer-3; Beckman Coulter, Brea, CA). 
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2.2.4 In Vitro Release Studies 
In vitro release behavior for all microparticle formulations was characterized by incubating 10 
mg of microparticles in 1 mL of phosphate buffered saline (PBS) on a roto-shaker at 37°C. At 
regular time intervals, microparticle suspensions were centrifuged, the supernatants were 
removed, and the microparticles were re-suspended in fresh PBS. Supernatant concentrations of 
released agents were quantified by fluorescence spectrophotometry (SpectraMax M5; Molecular 
Devices, Sunnyvale, CA) for fluorescently labeled peptides and ovalbumin, enzyme-linked 
immunosorbant assay (ELISA; R&D Systems) for CCL22 and CCL21, and Quant-iT dsDNA 
assay (Life Technologies) for the STAT3 cyclic decoy ODN. Release profiles generated from 
measured concentrations of peptide, protein, or ODN were normalized to total amounts 
encapsulated. All release assay experiments were performed in triplicate. 
2.2.5 Intraparticle pH Measurements 
As described previously [122, 123], hydrogen ion concentration of dissolved PLGA 
microparticles was measured and converted to average pH of the intraparticle microenvironment, 
based on the total aqueous volume of hydrated microparticles. Briefly, 10 mg of microparticles 
were incubated in 1 mL of PBS (pH 7.4) on a roto-shaker at 37°C. At predetermined time points, 
the microparticle suspensions were centrifuged, and the supernatant was removed. The 
remaining microparticles and associated aqueous microenvironment were then dissolved in 800 
μL of acetonitrile (ACN) by vigorous vortexing. Tubes were centrifuged a second time to 
remove any undissolved PLGA, and 800 μL of this ACN + PBS + PLGA solution was added to 
200 μL of deionized water (DIW) prior to pH measurements with an InLab Routine Pro pH 
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probe (Mettler Toledo, Columbus, OH). To determine the pH of the microparticles and aqueous 
microenvironment, we obtained a correlation between the pH of lactic acid monomers in PBS 
and lactic acid monomers in a mixture of PBS, ACN, and DIW (comparable to the dissolved 
PLGA microparticles). Based on the measured pH values and total aqueous volume of the 
hydrated microparticles, average intraparticle pH could be estimated. Supernatant pH was also 
measured. 
2.3 RESULTS 
2.3.1 Microparticle characteristics 
All microparticles containing peptides were prepared under similar conditions using three 
uncapped (–COOH acid-terminated) 50:50 PLGA polymers with different average initial 
molecular weights (7, 15, and 43 kDa), and a fourth ester-capped (–COOCH3 terminated) 50:50 
PLGA (15 kDa). Representative scanning electron micrographs (Figure 2-1) show spherical 
microparticles with smooth surface morphology, as observed for all formulations. Volume-
weighted size distributions of microparticles, measured with a Beckman Coulter Counter, are 
relatively consistent between batches, with mean diameters of 19.0 ± 3.4 μm (see Table 2-2 for 
size distributions for each formulation). Total peptide loading was also consistent, with an 
average encapsulation efficiency of 78 ± 14 percent across all formulations. Total peptide 




Figure 2-1. Scanning electron micrographs (SEM) of microparticles. Representative images show spherical 
particles with nonporous surface morphology, characteristic of all microparticle formulations used.  (A) 43 kDa 
PLGA containing +1.5 kDa-1 peptide at 1000x magnification.  (B) 15 kDa PLGA containing +2.7 kDa-1 peptide at 
2000x magnification. 
 
Table 2-2. Average microparticle diameter (μm) based on volume-weighted size distributions of 50,000 
particles per formulation 
PLGA 
Polymer 
Positively Charged Peptides Charge Changing Peptides 
0 +0.5 +1.4 +2.7 +3.1 CK1sub BA17 
7 kDa 20.3±9.3 21.7±12.0 19.5±12.2 21.3±11.9 20.9±9.1 23.5±9.9  
15 kDa 20.3±8.1 19.6±8.6 17.3±6.8 17.4±7.8 22.9±13.6 23.2±9.3 11.3±3.5 
43 kDa 23.2±9.3 17.4±7.9 16.8±6.5 21.7±8.9 25.8±14.2 18.9±8.9   






Table 2-3. Total peptide loading (ng/mg PLGA) based on 100% cumulative release (mean ± SD, n=3) 
PLGA 
Polymer 
Positively Charged Peptides Charge Changing Peptides 
0 +0.5 +1.4 +2.7 +3.1 CK1sub BA17 
7 kDa 602±25 535±24 575±27 430±30 562±167 417±9  
15 kDa 597±37 613±33 572±37 590±38 536±58 467±19 440±13 
43 kDa 603±13 513±22 497±25 524±11 472±32 342±5  
15 kDa-E 434±42 442±29 325±7 504±46 537±29 458±22 362±20 
 
Table 2-4. Encapsulation efficiency (%), given theoretical loading of 625 ng/mg PLGA (mean ± SD, n=3)   
PLGA 
Polymer 
Positively Charged Peptides Charge Changing Peptides 
0 +0.5 +1.4 +2.7 +3.1 CK1sub BA17 
7 kDa 96±4 86±4 92±4 69±5 90±27 67±1  
15 kDa 95±6 98±5 91±6 94±6 86±9 75±3 70±2 
43 kDa 97±2 82±4 80±4 84±2 76±10 55±1  
15 kDa-E 69±7 71±5 52±1 81±7 86±5 73±4 58±3 
 
2.3.2 Polymer chemistry dictates release kinetics of an uncharged peptide 
To establish a baseline for peptide release behavior with minimal electrostatic interactions and 
acylation reactions between the peptide and polymer matrix, a fluorescently labeled peptide with 
an amino acid sequence that yielded net neutral charge across a range of pH values was used. 
This peptide also lacked primary amine groups, which are common targets of acylation (i.e. no 
lysine residues, and N-terminus capped by 5-TAMRA fluorophore). This uncharged hydrophilic 
peptide was encapsulated in microparticles comprised of acid-terminated 50:50 PLGA with three 
different initial molecular weights (7 kDa, 15 kDa, and 43 kDa), and an ester-terminated 
(capped) 15 kDa PLGA (“15 kDa-E”). Ester-capped PLGA initially lacks carboxylic acid end 
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groups, is more hydrophobic, and thus degrades more slowly [124]. In vitro release assays for 
each formulation demonstrated a substantial effect of polymer molecular weight on release 
kinetics (Figure 2-2). For the lowest molecular weight (7 kDa) PLGA microparticles, release 
appeared to follow first-order kinetics with no initial delay in release, since the low molecular 
weight regions of the polymer matrix were already sufficiently permeable to the encapsulated 
peptide at the start of incubation. First-order release kinetics of the neutral peptide were 
progressively delayed with increasing PLGA molecular weight, resulting in initial lag phases of 
approximately 10 and 20 days for the 15 and 43 kDa PLGA, respectively. Due to less mobile 
higher molecular weight polymer chains [101], these matrices were initially less permeable to the 
encapsulated peptide. Therefore, the PLGA polymers degraded with minimal release (lag phase) 
until regions with sufficiently low molecular weight (permeable to the peptide) formed and bulk 
release could begin [101]. We also observed a substantial increase in lag phase duration and 
decrease in the rate of subsequent release for the slower degrading ester-capped 15 kDa PLGA. 
Complete release of the neutral peptide occurred within 13, 37, 46, and 58 days of incubation for 
uncapped 7, 15, and 43 kDa PLGA and ester-capped 15 kDa PLGA, respectively (Figure 2-2). 
These results indicate that with minimal electrostatic interactions and/or acylation reactions 
between a peptide and polymer matrix, polymer molecular weight and end-group chemistry 
control release kinetics, presumably by influencing the rate of matrix erosion and formation of 




Figure 2-2. Release kinetics for a neutrally charged peptide depend on PLGA initial molecular weight and 
end-group chemistry.  Comparative in vitro release profiles for a 2.6 kDa peptide with net neutral charge, 
encapsulated in microparticles with different PLGA molecular weights and end groups: 7 kDa (circles), 15 kDa 
(squares), 43 kDa (triangles), and ester-capped 15 kDa (diamonds). 
 
 
Figure 2-3. Proposed mechanism by which peptide charge influences release kinetics. Polymer degradation and 
matrix erosion over time form increasingly interconnected pores.  Unlike neutral (uncharged) peptides, cationic 
peptides may stick to the polymer matrix via electrostatic interactions and/or acylation, thereby impeding release. 
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2.3.3 Positive peptide charge hinders release from PLGA microparticles 
For positively charged peptides, we hypothesized that electrostatic interactions and/or acylation 
reactions with a negatively charged polymer matrix would essentially restrict diffusion of the 
peptides through the degrading matrix and impede release from microparticles (Figure 2-3, 
bottom). We further hypothesized that greater positive charge on a peptide would correspond to 
slower release.  In order to test the effects of peptide charge on release kinetics, we identified 
four fluorescently labeled peptides with positive net charges that were consistent across a range 
of pH values (Figure 2-4A). These hydrophilic peptides also had similar molecular weights (2.1-
2.6 kDa) to that of the neutral peptide (2.6 kDa), to eliminate any confounding effects of peptide 
size on release [101]. These peptides were encapsulated in microparticles comprised of each of 




Figure 2-4. Greater net positive charge on a peptide corresponds with slower release kinetics from negatively 
charged PLGA matrices. (A) Calculated net charge per mass, as a function of pH, for five peptides with similar 
molecular weights (2.3±0.2 kDa). (B-E) In vitro release kinetics for those five peptides, encapsulated in 
microparticles with different PLGA molecular weights and end-groups: (B) 7 kDa, (C) 15 kDa, (D) 43 kDa, (E) 
ester-capped 15 kDa-E. Release profiles are truncated at time points corresponding to complete release for the 
neutral peptide (black circles). 
 
Compared to the neutral peptide, positively charged peptides released more slowly from 
all PLGA polymers (Figure 2-4B-E).  For the peptide with the greatest net positive charge per 
mass (+3.1 kDa-1), release was most significantly impeded. In fact, less than 20 percent of the 
encapsulated cationic (+3.1 kDa-1) peptide was released by the time at which microparticles had 
degraded sufficiently to release nearly 100 percent of the neutral peptide. For each formulation, 
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nearly 100 percent of the total peptide encapsulated was eventually detected; however, for 
comparison, release profiles graphed in Figure 2-4 were cut off when the neutral peptide had 
completely released. As shown in Figure 2-2, complete release of the neutral peptide ranged 
from approximately two weeks for the 7 kDa PLGA to more than 8 weeks for the ester-capped 
15 kDa PLGA microparticles. Notably, we observed inverse correlations between peptide charge 
and release rate for each polymer formulation (summarized in Figure 2-5). These trends are 
especially consistent for each of the uncapped PLGA polymers; however, release from the ester-
capped PLGA appears to be somewhat less dependent on peptide charge. This may be due to the 
fact that with minimal electrostatic interactions or acylation, the maximum rate of release from 
the slower degrading ester-capped PLGA is less than that for the uncapped polymers (3.8% vs. 
6.6-6.9% of total peptide encapsulated per day). Counter to the trends described above, the +0.5 
kDa-1 and +1.4 kDa-1 peptides released slightly faster than the neutral peptide from 43 kDa 
and/or ester-capped 15 kDa PLGA microparticles, during days 3-9 (Figure 2-4D-E). These minor 
anomalies may be attributed to a combination of factors, including slight differences in particle 
size, peptide size, peptide loading, or peptide distribution within the microparticles. Additionally, 
since the neutral peptide is somewhat less hydrophilic than the positively charged peptides, it 
may exhibit greater hydrophobic interactions with the more hydrophobic (higher molecular 
weight or ester-capped) PLGA microparticles. Overall, the results of these release studies 
demonstrate that the amount of positive charge on peptides can influence their release kinetics 




Figure 2-5. Correlations between peptide charge and release rates from PLGA microparticles. Data represent 
maximum release rates for each microparticle formulation in Figure 2-4, grouped by polymer molecular weight. The 
maximum rate of release (i.e. the maximum d(Cumulative Fraction Released)/dt, or dCFR/dt) typically follows the 
lag phase, and any initial burst is not considered. dCFR/dt = 0.1 corresponds to a rate of 10 percent of total release 
per day. 
2.3.4 Polymer chemistry influences intraparticle pH during degradation 
Previous studies have noted that pH within degrading PLGA microparticles is acidic and 
dynamic, decreasing over time as more carboxylic acid end groups are produced by progressive 
hydrolysis of the PLGA backbone [107, 123, 125]; however, the effects of polymer initial 
molecular weight and end-group chemistry on intraparticle pH have not been examined. Changes 
in pH during particle degradation, or differences in intraparticle pH among polymer 
formulations, would have nominal effects on net charge of the aforementioned five peptides 
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(Figure 2-4A) since they are composed of uncharged and basic residues (positive at pH < 7). 
However, for peptides with a greater frequency of both acidic and basic residues, net charge 
would vary greatly depending on the pH of the surrounding microenvironment (for pH < 7), and 
could even switch from negative to positive as pH drops. More acidic intraparticle pH could also 
catalyze peptide acylation reactions [115].  
In order to determine the dynamic charge of such peptides, we first measured bulk 
intraparticle pH of four different PLGA microparticle formulations incubating in PBS for up to 
three weeks (Figure 2-6A). Comparison of intraparticle pH in the different microparticles 
illustrates the dramatic impact of PLGA initial molecular weight and end group chemistry on the 
evolution of intraparticle pH. For microparticles made of higher molecular weight or ester-
capped PLGA, intraparticle pH was higher initially and decreased more gradually. Average 
initial intraparticle pH (after 1 hour of incubation in PBS) was 6.0 and 5.9 for the 43 kDa and 
ester-capped 15 kDa PLGA microparticles, compared to 4.5 and 3.6 for the lower molecular 
weight, uncapped polymers (7 and 15 kDa). Intraparticle pH of the 7 kDa PLGA microparticles 
dropped considerably to 3.3 by day 3 and gradually decreased to a minimum of 2.2 by day 12. 
The 15 kDa PLGA microparticles exhibited a similar decrease in pH to a minimum of 2.4 by day 
18. In contrast, microparticles comprised of 43 kDa or ester-capped 15 kDa PLGA polymers had 
more moderate drops in intraparticle pH to 3.2 or 3.4 by day 21 (Figure 2-6A). Lower 
intraparticle pH for 7 and 15 kDa PLGA microparticles was accompanied by marked decreases 
in supernatant pH to 3.5 (7 kDa, day 12) and 4.1 (15 kDa, day 18) (Figure 2-6B). In contrast, 
supernatant pH for the 43 kDa and ester-capped 15 kDa PLGA microparticles never dropped 
below 5.7 or 6.4, respectively, after 21 days (Figure 2-6B). Collectively, the intraparticle pH 
measurements suggest that agents encapsulated in PLGA microparticles with different polymer 
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chemistry (molecular weight and end-groups) would experience microenvironments with 
different pH. 
 
Figure 2-6. Intraparticle pH and supernatant pH are dynamic and depend on PLGA initial molecular weight 
and degradation rate. (A) Intraparticle pH measurements for microparticles made of 7 kDa (black circles), 15 kDa 
(red squares), 43 kDa (green triangles), or ester-capped 15 kDa-E PLGA (blue diamonds). (B) Corresponding 
measured supernatant pH for the microparticle formulations. Dashed line at pH 7.4 represents the pH of PBS. Data 
represent mean ± SD for 3-6 independent samples. 
2.3.5 Release of pH-sensitive peptides depends on intraparticle pH 
To investigate the effects of pH-dependent peptide charge on release kinetics, we identified a 
fluorescently labeled peptide (“CK1sub”) with a low isoelectric point (pI 4.16) that falls within 
the range of intraparticle pH observed in degrading PLGA microparticles (Figure 2-6A). Net 
charge of this peptide—and others that contain abundant acidic (Asp, Glu) and basic (Arg, Lys, 
His) amino acid residues—depends greatly on pH, and transitions from negative to positive as 
pH drops below its isoelectric point (Figure 2-7A). Based on intraparticle pH measurements 
(Figure 2-6A) and CK1sub’s pH-dependent charge (Figure 2-7A), we were able to estimate its 
net charge over time in the various polymer formulations. Notably, the lower initial intraparticle 
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pH for uncapped 15 kDa PLGA microparticles, relative to ester-capped 15 kDa PLGA 
microparticles (Figure 2-6A), contributed to striking differences in peptide charge during the 
initial week of release (Figure 2-7B). Specifically, initial net charge of the CK1sub peptide was 
predicted to be positive in uncapped PLGA (Figure 2-7B, red), due to the lower initial 
intraparticle pH, but negative in ester-capped PLGA (Figure 2-7B, blue), due to the higher initial 
pH. Accordingly, we hypothesized that CK1sub would exhibit greater early release from ester-
capped PLGA than from uncapped PLGA, due to fewer electrostatic interactions with the 
polymer matrix. As predicted, release profiles indicated accelerated early release kinetics and 
greater initial burst from ester-capped PLGA when compared to uncapped PLGA (Figure 2-7C). 
This result was consistent with our hypothesis, but could otherwise appear to be counterintuitive 
under the expectation that the more hydrophobic, slower degrading, ester-capped polymer would 
produce slower release [126]. Similar results for another pH-dependent peptide (beta-amyloid 
“BA17”) with a low isoelectric point (pI 5.75) corroborate the trends in release we observed for 




Figure 2-7. Initial burst of pH-dependent peptides is influenced by initial charge, which depends on initial pH 
of the microenvironment in hydrated microparticles. (A) Net charge as a function of pH (normalized to peptide 
mass) for CK1sub and BA17 peptides, which have low isoelectric points (pI < 6) and pH-dependent charge. (B) 
Temporally dynamic net charge estimates for peptides encapsulated in uncapped (red) or ester-capped (blue) 15 kDa 
PLGA microparticles. Charge predictions are based on intraparticle pH measurements and pH-dependent peptide 
charge. (C) Cumulative release profiles for peptides encapsulated in uncapped (red squares) or ester-capped (blue 
diamonds) 15 kDa PLGA microparticles, showing greater early release from ester-capped PLGA microparticles. 
 
For all peptides studied (pH dependent and independent), we observed distinct inverse 
correlations between initial burst (fraction released within the first 24 hours) and initial peptide 
charge within certain PLGA matrices (Figure 2-8). When encapsulated in 7 kDa or ester-capped 
15 kDa PLGA microparticles, peptides with negative initial net charge (Figure 2-8, data points in 
grey regions) exhibited greater burst release than those with positive net charge. This suggests 
that initial burst of positively charged peptides is inhibited by electrostatic interactions with these 
polymer matrices. Since the initial intraparticle pH for uncapped 15 kDa PLGA microparticles 
(pH 3.6, Figure 2-6A) was below the isoelectric points of all peptides (see Figure 2-4A and 
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Figure 2-7A), none of these peptides were negatively charged when encapsulated in these 
microparticles. This includes the pH-dependent peptides (BA17 and CK1sub, identified by 
arrows in Figure 2-8), which though negatively charged in the ester-capped 15 kDa PLGA 
microparticles, were positively charged in uncapped 15 kDa PLGA microparticles. 
Consequently, minimal initial burst of all peptides from uncapped 15 kDa PLGA microparticles 
can be attributed to electrostatic interactions with the polymer matrix. On the other hand, 
minimal initial burst of all peptides from 43 kDa PLGA microparticles (Figure 2-8), including 
those with negative or neutral initial charge, suggests that peptides are retained in these 
microparticles by physical barriers (i.e. a less permeable matrix). This result is consistent with 
previous reports that initial burst is influenced by polymer molecular weight, with less initial 
burst from higher molecular weight polymers [126]. In fact, for negatively charged peptides, 
burst release decreased with increasing polymer molecular weight, or decreasing matrix 
permeability (Figure 2-8, left to right). Specifically, initial burst of negatively charged peptides 
was 60-80%, 20-30%, and <10% for uncapped 7 kDa, ester-capped 15 kDa, and uncapped 43 
kDa PLGA microparticles, respectively (Figure 2-8). Taken together, these results suggest that 
burst release depends on both electrostatic interactions and matrix permeability, and negatively 
charged peptides exhibit significantly greater initial burst than positively charged peptides, from 
polymer matrices with sufficient initial permeability. 
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Figure 2-8. Magnitude of initial burst is influenced by initial peptide charge. Peptide release in the first 24 hours 
(initial burst) is presented as a fraction of total peptide encapsulated for all controlled release formulations, including 
those for positively charged peptides (from Figure 2-4) and pH-dependent peptides (from Figure 2-7). Each 
peptide’s initial net charge is estimated using initial intraparticle pH measurements and the peptide’s charge vs. pH 
relationship. Arrows identify pH-dependent CK1sub (solid) and BA17 (dashed) peptides, which are positively 
charged in uncapped 15 kDa PLGA (red), but negatively charged in ester-capped 15 kDa PLGA (blue). Peptides in 
the grey regions would have minimal electrostatic interactions with the negatively charged PLGA matrix, but may 
be retained physically by less permeable matrices associated with higher molecular weight polymers [114, 126]. 
2.3.6 Influence of electrostatic interactions on release of larger biomolecules 
To determine whether the effects of electrostatic interactions and/or acylation reactions between 
positively charged agents and negatively charged PLGA microparticles extend to larger 
biomolecules, we examined release kinetics of several therapeutically relevant proteins and 
oligonucleotides (8 to 43 kDa molecular weight). Specifically, we compared release kinetics of 
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proteins with greater positive charge density (CCL21, CCL22, and TGF-β1) to release kinetics of 
two less positively charged proteins (ovalbumin and IL-2), or an oligodeoxynucleotide (ODN; 
STAT3 cyclic decoy [118]) with net negative charge. For each of the six biomolecules, net 
charge (per mass) across a range of intraparticle pH (2 to 7) is presented in Figure 2-9A. CCL21, 
CCL22, and TGF-β1, with high isoelectric points (pI 8.2-10.4), are positively charged at any 
intraparticle pH. In contrast, ovalbumin and IL-2 (pI 5.0 and 4.7) have net charge that shifts from 
negative to neutral to positive with a drop in intraparticle pH. Even at pH 2, CCL21 and CCL22 
have approximately twice the positive charge per mass as ovalbumin and IL-2 (Figure 2-9A). 
When encapsulated in 7 kDa PLGA microparticles, positively charged CCL22 released 
considerably slower than neutral/negative ovalbumin (Figure 2-9B), even though CCL22 is five 
times smaller than ovalbumin. Similarly, when encapsulated in 15 kDa PLGA microparticles, 
positively charged TGF-β1 released substantially slower than ovalbumin (Figure 2-9C), again 
despite the fact that TGF-β1 is smaller than ovalbumin. Even in the case of initially porous 
microparticles, which may have faster release kinetics due to greater accessibility of the 
encapsulated agent to the release media [127], positive charge on an encapsulated biomolecule 
seemed to considerably decrease the release rate. For example, release of IL-2 from porous 15 
kDa PLGA microparticles was substantially faster than release of CCL22 from similar 
microparticles (Figure 2-9D). For both formulations, comparable porosity was achieved by 
adjusting the osmolality between the inner and outer aqueous phases of the double emulsions 
(+30 mM ions in inner aqueous phase) [120, 121]. Notably, 73% of IL-2 released in an initial 
burst, compared to only 14% of CCL22. Finally, release of CCL21 was substantially slower than 
that of a STAT3 cyclic decoy ODN from nonporous 15 kDa PLGA microparticles (Figure 2-9E). 
Taken together, these four examples suggest that charge density on larger biomolecules can also 
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contribute to release kinetics, with slower release of more positively charged biomolecules from 
similar PLGA microparticles. 
 
Figure 2-9. PLGA microparticles release more positively charged proteins slower than biomolecules with less 
positive charge. (A) Plot of net charge density as a function of pH for each protein or oligodeoxynucleotide (ODN), 
and table showing agent molecular weight (MW) and isoelectric point (pI).  (B-E) Cumulative release profiles for 
(B) ovalbumin vs. CCL22, (C) ovalbumin [128] vs. TGF-β1 [121], (D) IL-2 [121] vs. CCL22 [120], and (E) STAT3 
ODN vs. CCL21. For each comparison, both biomolecules were encapsulated in comparable PLGA microparticle 
formulations, fabricated from the indicated PLGA. Microparticles were non-porous, unless otherwise indicated. 
2.4 DISCUSSION 
For agents encapsulated within a biodegradable polymer matrix, both physical barriers to 
diffusion (i.e. impermeable regions of surrounding polymer) and electrostatic or covalent 
interactions between the agent and matrix may contribute to sustained release kinetics.  
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Numerous previous studies have identified key properties of polymer matrices that 
influence release behavior (reviewed in [99] and [107]), and mathematical models have 
been used to predict release kinetics based on such factors, which include matrix 
geometry, polymer chemistry, and molecular weight of the encapsulated agent [101, 102].  
Such parameters dictate the timeframe of matrix erosion and the extent of erosion needed 
for an encapsulated agent to diffuse out of the matrix, based on the molecular weight of 
the agent.  For example, a matrix comprised of higher molecular weight and/or slower 
degrading PLGA generally takes longer to become sufficiently permeable for release (as 
in Figure 2-2), and larger encapsulated agents (e.g. acylated peptide-PLGA adducts or 
fluorescently labeled peptides, relative to unlabeled native peptides) generally require 
formation of larger interconnected pores.  Electrostatic interactions and acylation 
reactions between cationic therapeutic agents and negatively charged polymeric delivery 
systems have also been cited as factors affecting release kinetics [108, 115, 116].  A few 
studies have even shown that adsorption/desorption of certain cationic proteins or 
peptides to/from the surfaces of PLGA constructs depends on negative charge density of 
the polymers.  For example, the amount of BMP-2 (positively charged growth factor) 
adsorbed to the surface of porous PLGA microparticles was directly related to the 
negative charge density of the PLGA polymer [129].  Furthermore, “release” (i.e. 
desorption) of BMP-2 was most prolonged through the use of low molecular weight, acid-
terminated PLGA, which had the greatest negative charge density [129].  Another recent 
study showed that therapeutic cationic peptides could be sustainably “released” from the 
surface of low molecular weight, acid-terminated PLGA microparticles and films for 
more than two weeks [114].  In both of these studies, the PLGA constructs were soaked in 
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solutions of a particular cationic protein or peptide, so sustained “release” was entirely 
due to prolonged surface desorption resulting from agent-polymer electrostatic 
interactions.  Additionally, these studies investigated the effects of polymer matrix charge 
density on “release,” rather than the influence of the amount of positive charge on the 
peptide or protein [114, 129].   
 Accordingly, in the studies presented in this chapter, we investigated the influence 
of peptide charge on release kinetics from a given PLGA formulation.  Here, the peptides 
were encapsulated within PLGA microparticles by a common emulsion-solvent 
evaporation method, instead of being sorbed to the surface of pre-fabricated PLGA 
constructs.  Compared to surface sorption, encapsulation of peptides within PLGA 
microparticles generally enables release for longer periods of time (depending on the 
polymer), and may better protect peptides from enzymatic degradation in vivo [130, 131].  
Encapsulation, as opposed to surface sorption, also means that release kinetics would be 
influenced both by erosion of the surrounding polymer matrix and by peptide-polymer 
electrostatic interactions.  Specifically, as a polymer matrix becomes sufficiently porous 
and diffusion is no longer physically constrained, we hypothesized that release would be 
hindered by peptide-polymer interactions, in proportion to the positive charge (per mass) 
of the peptide.  Indeed, we observed striking inverse correlations between net positive 
charge on a peptide and release rates (following the lag phase) from all polymers, 
including high molecular weight and ester-capped PLGAs (Figure 2-4 and Figure 2-5).  
Notably, since peptide release was detected by fluorescence, native peptide and acylated 
peptide-PLGA adducts in release media are not differentiated (as by HPLC-MS [115]).  
Therefore, this study does not specifically distinguish between contributions of 
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electrostatic interactions and peptide acylation to slower release kinetics for more 
positively charged peptides.  
 Attention to electrostatic or covalent interactions between charged peptides and 
polymers could also give key insight into new strategies to achieve desired release 
kinetics.  For instance, whereas fast release of uncharged agents would traditionally be 
achieved with fast degrading, acid-terminated, low molecular weight polymers (as in 
Figure 2-2), such polymers substantially delay release of positively charged agents (as in 
Figure 2-4B and Figure 2-9B), due to agent-polymer interactions.  Therefore, faster 
release of cationic peptides and proteins might be accomplished instead by using very low 
molecule weight ester-capped PLGA.  Although ester-capped PLGA degrades more 
slowly than uncapped PLGA of similar molecular weight [124], it would exhibit less 
negative charge, and thus reduced interactions with cationic agents.  Furthermore, rapid 
bulk erosion of the polymer matrix, due to the low initial molecular weight, would 
translate to fewer physical barriers to egress of encapsulated agents.  Despite the fact that 
PLGA has a proven track record with the FDA, and is therefore widely used, alternate 
biodegradable polymers with neutral or positive charge (e.g. polyketals [132], 
polyphosphazenes [133], or poly(β amino esters) [122]) may actually be used to enable 
faster release of cationic agents, or more sustained release of anionic agents.  Finally, co-
encapsulation of excipients that would neutralize electrostatic interactions between PLGA 
and cationic peptides may accelerate release kinetics.  For example, inorganic divalent 
cations (e.g. Ca2+ or Mn2+) have been shown to reduce adsorption of a cationic peptide on 
the surface of acid-terminated PLGA, as well as subsequent acylation reactions [111, 
117].  Alternatively, polyanionic excipients (e.g. chondroitin sulfate [134]) that complex 
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with cationic peptides could also reduce peptide-polymer electrostatic interactions and 
permit faster release by masking the positive charge of the peptide.  
 While the aforementioned approaches to tune release kinetics involve altering 
properties of the delivery system, correlations between agent charge and release kinetics 
could also motivate novel ways to control release by modifying the encapsulated agent 
itself.  Desired release kinetics for a given agent are traditionally attained by selecting a 
polymer with a particular combination of initial molecular weight, hydrophobicity (end-
group chemistry), and lactide to glycolide ratio.  Unfortunately, polymers chosen for 
preferable release rates may not have ideal physical properties for the intended 
application.  Since the amount of positive charge on a peptide influences its rate of release 
from each polymer (Figure 2-4 and Figure 2-5), chemical modification of therapeutic 
agents to increase or reduce positive charge could prolong or accelerate release from any 
polymer chosen for its physical properties.  For peptides and proteins, various chemical 
modifications (acetylation, methylation, PEGylation, aminoalkylation, etc.) have been 
used to increase half-life, or alter bioavailability, bioactivity, and solubility.  Addition or 
deletion of charged amino acids (without altering protein function), or modification of 
charged residues can eliminate or enhance positive or negative charge (and acylation 
targets, such as primary amine groups), and the degree of modification can be controlled 
by reagent stoichiometry [135].  Just as chemical modification of proteins has been used 
to study effects of protein surface charge on self-assembly with gold nanoparticles [136], 
modification of peptides and proteins may also be used to tune release kinetics from a 
given polymer.    
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 In contrast to invariant net charge of some cationic peptides, net charge of some 
peptides with low isoelectric points is a function of the pH of the local microenvironment 
(Figure 2-7A).  Previous studies have noted inverse relationships between “acid number” 
(a measure of carboxylic acid content of a polymer) and PLGA molecular weight or end-
group chemistry [129, 137].  Here, we show that initial polymer chemistry also dictates 
evolution of bulk intraparticle pH during microparticle degradation (Figure 2-6A).  
Specifically, higher molecular weight (43 kDa) and ester-capped PLGA microparticles 
have higher initial intraparticle pH and more gradual decreases in pH than lower 
molecular weight uncapped PLGA (Figure 2-6A).  Importantly, pH within microparticles 
degrading in vivo may differ from that measured in vitro, due to differences in external 
volume, buffering capacity of interstitial fluid, and the presence of enzymes that 
contribute to PLGA degradation in vivo.  Still, understanding the dynamic intraparticle 
microclimate enables estimates of peptide charge, which in turn could explain 
unconventional release kinetics.  For example, without peptide-polymer interactions, we 
would expect faster release and greater initial burst from more hydrophilic uncapped 
PLGA, due to faster hydration and degradation [126].  Instead, some peptides have 
greater early release from ester-capped PLGA microparticles (Figure 2-7), likely due to 
higher intraparticle pH and resultant less positive peptide charge.  Since acylated peptide 
adducts form over the course of particle degradation, and not during particle fabrication 
[116], initial burst release may not be influenced by peptide acylation; however, faster 
evolution of more acidic intraparticle pH in some PLGA microparticles (Figure 2-6) may 
promote greater acylation and contribute to slower release at later time points, since 
acylation reactions are catalyzed by acidic pH [115].   
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 It is worth noting that measurements of bulk intraparticle pH may overestimate 
acidity near the particle surface, since radial pH gradients exist in microparticles [125, 
138, 139].  This could translate into slight overestimates of net charge for pH-dependent 
peptides (Figure 2-7B), especially near the surface of microparticles.  Microclimate pH 
near the particle surface is, however, likely still lower than external supernatant pH, since 
continuous ester hydrolysis generates tethered carboxylic acid groups at the matrix 
surface faster than associated protons can diffuse away with buffer salt counterions.  This 
is evidenced by the presence of radial pH gradients in well-hydrated matrices, which 
would be permeable to buffer salts from external media [125, 138, 139].  Additionally, 
since peptides are initially sorbed to dry PLGA matrix (before hydration), pre-sorbed 
peptides may compete with incoming buffer salts for the protons associated with tethered 
carboxylic acid groups on the matrix. 
 Differences in early release from uncapped and ester-capped PLGA microparticles 
(Figure 2-7C) could also be attributed in part to competing electrostatic interactions 
within a single peptide, between multiple peptides, or between a peptide and the PLGA 
matrix.  In a somewhat less acidic microclimate, the pH-dependent peptides would 
contain both unprotonated acidic residues (negatively charged) and protonated basic 
residues (positively charged).  Negative or neutral net charge (due to more acidic 
residues) could mask the fact that positively charged residues may interact 
electrostatically with negatively charged residues from the same or nearby peptides, or 
with the negatively charged PLGA matrix.  In a matrix with less negative charge density 
(e.g. ester-capped PLGA), electrostatic interactions among peptides might dominate, 
whereas in a matrix with greater negative charge density (e.g. uncapped PLGA), 
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electrostatic interactions between peptides and the matrix might be dominant.  This 
competition for electrostatic interactions could contribute to faster release of CK1sub 
peptide from ester-terminated PLGA, relative to uncapped PLGA (Figure 2-7C).  In terms 
of cationic peptides with few acidic residues (e.g. +3.1/kDa peptide), less intra- and inter-
peptide electrostatic interactions may allow peptide-PLGA interactions to dominate, 
resulting in impeded release even from ester-capped PLGA with less negative charge 
density (Figure 2-4E). 
 Admittedly, peptide-polymer electrostatic interactions are not the only factor that 
influences early release kinetics.  For example, greater initial burst for peptides with 
initial negative charge from low molecular weight 7 kDa PLGA microparticles and 
minimal burst of those peptides from 43 kDa PLGA microparticles (Figure 2-8) may be 
attributed to greater matrix permeability of microparticles made of the lower molecular 
weight 7 kDa PLGA.  This notion is consistent with a previous report indicating that 
peptides can penetrate hydrophilic (acid-terminated), low molecular weight PLGA to a 
much greater extent than higher molecular weight PLGA, which lacks sufficiently 
mobilized polymer chains [114].  It is also supported by our observation of initial higher 
intraparticle pH and lower supernatant pH for 7 kDa, relative to 15 kDa, PLGA 
microparticles (Figure 2-6), which indicates a substantial number of acidic PLGA 
polymer chains may able to diffuse out of the 7 kDa PLGA microparticles upon 
hydration.  We expect this is due to the lower initial molecular weight PLGA having more 
polymer chains below the critical molecular weight for water solubility (~1050 Da [140]).  
 In the past decade, research (by our lab and others) has focused on controlled 
delivery of chemokines, cytokines, protein antigens, and growth factors from polymeric 
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microparticles and scaffolds, with numerous therapeutic applications [120, 121, 128, 130, 
141, 142].  Notably, many of these proteins have significant positive charge at varying 
intraparticle pH (Figure 2-9A and Table 2-5), which could contribute to impeded release 
from negatively charged polymeric delivery systems.  Comparisons of release kinetics for 
several proteins and oligonucleotides with different net charge profiles (Figure 2-9) 
suggest that, as with smaller peptides, release of larger biomolecules is impacted by 
electrostatic interactions.  Specifically, a high degree of net positive charge on proteins 
(e.g. CCL21, CCL22, and TGF-β1) considerably slows their release, even from porous 
microparticles, which have pre-established pathways for release of even large 
encapsulated agents.  In contrast, proteins and oligonucleotides with less positive charge 
or negative charge tend to release faster from microparticles with similar formulation 
characteristics.  Overall, our observations of early release kinetics for peptides and release 
of larger biomolecules are consistent with anecdotal reports of greater initial burst for 
proteins with lower isoelectric points (i.e. those that could have initial net negative charge 
within some PLGA microparticles).  For example, Lee et al. noted 20-50 percent initial 
burst of insulin (pI 5.4), compared to less than 10 percent initial burst for VEGF (pI 8.5), 
both encapsulated in 10 kDa PLGA microparticles [143].  Therefore, we expect 
examination of protein charge vs. pH relationships and prediction of dynamic intraparticle 
pH will lead to better design of formulations to achieve desired release kinetics for a wide 
variety of peptide and protein therapeutics, including those in Table 2-5.  Furthermore, 
agent-polymer charge interactions may have an even greater impact on release of 
positively charged small molecule drugs, which may have greater charge density (e.g. 
gentamicin +10.5/kDa, metformin +15.5/kDa, or olanzapine +6.1/kDa at pH 3).  The 
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small size of these drugs would allow them to diffuse more freely through a given 
polymer matrix, so considerable positive charge density could have a more striking 
impact on impeding release.  Finally, drug analogs with added positive charge may enable 
more sustained release of small molecules, for which even very high molecular weight, 
slow degrading polymers may not serve to sufficiently sustain release.   
  
Table 2-5. Therapeutic peptides and proteins with positive or variable net charge. 
Protein / Peptide NCBI / Drug Bank Accession (residues) 
Mw 
(kDa) pI 
Charge per kDa 
pH 5 pH 3 
CXCL10 (IP-10) P02778 (22-98) 8.6 10.7 +1.38 +1.95 
CXCL12 (SDF1α) P48061 (22-89) 8.0 10.3 +1.42 +1.87 
bFGF P09038 (143-288) 16.4 9.9 +0.88 +1.64 
PDFG-BB (dimer) P01127 (82-190) 24.6 9.3 +0.83 +1.51 
TGF-β1 (dimer) P01137 (279-390) 25.6 8.2 +0.59 +1.13 
BMP-2 (dimer) P12643 (283-396) 25.8 7.9 +0.67 +1.41 
IL-12p40 P29460 (23-328) 34.7 5.3 +0.07 +1.13 
GM-CSF P04141 (18-144) 14.5 5.0 0.00 +0.97 
EGF P01133 (971-1023) 6.2 4.6 -0.20 +1.02 
Exenatide DB01276 4.2 4.5 -0.30 +0.91 
Enfuvirtide DB00109 4.5 4.1 -0.70 +0.62 
Thymalfasin DB04900 3.1 4.0 -1.27 +1.14 
2.5 CONCLUSIONS 
We have identified pronounced, inverse correlations between positive net charge on peptides and 
the rates of release from PLGA microparticles.  Our empirical measurements of intraparticle pH 
demonstrate considerable influence of PLGA chemistry, with less acidic microenvironments 
present in higher molecular weight or ester-capped PLGA microparticles.  Such information 
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enabled estimates of peptide charge in degrading PLGA microparticles, which suggest that initial 
net charge of certain peptides (with low isoelectric points) may be negative in ester-capped 
PLGA, but positive in uncapped PLGA.  This could explain the otherwise counterintuitive, faster 
early release from the slower degrading ester-capped PLGA microparticles, relative to faster 
degrading uncapped PLGA microparticles.  By demonstrating that our results with model 
peptides extend to larger biomolecules (proteins and oligonucleotides), we underscore the 
importance and broad relevance of agent-polymer charge interactions to the field of controlled 
release.  Finally, we expect that these trends between biomolecule charge and release kinetics 
will improve future design of controlled release formulations for a wide range of therapeutically 
relevant peptides and proteins, and may be incorporated into mathematical models of controlled 
release to improve their predictive capacity. 
2.6 IMPLICATIONS FOR DELIVERY OF TREG-INDUCING FACTORS 
As mentioned in Chapter 1.4.1, our lab previously demonstrated in vitro Treg induction using 
TRI MPs, which sustain release of TGF-β1 (a positively charged protein), rapamycin (a small 
molecule), and IL-2 (a negatively charged protein) [121].  Results of studies presented in this 
chapter suggest that the initial two-week lag in release of TGF-β1 [121], which was unexpected 
given existing predictive models of release from biodegradable PLGA MPs [99, 101, 102], may 
be attributed to protein-polymer electrostatic interactions.  Based on our previous understanding 
of factors affecting release kinetics (independent of charge), re-formulating TGF-β1 MPs to 
eliminate the lag phase would have involved using a lower molecular weight PLGA; however, 
since TGF-β1 is cationic, the lessons from this chapter indicate that a lower molecular weight 
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polymer would likely lead to more electrostatic interactions and slower release kinetics.  
Therefore, we instead used a blend of ester-terminated PLGA and PEG-PLGA di-block co-
polymer to increase the hydrophilicity and rate of hydration, while also decreasing electrostatic 
interactions between the particle matrix and encapsulated TGF-β1.  The next chapter describes 
these new PEG-PLGA TRI MP formulations and their therapeutic application in acute murine 
models of allergic contact dermatitis. 
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3.0  BIOMIMETIC DELIVERY OF TREG-INDUCING FACTORS WITH 
MICROPARTICLES PROMOTES IMMUNE TOLERANCE AND SUPPRESSES 
ALLERGIC CONTACT DERMATITIS † 
As discussed in Chapter 1.1.2, corticosteroids typically used to treat allergic contact dermatitis 
(ACD) act transiently and non-specifically, but ultimately fail to address the underlying allergen-
specific adaptive immune responses or prevent future allergic reactions [6].  In this chapter, we 
present the first of two approaches to “re-educate” the immune system by conveying 
immunological context that directs tissue-protective tolerogenic responses to contact allergens, 
rather than destructive pro-inflammatory ones.  Specifically, this therapeutic approach involves 
using TReg-Inducing “TRI” microparticles (MPs) to condition the local skin draining lymph 
node (DLN) microenvironment to promote induction of allergen-specific Tregs in murine models 
of ACD.  These TRI MPs, which partially mimic the Treg-inducing function of tolerogenic DCs 
by providing sustained release of TGF-β1 and IL-2 (and rapamycin), are similar to formulations 
previously shown by our group to induce Treg differentiation in vitro [121].  With insight from 
the studies in Chapter 2 [144], the current MP formulations were engineered to provide short-
term (~1 week) sustained release of all three factors, and eliminate the extended lag-phase of the 
original TGF-β1 MPs that required pre-incubation before use [121].  Here, we demonstrate that 
                                                 
†  This chapter is adapted from Balmert SC, Donahue C, Vu JR, Falo LD, and Little SR. In vivo induction of 
regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis. Journal of Controlled 
Release (2017) 261:223-33, with permission from Elsevier.  
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these new TRI MPs expand Treg populations and reduce effector T-cell populations in acute 
murine models of hapten- and protein-mediated ACD.  Furthermore, in vivo Treg-induction with 
TRI MPs effectively suppresses delayed-type hypersensitivity (DTH) responses and protects skin 
from subsequent allergen exposures. 
3.1 MATERIALS AND METHODS 
3.1.1 Mice 
Female C57BL/6 and congenic CD45.1 B6 (B6.SJL-Ptprca Pepcb/BoyJ) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME) and used at 8-12 weeks of age.  OVA TCR-
transgenic B6 Rag1-/- OT-I (B6.129S7-Rag1tm1Mom Tg(TcraTcrb)1100Mjb) and B6 Rag2-/- OT-II 
(B6.129S6-Rag2tm1Fwa Tg(TcraTcrb)425Cbn) mice were purchased from Taconic (Rensselaer, 
NY).  All mice were maintained under specific pathogen-free conditions at the University of 
Pittsburgh, and experiments were conducted in accordance with institutional animal care and use 
committee guidelines.    
3.1.2 Microparticle Fabrication 
Poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles (MPs) were 
fabricated using an emulsion-solvent evaporation method [93].  A 2.5% (wt/vol) polymer 
solution was prepared by dissolving 40 mg mPEG-PLGA (5 kDa PEG:20 kDa PLGA; 
PolySciTech, West Lafayette, IN) and 160 mg ester-capped PLGA (14 kDa for IL-2 MP and 
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Rapa MP or 40 kDa for TGF-β1 MP, 50:50 LA:GA; Sigma Aldrich, St. Louis, MO) in 8 mL 
dichloromethane.  For IL-2 and TGF-β1 MPs, 5 μg of recombinant protein (rmIL-2 from R&D 
Systems, Minneapolis, MN; or rhTGF-β1 from PeproTech, Rocky Hill, NJ) was dissolved in 200 
μL deionized water (diH2O), added to the organic polymer phase, and sonicated at 25% 
amplitude for 10 sec (Vibra-Cell, Newton, CT).  For Rapa MPs, 1.5 mg rapamycin (Alfa Aesar, 
Ward Hill, MA) was dissolved in 150 μL DMSO and added to the polymer phase without 
sonication.  The resulting primary emulsion (solution for rapamycin) was transferred to 60 mL of 
2% (wt/vol) poly(vinyl alcohol) (PVA, MW ~25 kDa, 98% hydrolyzed; Polysciences, 
Warrington, PA) in diH2O and homogenized (L4RT-1; Silverson, East Longmeadow, MA) on 
ice at 10,000 rpm for 1 min.  The resulting double or single emulsion was then added to 80 mL 
of 1% PVA, and stirred (600 rpm) for 3 hours on ice to allow the dichloromethane to evaporate.  
Subsequently, MPs were centrifuged (3000 g, 8 min, 4°C), washed 4 times in diH2O to remove 
residual PVA, re-suspended in 10 mL diH2O, flash frozen, and lyophilized for 72 hrs (Virtis 
Benchtop K freeze dryer, Gardiner, NY). 
3.1.3 Microparticle Characterization 
Surface characterization of MPs was conducted using a scanning electron microscope (JSM-
6330F; JEOL, Peabody, MA), and particle size distributions were determined by volume 
impedance measurements using a Multisizer-3 (Beckman Coulter, Brea, CA).  For IL-2 or TGF-
β1 release assays, 5 mg MPs were suspended in 1 mL PBS with 1% bovine serum albumin, and 
incubated at 37°C with end-over-end rotation.  Supernatant release media was sampled and 
replaced daily, and IL-2 or TGF-β1 quantified by ELISAs (R&D Systems).  For rapamycin 
release assays, 5 mg MPs were suspended in 1 mL PBS with 0.2% Tween80 (to maintain sink 
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conditions [145]), and rapamycin concentrations in supernatant were determined by 
spectrophotometry (absorbance at 278 nm).  Total loading of IL-2 and TGF-β1 was determined 
using a two-phase extraction method with surfactant [146].  Briefly, 5 mg MPs were dissolved in 
0.5 mL dichloromethane and cytokines extracted three times into 0.25 mL volumes of PBS + 
0.1% sodium dodecyl sulfate (SDS; Sigma).  Cytokine concentrations in the pooled aqueous 
phases were determined by ELISAs, and used to calculate total encapsulation.  Rapamycin 
loading was determined by dissolving 5 mg Rapa MPs in acetonitrile and measuring absorbance 
(278 nm) of the resulting solution.  Acetonitrile spiked with rapamycin was used to generate a 
standard curve.  Encapsulation efficiencies are expressed as ratios of actual to theoretical 
loading.   
Bioactivity of encapsulated IL-2 and TGF-β1 was assessed by IL-2-induced proliferation 
of HT-2 cells, or TGF-β1-mediated inhibition of IL-4-induced HT-2 proliferation [147].  HT-2 
cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS; Atlanta 
Biologicals, Atlanta, GA), 10 mM Hepes (Lonza, Walkersville, MD), 2 mM L-glutamine (Gibco 
by Life Technologies, Thermo Fisher), 1 mM sodium pyruvate (Sigma), 1X antibiotic-
antimycotic solution (Sigma), 1X non-essential amino acids (NEAA; Lonza), and 55 μM 2-
mercaptoethanol (Gibco).  For HT-2 expansion, media also contained 10 ng/mL rmIL-2.  To 
assay encapsulated IL-2 and TGF-β1, 10 mg MPs were incubated at 37°C in 1 mL supplemented 
RPMI, and release samples taken at 24 and 48 hours.  IL-2 and TGF-β1 concentrations in the 
release samples were determined by ELISAs.  Unencapsulated, stock cytokines and release 
samples were serially diluted in supplemented RPMI, and added to 96-well flat-bottom plates 
(100 μL / well).  HT-2 cells in the log-phase of growth (2 days after last sub-culture) were 
washed three times, re-suspended in supplemented media without IL-2, and added to each well 
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(100 μL, 2x104 cells / well).  For the TGF-β1 assay, all wells also contained 7.5 ng/mL rmIL-4 
(PeproTech).  HT-2 cells were cultured for 48 hours at 37°C and 5% CO2, and cell proliferation 
measured with a colorimetric MTS assay (CellTiter 96 AQueous One Solution Cell Proliferation 
Assay; Promega, Madison, WI). 
3.1.4 Identification of Microparticle in Skin Draining Lymph Nodes after Injection 
To enable detection in skin DLN, MPs were fluorescently labeled by encapsulating TRITC-
dextran (1 mg per 200 mg polymer; Sigma Aldrich), or by incorporating FITC-labeled PLGA 
(45 mg per 200 mg total polymer; Mw = 31.6 kDa; 0.78 μg FITC per mg PLGA; PolySciTech).  
Fluorescent MPs were suspended in sterile PBS and injected subcutaneously at the base of ears 
of mice.  Mice were euthanized, and DLN were excised and flash frozen in Optimal Cutting 
Temperature (OCT) compound (Fisher Scientific, Pittsburgh, PA) 90 minutes or 48 hours post-
injection.  Frozen DLN were cryosectioned and mounted in aqueous media for fluorescent 
microscopy imaging.  Some sections were stained with DAPI and Alexa Fluor 647-labeled 
antibodies specific for DCs (CD11c, N418; BioLegend, San Diego, CA).  Lymph node sections 
were imaged with an epifluorescence microscope (Olympus Provis AX-70; Center Valley, PA). 
3.1.5 Sequestration of Microparticles at Injection Sites 
To test the importance of lymphotropic microparticle trafficking for TRI MP therapeutic 
efficacy, microparticles were sequestered at sites of injection using a thermoresponsive hydrogel.  
Specifically, MPs were suspended in a 10 wt% solution of poly(N-isopropylacrylamide) 
(pNIPAM; Sigma Aldrich) in PBS for injection.  This pNIPAM solution transitions from a liquid 
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at room temperature to a solid hydrogel above 32 °C [148], thereby sequestering MPs upon 
injection in mice (37 °C).   
3.1.6 Hapten-Mediated Murine DTH Model  
Two chemical haptens, 2,4-dinitrofluorobenzene (DNFB) and 4-Ethoxymethylene-2-phenyl-2-
oxazolin-5-one (oxazolone, OXA) were purchased from Sigma Aldrich and dissolved in acetone 
and olive oil (4:1 v/v).  C57BL/6 mice were sensitized by topical application of 20 μL of 0.5% 
DNFB (or 1.0% OXA) to the dorsal size of both ears.  Alternatively, 50 μL of 0.5% DNFB was 
applied to the shaved abdomen for sensitization.  To elicit a DTH response, mice were 
challenged 10 days post-sensitization (5 days if sensitized on abdomen) with 20 μL of 0.5% 
DNFB (or 1.0% OXA) applied to both ears.  For the re-challenge experiment, mice were 
challenged with DNFB a second time 10 days after the first challenge.  Ear thickness was 
measured immediately prior to challenge (or re-challenge) and 24, 48, 72, and 96 hours post-
challenge using an engineer’s spring-loaded micrometer (Mitutoyo, Aurora, IL).  Increases in ear 
thickness (i.e. ear swelling), relative to the baseline measurements, were indicative of 
inflammation.  
3.1.7 Protein-Mediated (OVA) Antigen-Specific Murine DTH Model 
OVA-specific CD8+ and CD4+ T cells were isolated from spleens of OT-I and OT-II mice 
(CD45.2+) and adoptively transferred to congenic CD45.1 B6 mice by tail vein injection (5x106 
OT-I and 5x106 OT-II cells per mouse).  One day later, the mice were sensitized to ovalbumin 
(OVA) by transdermal application of dissolvable microneedle arrays (MNAs), each containing 
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100 μg OVA (Grade V, Sigma Aldrich), to both ears.  The carboxymethyl cellulose-based MNAs 
were fabricated according to the spin-casting method described in [98].  To elicit a DTH 
response, mice were challenged 5 days post-sensitization by applying an OVA (100 μg) MNA to 
the right ear.  A blank (empty) MNA was applied to the left ear to control for any swelling 
caused by MNA application itself.  Ear thickness was measured prior to the OVA challenge, and 
at 24, 48, 72, and 96 hours post-challenge, and data presented as differences between OVA 
MNA-treated and contralateral Blank MNA-treated ears. 
3.1.8 Suppression of Skin DTH with TRI MPs 
Mice received subcutaneous MP injections at the base of each ear two days before hapten 
sensitization, or immediately prior to OVA sensitization.  For treatment of previously sensitized 
mice, TRI MP were injected at the base of each ear immediately prior to DNFB challenge.  For 
some experiments, MPs were injected intradermally at the abdomen.  Each injection (2 per 
mouse) contained a total of 8 mg “Blank” (empty) or TRI MPs in 150 μL sterile PBS.  TRI MPs 
included a mix of 2.2 mg IL-2 MPs, 4.3 mg TGF-β1 MPs, and 1.5 mg Rapa MPs.  For the OVA-
specific DTH model, some mice were treated with TRI MPs supplemented with soluble (un-
encapsulated) Treg-inducing factors (50 ng IL-2, 75 ng TGF-β1, and 10 μg rapamycin per 
injection; 2 per mouse).  Additional controls for some experiments included soluble TRI, as well 
as individual TRI MP formulations or combinations of two TRI MPs (e.g. IL-2 MP + TGF-β1 
MP).  For these treatments, the total mass of MPs was kept constant by supplementing with 
Blank MPs. 
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3.1.9 Inhibiting Treg-Mediated Suppression with Anti-GITR or Anti-CD25 
To inhibit effects of Treg-mediated suppression on effector T cells, a monoclonal antibody 
specific for glucocorticoid-induced TNFR-related protein (GITR, clone DTA-1; BioXcell, West 
Lebanon, NH) was injected intraperitoneally (0.5 mg per mouse) 3 days prior to DNFB 
challenge.  Alternatively, anti-CD25 (clone PC-61.5.3; BioXcell) was injected intraperitoneally 
(0.5 mg per mouse) 3 days prior to DNFB challenge to deplete CD25+ Tregs.   
3.1.10 Phenotypic Analysis of T-cell Populations in Skin Draining Lymph Nodes by Flow 
Cytometry 
Four days after sensitization with DNFB or OVA, ear-draining cervical lymph nodes (or non-
draining inguinal lymph nodes) were harvested, passed through 70 μm filters to create single cell 
suspensions, stained for T-cell markers, and analyzed with a flow cytometer (LSR-II; BD 
Biosciences, San Jose, CA).  Lymphocytes were also counted with a hemocytometer to 
determine total cells per lymph node.  Cells were stained with fluorescently labeled antibodies 
purchased from BD Biosciences, eBioscience (San Diego, CA), or BioLegend (San Diego, CA).  
To identify Treg, Th1, and Tc1 populations, lymphocytes were blocked with anti-CD16/32 
(2.4G2; BD) and stained for CD4 (RM4-5; eBio), CD8b (H35-17.2; eBio), CD25 (PC61; BD), 
FoxP3 (FJK-16s; eBio), and T-bet (O4-46; BD).  Adoptively transferred OVA-specific T cells 
were identified by staining for CD45.2 (104; BD).  For further Treg phenotypic analysis, cells 
were also stained for CTLA-4 (CD152, UC10-4B9; eBio), LAP (TGF-β1, TW7-16B4; 
BioLegend), CD39 (Duha59; BioLegend), and GITR (DTA-1; eBio).  FlowJo (Tree Star, 
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Ashland, OR) software was used for analysis, and population gates were set based on isotype, 
single-stain, and fluorescence minus one controls. 
3.1.11 In Vitro Suppression Assay 
OT-II cells were adoptively transferred to CD45.1 B6 mice (5x106 cells / recipient) one day prior 
to sensitization of ears with OVA MNA and local injection of TRI MP and soluble factors.  Four 
days post-sensitization, DLN from five mice were harvested under sterile conditions, passed 
through 70 μm filters to create a single cell suspension, and stained with fixable viability dye 
(eBioscience) and antibodies for CD45.2, CD4, and CD25.  Live CD45.2+ CD4+ CD25+ cells 
(CD25+ OT-II) were isolated by FACS sorting (FACSAria; BD Biosciences).  Conventional T 
cells (Tconv; CD4+ CD25-) were isolated from the spleen of a naïve CD45.1 B6 mouse using a 
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec, San Diego, CA), and labeled with 
5 μM CFSE (Vybrant CFDA SE Cell Tracer Kit; Invitrogen, Thermo Fisher).  Suppression 
assays were performed in 96-well round-bottom plates in 200 μL supplemented RPMI per well.  
Tconv (5x104 cells / well) were cultured with anti-CD3/CD28-coated beads for stimulation 
(5x104 beads / well; Dynabeads Mouse T-Activator; Life Technologies, Thermo Fisher) and 
different quantities of CD25+ OT-II cells.  After 3 days, cells were stained with fixable viability 
dye and antibodies for CD45.2 and CD4.  Proliferation of Tconv (live CD45.2- CD4+ cells), as 
indicated by CFSE-dilution, was analyzed by flow cytometry (LSR Fortessa; BD Biosciences). 
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3.1.12 Phenotypic Analysis of DCs in Skin Draining Lymph Nodes by Flow Cytometry 
Four days after sensitization with DNFB, ear-draining cervical lymph nodes were harvested, 
passed through 70 μm filters to create single cell suspensions, stained for DC phenotypic and 
maturation markers, and analyzed with a flow cytometer (LSR-II).  Cells were also counted with 
a hemocytometer to determine total cells per lymph node.  Cells were blocked with anti-
CD16/32 (2.4G2; BD) and stained with fluorescently labeled antibodies: CD11c (HL3; BD), I-Ab 
(AF6-120.1; BD), CD80 (16-10A1; BioLegend), and CD86 (GL1; BD). FlowJo software was 
used for analysis, and population gates were set based on isotype, single-stain, and fluorescence 
minus one controls. 
3.1.13 Functional Analysis of DCs from Skin Draining Lymph Nodes After TRI MP 
Treatment 
Forty-eight hours after application of OVA (100 μg) MNAs to both ears of mice and injection of 
Blank MP or TRI MP plus soluble TRI at the base of each ear, ear-draining cervical lymph nodes 
were isolated and cultured in serum-free RPMI 1640 (HyClone, Fisher Scientific) with 
Collagenase D (1 mg/mL; Roche, Sigma Aldrich), and incubated 45 minutes at 37°C.  DLN were 
then passed through 70 μm filters and washed with sterile MACS buffer.  CD11c+ DCs were 
isolated from each DLN by positive-selection, using CD11c MicroBeads UltraPure with MS 
Columns and an OctoMACS Separator (Miltenyi Biotec, San Diego, CA).  The purity of some 
sorted cells from each DLN was assessed by flow cytometry, with staining for CD11c (HL3; 
BD) and I-Ab (AF6-120.1; BD).  After selection, 2x104 CD11c+ DCs were plated with 2x105 OT-
I or OT-II T cells in a 96-well round-bottom plate.  Prior to culture, T cells were stained with 
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5(6)-carboxyfluorescein diacetate succinimidyl ester (5 nM CFSE, CellTrace Cell Proliferation 
Kit; Thermo Fisher Scientific, Pittsburgh, PA).  T cells cultured without DCs were used as un-
stimulated controls.  After 3 days, flow cytometry analysis of CFSE-dilution was used to 
quantify T-cell proliferation.  Cells were also stained for CD3 (17A2; eBio) and CD4 (RM4-5; 
eBio) or CD8a (53-6.7; BD).   
3.1.14 Cutaneous Histology and Immunohistochemistry 
Ears from mice sacrificed 4 days after DNFB (or OVA) challenge or re-challenge were excised 
and flash frozen in OCT compound.  Skin cross-sections (7 μm thick) were stained with 
hematoxylin and eosin and imaged with a Nikon Eclipse E400 microscope.  For fluorescent 
immunohistochemistry (IHC), 10 μm thick sections were fixed with 96% ethanol, blocked with 
PBS containing 5% donkey serum and 1% Tween20, and treated with a streptavidin/biotin 
blocking kit (Vector Labs, Burlingame, CA).  Blocked sections were incubated overnight at 4°C 
with primary antibodies: biotin-FoxP3 (FJK-16s; eBio), biotin-CD8a (53-6.7, eBio), or CD3 
(SP7, monoclonal rabbit IgG; Thermo Scientific, Waltham, MA).  Sections were then incubated 
with Cy3-streptavidin (Jackson ImmunoResearch Laboratories, West Grove, PA) or Alexa Fluor 
555 donkey anti-rabbit IgG (Thermo Scientific) for 1 hour at room temperature, counterstained 
with DAPI, and fixed with 2% paraformaldehyde.  Slides were imaged with an epifluorescence 
microscope (Olympus Provis AX-70; Center Valley, PA).  For histology and IHC, ears from 
naïve mice were used as controls.   
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3.1.15 Cutaneous Cytokine Expression by qRT-PCR 
Two days after DNFB challenge, total RNA was extracted from excised ear tissue using TRI-
reagent (Molecular Research Center, Cincinnati, OH), according to the manufacturer’s 
instructions, and quantified using a NanoDrop 2000 (Thermo Scientific).  For each reverse 
transcriptase assay, 2 μg RNA was converted to cDNA using a QuantiTect Reverse Transcription 
Kit (Qiagen, Valencia, CA).  Quantitative real-time PCR was then performed using VeriQuest 
Probe qPCR Mastermix (Affymetrix, Santa Clara, CA), according to the manufacturer’s 
instructions, with 5’ nuclease PrimeTime qPCR assays (Integrated DNA Technologies, 
Coralville, IA) specific for IFNγ, IL-1β, TNF, and β-glucuronidase (GUSB, endogenous control).  
Duplex reactions (target gene + GUSB) were run and analyzed on a StepOnePlus Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA).  Relative fold changes of IFNγ, IL-1β, and 
TNF expression were calculated and normalized based on the 2-ΔΔCt method, with naïve ear skin 
as the untreated control. 
3.1.16 Statistical Analyses 
Statistical analyses were performed with GraphPad Prism v6 (San Diego, CA).  For cytokine 
bioactivity assays, ED50 values were determined by nonlinear 4- or 5-parameter logistic 
regression.  Data from experiments with multiple treatment groups were analyzed by one-way 
ANOVA, followed by Tukey’s post-hoc testing.  For experiments with only two groups, two-
tailed independent t-tests were used.  Ear thickness measurements from multiple time points 
were analyzed by two-way mixed ANOVA, followed by post-hoc testing of treatment effect with 
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a Sidak correction.  Differences were considered significant if p < 0.05.  Data represent mean ± 
SD, except for ear thickness measurements, which are mean ± SEM. 
3.2 RESULTS 
3.2.1 TRI MPs release TGF-β1, Rapamycin, and IL-2 for about 1 week. 
We previously reported encapsulation and sustained release of Treg-inducing factors from 
biodegradable PLGA MPs [93].  For the current study, particle formulations were re-engineered 
to achieve faster release kinetics (i.e. greater release within the first week), which is more 
suitable for short-term immunomodulation during acute immune responses, such as allergen 
sensitization.  Accordingly, we encapsulated the Treg-inducing factors in MPs composed of a 
blend of ester-terminated poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG)-
PLGA diblock copolymer.  New formulations contained PEG (4 wt%, MW ~5 kDa), which 
helped to augment early release by enhancing the hydration rate and matrix swelling [149], and 
ester-terminated PLGA, which served to reduce electrostatic interactions with positively charged 
amino acid residues [144].   
Surface morphology and particle size distributions were consistent for all formulations, 
regardless of whether they were fabricated using a single emulsion (Rapa MP) or double 
emulsion protocol (IL-2 MP and TGF-β1 MP). A representative scanning electron micrograph 
(Figure 3-1A) shows spherical particles with somewhat irregular surface morphology, consistent 
with that reported for other PEG-coated MPs [150]. Particle size distributions (Figure 3-1B) are 
also consistent across all formulations, with volume-average diameters of 1.78±0.92 μm (TGF-
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β1 MP), 1.77±0.89 μm (Rapa MP), and 1.73±0.90 μm (IL-2 MP).  Total loading of TGF-β1, 
rapamycin, and IL-2 were 12.64 ± 0.97 ng, 5.53 ± 0.04 μg, and 16.92 ± 1.11 ng per mg MP, 
respectively.  Given theoretical loading of 25 ng TGF-β1, 7.5 μg rapamycin, or 25 ng IL-2 per 
mg MP, encapsulation efficiencies for TGF-β1, rapamycin, and IL-2 were 50.6 ± 3.9 %, 73.8 ± 
0.5 %, and 67.7 ± 4.4 %, respectively.  PEG-PLGA MPs provide sustained release of each factor 
over a period of approximately one week (Figure 3-1C).  For Rapa MP, 95.7 ± 3.8 % of total 
encapsulated drug was released within 7 days; however, for TGF-β1 and IL-2 MPs, only 23.5 ± 
3.6 % and 30.2 ± 3.7 % of total encapsulated cytokines were released in the first week.  Release 
assays for IL-2 and TGF-β1 MPs were carried out to 22 days, and no cytokine release was 
detected between days 8 and 22 (not shown), consistent with a lag phase.  Finally, bioactivity of 
IL-2 and TGF-β1 released from MPs and detected by ELISAs was comparable to that of 
unencapsulated cytokines, as determined by HT-2 cell-based bioassays (Figure 3-2).  
 
 
Figure 3-1. Microparticle characterization. (A) Representative scanning electron micrograph showing surface 
morphology of PEG-PLGA MPs (5000x magnification).  (B) Number-weighted size distributions for IL-2, TGF-β1, 
and Rapamycin (Rapa) MPs, determined by volume impedance measurements of 50,000 particles. (C) Cumulative 
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release profiles for IL-2, TGF-β1, and Rapa formulations (N=3-6). In vitro release was measured for MPs incubating 
at 37°C in PBS with 1% BSA for IL-2 and TGF-β1, or PBS with 0.2% Tween-80 for Rapa. 
 
 
Figure 3-2. IL-2 and TGF-β1 released from MPs and detected by ELISAs are bioactive. (A) IL-2 released from 
MPs induces proliferation of HT-2 cells with potency and efficacy comparable to unencapsulated IL-2 standard.  (B) 
TGF-β1 released from MPs inhibits IL-4-induced proliferation of HT-2 cells with potency and efficacy comparable 
to unencapsulated TGF-β1 standard.  For both bioassays, MPs were incubated in complete RPMI media, release 
samples taken at 24 and 48 hours, and cytokine concentrations determined by ELISA.  Total proliferation of HT-2 
cells after 48 hours of culture with cytokines was measured by MTS assay, and half-maximal effective 
concentrations (EC50) determined by nonlinear regression on dose-response curves.  Data are representative of 
release samples from two different batches of MPs per cytokine, and HT-2 cultures were performed in triplicate. 
3.2.2 Prophylactic treatment with TRI MPs during hapten sensitization increases the 
Treg/Teff ratio in skin draining lymph nodes. 
We previously demonstrated that TRI MP induce differentiation of naïve CD4+ T cells to CD4+ 
FoxP3+ regulatory T cells (Tregs) in vitro in the presence of T-cell activating microbeads [93]. 
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To determine whether our new TRI MP formulations could promote Treg differentiation and 
enhance Treg populations in vivo, TRI MP were injected subcutaneously at the base of the ears 
two days prior to sensitization of the ears with 2,4-dinitrofluorobenzene (DNFB), a small 
molecule hapten and model contact allergen. Naïve mice, sensitized but untreated mice (DNFB 
only), and sensitized mice treated with Blank MP served as controls. Flow cytometry analysis on 
DLN from four days post-sensitization revealed significant effects of DNFB and TRI MPs on T-
cell populations. Relative to naïve mice, sensitized mice (with or without Blank MP) had 
significantly greater Treg, Th1, and Tc1 frequencies and numbers in the DLN (Figure 3-3A and 
Figure 3-4). Notably, TRI MP treatment dramatically enhanced the frequency and absolute 
number of CD4+ FoxP3+ Tregs (including both CD25+ and CD25- Treg subsets), relative to 
sensitized controls (Figure 3-3A and Figure 3-4). Tregs from TRI MP-treated mice expressed 
several characteristic markers important for suppressive function, including CD25 (IL-2Rα), 
CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4), GITR (Glucocorticoid-Induced TNFR-Related 
protein), LAP (Latency Associated Peptide, pro-TGF-β1), and CD39 (ectonucleotidase that 
generates anti-inflammatory adenosine) [14]. Furthermore, expression of CTLA-4, GITR, and 
LAP was slightly greater on Tregs from TRI MP-treated mice, relative to naïve Tregs (Figure 
3-3D). In addition to expanding Treg populations, TRI MP treatment led to decreases in 
frequencies and numbers of proinflammatory CD4+ T-bet+ Th1 and CD8+ T-bet+ Tc1 effector T 
cells (Teff) (Figure 3-3A and Figure 3-4B). Concurrent enhancement of Treg populations and 
reduction of Teff populations contributed to a dramatic increase in the Treg/Teff ratio in TRI 
MP-treated mice, relative to naïve and sensitized controls (Figure 3-3B). Despite shifts in T-cell 
sub-populations, total numbers of lymphocytes in DLN were consistent across all sensitized 
groups, and significantly greater than in DLN from naïve mice (Figure 3-3C). Finally, we 
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observed similar trends in T-cell populations using a second model hapten, oxazolone (OXA). 
Specifically, treatment with TRI MPs prior to topical application of OXA, nearly doubled the 
Treg/Teff ratio in skin DLN by expanding Treg and suppressing Th1 and Tc1 populations 
(Figure 3-5). These data suggest that our approach to in vivo modulation of T cell responses 
during allergen sensitization is not restricted to a particular hapten, and could potentially be 
extended to a variety of other allergens. 
 
 
Figure 3-3. Treatment with TRI MP during DNFB sensitization enhances Treg populations and reduces 
effector T-cell populations (Teff; Th1 and Tc1) in skin draining lymph nodes (DLN). Sustained release TRI MP 
were injected 2 days prior to sensitization and DLN were isolated and analyzed by flow cytometry four days post-
sensitization.  Naïve (unsensitized) mice were used as a control. (A) Relative frequencies of Treg (CD4+ FoxP3+), 
Th1 (CD4+ T-bet+), and Tc1 (CD8+ T-bet+) populations in DLN. (B) Ratios of anti-inflammatory Treg to pro-
inflammatory Teff in DLN. (C) Total cells per DLN as counted with a hemocytometer.  (D) Representative 
histograms showing expression of characteristic Treg markers by CD4+ FoxP3+ Tregs from DLN of TRI MP treated 
or naïve mice. CD4+ FoxP3- T cells and isotype controls are also shown. Significant differences, relative to DNFB 




Figure 3-4. TRI MP treatment expands CD25+ and CD25- Treg populations and alters absolute numbers of 
Tregs and effector T cells in skin DLN. (A) Treatment with TRI MPs during DNFB sensitization expands both 
CD25+ (black) and CD25- (grey) populations of CD4+ FoxP3+ Tregs in skin DLN four days post-sensitization. 
Overall Treg frequencies (% FoxP3+ CD25+/- of CD4+) are also presented in Figure 3-3A. (B) TRI MPs also increase 
absolute numbers of Tregs and decrease absolute numbers of Th1 and Tc1 cells in skin DLN.  Numbers are cells per 
DLN.  Significant differences, relative to DNFB alone, are indicated by *p < 0.05, **p < 0.001, ***p < 0.0001 
(N≥14 for % Treg; N=5-10 for absolute numbers). 
 
 
Figure 3-5. TRI MPs modulate T-cell responses to another chemical hapten (OXA). Frequencies of T-cell 
subsets in skin DLN at 4 days post-sensitization with OXA. Treg / Teff is the ratio of Treg to Th1 and Tc1 
populations. Significant differences indicated by *p < 0.05 (N=5). 
 
 To investigate the importance of sustained delivery of Treg-inducing factors during the 
sensitization phase, some mice were treated with a single local bolus of soluble TRI (TGF-β1, 
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Rapamycin, and IL-2 without MPs). Unlike treatment with sustained release TRI MPs, soluble 
TRI injected one or two days before sensitization (as with MP treatments) did not affect Treg or 
effector T-cell populations (Figure 3-6A). Interestingly, local injection of soluble TRI at the time 
of sensitization (day 0), or 1 to 3 days after sensitization, reduced Th1 and Tc1 frequencies, but 
failed to expand Treg populations (Figure 3-6A). This suggests that these mediators must be 
present at the time of antigen exposure, and that Treg induction requires their sustained presence 
throughout antigen presentation.  
Finally, while IL-2 and TGF-β1 are essential for Treg induction [151], and addition of 
rapamycin significantly enhanced Treg-induction efficiency in vitro [93], we wanted to 
determine whether delivery of all three factors was essential to enhance Treg populations and 
suppress Th1 and Tc1 populations in vivo. Treatment with different combinations of TRI MP 
revealed that all three factors were in fact required to significantly enhance Treg frequencies and 
reduce Th1 and Tc1 frequencies (Figure 3-6C). The combination of TGF-β1 MP and Rapa MP 
also increased Treg frequencies and reduced Th1 frequencies, but did not have a significant 
effect on Tc1 frequencies (Figure 3-6C). Together, these data suggest that sustained delivery of 





Figure 3-6. Effects of sustained local delivery and different combinations of TRI MP on Treg (CD4+ FoxP3+), 
Th1 (CD4+ T-bet+) and Tc1 (CD8+ T-bet+) populations in DLN four days after sensitizing ears with DNFB. 
(A) Two days prior to sensitization, TRI MP were injected near the sensitization site (base of ears). Alternatively, a 
bolus of soluble TRI (IL-2, TGF-β1, and Rapa w/o MPs) was injected at the base of the ears at the indicated time 
point with respect to sensitization (N≥5). (B) TRI MP were injected at the base of the ears (local) or at the abdomen 
(distal) two days prior to sensitization (N=7). (C) Mice were treated with different combinations of TRI MP two 
days prior to DNFB sensitization (N=3). Total mass of injected particles was kept constant by supplementing single 




3.2.3 TRI MP treatment during hapten sensitization suppresses maturation of migratory 
DCs in skin DLN. 
In addition to direct effects on T-cell differentiation, TGF-β1 and rapamycin can directly 
influence the phenotype of DCs [43].  Specifically, DCs cultured with rapamycin and/or TGF-β1, 
in soluble form or encapsulated in MPs, exhibited lower expression of MHC-II, co-stimulatory 
molecules (CD80 and CD86), and pro-inflammatory cytokines (IL-12) [145, 152-154].  Such 
DCs were also less able to stimulate allogeneic T-cell proliferation [145, 152-154], though 
rapamycin conditioned DCs did support Treg proliferation [153].  Given these reported effects of 
TRI factors on DCs, we examined the phenotype of skin migratory DCs (CD11c+ MHC-IIhigh) 
and lymph node resident DCs (CD11chigh MHC-IIint) in DLN after treatment with TRI MPs and 
sensitization with DNFB.  Sensitization increased migration of skin DCs to DLN, and MPs had 
no effect on absolute numbers of migratory DCs in the DLN (Figure 3-7B).  Sensitization also 
induced maturation of skin migratory DCs, as evidenced by enhanced expression of co-
stimulatory CD80 and CD86 (Figure 3-7C-D).  Interestingly, treatment with TRI MPs 
significantly inhibited DNFB-induced expression of CD80 and CD86 on migratory DCs (Figure 
3-7C-D), but did not alter expression on lymph node resident DCs (data not shown).  
Unexpectedly, Blank MPs also seemed to reduce expression of CD80 and CD86 on migratory 
DCs, though to a lesser extent than TRI MPs (Figure 3-7C-D).  This may reflect inclusion of 
cells that migrated to the skin DLN after ingesting Blank MPs, instead of in response to DNFB 
exposure; however, this phenomenon will require further investigation.  Ultimately, these results 
suggest that the effects of TRI MPs on T-cell populations (seen in Figure 3-3) could also 
potentially be mediated indirectly through effects on DCs. 
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Figure 3-7. TRI MP treatment during DNFB sensitization suppresses maturation of skin migratory DCs.  TRI 
MPs or Blank MPs were injected 2 days prior to sensitization with DNFB, and DLN were isolated and analyzed by 
flow cytometry four days post-sensitization.  Naïve mice were used as a control.  (A) Representative flow cytometry 
plot shows gating for (i) skin migratory DCs (CD11c+ MHC-IIhigh) and (ii) lymph node resident DCs (CD11chigh 
MHC-IIint).  (B) Absolute numbers of migratory DCs in skin DLN, as determined by flow cytometry and total cell 
counts with a hemocytometer (N=10).  (C) Fluorescence intensity histograms for co-stimulatory molecules CD80 
and CD86, which are up-regulated upon DC maturation. Colors correspond to experimental groups identified in B 
and D, and grey histograms are isotype controls.  (D) Median fluorescence intensity (MFI) for CD80 and CD86 
(N=5, representative of two independent experiments).  Significant differences, relative to DNFB sensitized 
controls, are indicated by * p<0.05 and ** p<0.001. 
3.2.4 TRI MP treatment suppresses T-cell stimulatory function of DCs. 
To assess the stimulatory function of DCs following TRI MP treatment, CD11c+ DCs were 
isolated from skin DLN of mice 48 hours after application of OVA MNA and treatment with TRI 
MP plus soluble TRI factors or Blank MP.  These DCs were then co-cultured with CFSE-
labeled, OVA-specific TCR transgenic OT-I and OT-II T cells, in order to evaluate their function 
in the absence of TRI MP-induced Tregs, which could suppress T-cell proliferation.  Positive 
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selection with MACS columns yielded an average of 84% CD11c+ cells, which included similar 
sized populations of migratory DCs (CD11chigh MHC-IIint) and lymph node resident DCs 
(CD11c+ MHC-IIhigh) (Figure 3-8A-B).  Notably, compared to DCs from Blank MP treated mice, 
those from mice treated with TRI MP plus soluble TRI induced significantly less proliferation of 
OT-I and OT-II T cells, as evidenced by fewer CFSElow T cells (Figure 3-8C-E).  These results 
suggest that TRI MPs (with additional soluble TRI factors) can suppress the T-cell stimulatory 
function of DCs independent of Treg-mediated suppression.  
  
Figure 3-8. Treatment with TRI MP plus a bolus of soluble TRI factors impairs stimulatory capacity of DCs 
in skin DLN.  Blank MP or TRI MP + Soluble TRI were injected at the base of ears of mice immediately before 
application of OVA (100 μg) MNA to ears.  After 48 hours, CD11c+ cells were isolated from skin DLN by MACS, 
and co-cultured with CFSE-labeled OT-I or OT-II T cells (1:10 DC:T cell).  (A) Representative flow cytometry 
analysis of cells after CD11c isolation.  (B) Percentages of lymph node resident DCs (CD11chigh MHC-IIint) and skin 
migratory DCs (CD11c+ MHC-IIhigh) based on gating in (A).  (C) Representative CFSE dilution (proliferation) of 
CD3+ CD8+ cells (OT-I T cells) after 3 days co-culture with DCs.  Gates indicate percent proliferating (CFSElow) 
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cells.  (D-E) Frequencies of proliferating OT-I (D) and OT-II (E) T cells, as identified by CFSE dilution.  Significant 
differences are indicated by * p < 0.05 (N=5).   
3.2.5 Prophylactic treatment with TRI MPs during hapten sensitization suppresses DTH 
responses to multiple subsequent exposures. 
Since TRI MPs expanded suppressive Treg populations and reduced pro-inflammatory Th1 and 
Tc1 populations after sensitization, we hypothesized that TRI MP treatment would suppress 
DTH responses to subsequent allergen exposure (challenge). To test this hypothesis, mice treated 
with TRI MP and sensitized to DNFB were challenged by re-painting the ears with DNFB 10 
days after sensitization (see experimental timeline in Figure 3-9A). DNFB sensitized mice (with 
or without Blank MP) served as controls. Ear swelling responses, indicative of cutaneous 
inflammation, were measured after DNFB challenge. Notably, TRI MP treatment significantly 
reduced ear swelling compared to sensitized controls (Figure 3-9B). Furthermore, tolerance 
induced by TRI MP treatment was persistent enough to suppress the hypersensitivity response to 
a second allergen challenge (“re-challenge”) 10 days after the first (Figure 3-9C). Importantly, 
this effect was generalized, as TRI MP treatment was also able to suppress DTH responses to a 
second model hapten, OXA, in OXA-sensitized mice (Figure 3-10), suggesting that in vivo 
expansion of Treg populations with TRI MP may be a viable therapeutic approach for a variety 




Figure 3-9. Prophylactic treatment with TRI MP, prior to sensitization, protects skin and suppresses DTH 
responses to repeated challenges with DNFB. (A) Experimental timeline. (B-C) Increases in ear thickness 
(swelling) after (B) DNFB challenge (N=20, N=5 for anti-GITR) or (C) re-challenge (N=6-7), relative to pre-
challenge or pre-re-challenge thickness. (D-F) Representative ear skin histology (H&E) from 4 days post-challenge 
(D) or re-challenge (E), or from naïve ears not exposed to DNFB (F). DNFB was applied to the dorsal side of ears 
(top of images). Scale bars are 100 μm. (G) Average epidermal thickness as measured from histology images as in 
(D-F) (N=5-8). (H) T-cell counts in skin sections from 4 days post-challenge. Representative immunofluorescence 
images (fields) used for cell counts are presented in Figure 3-11 (N=5). A high FoxP3+ / CD8+ T-cell ratio is 
indicative of a more tolerogenic microenvironment. (I) Expression of pro-inflammatory cytokines in skin tissue 48 
hours post-challenge (N=5). mRNA was quantified by qRT-PCR, and expression is relative to naïve skin (2-ΔΔCt). 




Figure 3-10. TRI MPs suppress inflammatory response to OXA challenge. Increases in ear thickness (swelling) 
relative to baseline (pre-challenge) measurements. Significant differences indicated by *p<0.05 or **p<0.001 (N=5). 
  
In addition to macroscopic differences in ear swelling, histological evaluation of ear skin 
from four days after DNFB challenge or re-challenge revealed remarkable differences in skin 
morphology from TRI MP treated mice, compared to sensitized controls (Figure 3-9D,E). After 
DNFB challenge or re-challenge, skin from sensitized controls showed acanthosis (epidermal 
hyperplasia), hyperkeratosis (thickening of the stratum corneum), some spongiosis (intercellular 
edema between keratinocytes), and lymphocyte infiltrates in the epidermis and dermis (Figure 
3-9D,E). These features are consistent with subacute allergic dermatitis [155]. Notably, TRI MP 
treatment reduced acanthosis, hyperkeratosis, spongiosis, and cellular infiltrates (Figure 3-9D,E), 
resulting in skin that looked more like naïve skin histologically (Figure 3-9F). Quantification of 
epidermal thickness also confirmed that TRI MP treatment significantly reduced epidermal 
hyperplasia associated with repeated allergen exposure (Figure 3-9G). To better characterize 
cutaneous T cell infiltrates, skin sections were stained for CD3, CD8, or FoxP3 and evaluated by 
immunofluorescence (Figure 3-11). Quantification of cells in imaged fields revealed 
considerable CD3+ T-cell infiltrates in skin from sensitized controls after DNFB challenge, the 
majority of which were CD8+ effector T cells (Figure 3-9H). In contrast, skin from TRI MP 
treated mice contained significantly fewer total T cells, including fewer total FoxP3+ Tregs; 
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however, the ratio of FoxP3+ / CD8+ T cells was roughly twofold greater than in sensitized and 
naïve controls (Figure 3-9H).  
 
 
Figure 3-11. Representative immunofluorescence images of ear sections used for T-cell counts in Figure 3-9. 
Sections of naïve ears or ears from four days post-challenge were stained for FoxP3 (Tregs), CD8α (cytotoxic T 
cells), or CD3 (total T cells), and counterstained with DAPI. False-colored immunofluorescence images were taken 
using a 20X objective. Large scale bars are 150 μm. Scale bars in magnified insets are 15 μm. 
 
To determine whether treatment with TRI MP suppressed cutaneous production of 
inflammatory cytokines in response to DNFB challenge, skin tissue was harvested 48 hours post-
challenge and mRNA extracted for qRT-PCR analysis.  Specifically, we examined expression of 
IL-1β and TNF, which are predominantly produced by keratinocytes and neutrophils [45], as 
well as IFN-γ, which is produced by Th1 and Tc1 cells, in response to allergen challenge [156].  
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As expected, expression of IL-1β, TNF, and IFN-γ was considerably enhanced in DNFB 
challenged skin from DNFB sensitized controls, relative to naïve tissue (Figure 3-9I). TRI MP 
treatment significantly suppressed expression of these three pro-inflammatory cytokines, though 
expression levels were still greater than in naïve tissue (Figure 3-9I).   
Finally, to confirm that suppression of hypersensitivity responses was mediated by 
expanded Treg populations, we used a GITR agonist to inhibit the suppressive function of Tregs 
[157]. Anti-GITR (DTA-1, 0.5 mg/mouse) was injected intraperitoneally 3 days before DNFB 
challenge of TRI MP treated mice (Figure 3-9A). These mice developed a robust DTH response 
to DNFB challenge, comparable to sensitized controls without TRI MP, as indicated by ear 
swelling (Figure 3-9B) and histological features of skin tissue 4 days post-challenge (Figure 
3-9D,G). Together, these data suggest that blocking Treg function abrogates the suppressive 
effects of Treg-induction therapy with TRI MPs.  Interestingly, treatment of mice with a Treg-
depleting antibody (anti-CD25, PC-61) after DNFB sensitization only modestly abrogated the 
suppressive effects of TRI MPs (Figure 3-12). TRI MP treatment, with or without anti-CD25, 
significantly inhibited ear-swelling responses to DNFB challenge; however, ear swelling was 
somewhat greater 1-2 days post-challenge for mice treated with anti-CD25 (Figure 3-12B).  Four 
days post-challenge, ear DLN from mice treated with TRI MP and anti-CD25 contained fewer 
FoxP3+ Tregs (Figure 3-12C) than those from mice treated with TRI MP alone.  These results 
indicate that suppression of DTH responses by TRI MPs is not completely reversed by anti-
CD25, possibly due to incomplete depletion of allergen-specific FoxP3+ Tregs, many of which 
are likely CD25low (Figure 3-3D).  Additionally, depletion of CD25+ effector T cells could inhibit 
the DTH response, offsetting the effects of depleting CD25+ Tregs [158].   
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Figure 3-12. Depletion of CD25+ Tregs with anti-CD25 (PC-61) modestly impairs TRI MP-mediated 
suppression of DTH.  (A) Experimental timeline.  Anti-CD25 (PC-61, 0.5 mg i.p.) was used to deplete CD25+ 
Tregs.  (B) Measurement of DTH response to DNFB challenge of ears.  Increases in ear thickness (swelling) are 
relative to baseline (pre-challenge) measurements.  (C) FoxP3+ Treg frequency in ear DLN at 4 days post-challenge, 
as determined by flow cytometry.  Significant differences (relative to DNFB in B) are indicated by * p < 0.001.  
Significant differences relative to DNFB + TRI MP are indicated by # p < 0.05 (N = 4-5 mice per group). 
3.2.6 Treg-inducing factors must be delivered locally (near the sensitization site), but 
generate systemic and specific tolerance to contact allergens. 
To determine whether local treatment (at the same site as hapten challenge) was necessary, we 
injected TRI MPs at the abdomen, a distal site that doesn’t drain to the cervical LN, and 
examined T-cell populations in ear DLN four days after sensitizing ears with DNFB. 
Interestingly, treatment at a distal site had no effect on Th1 and Tc1 populations in ear DLN, and 
a significantly diminished effect on Treg frequencies (Figure 3-6B). This led to Treg / Teff ratios 
similar to those seen in DNFB sensitized mice without treatment, and more than two-fold less 
than Treg / Teff ratios in DLN of mice treated with TRI MP near the sensitization site (Figure 
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3-13A). Since we observed significantly greater Treg / Teff ratios in non-draining inguinal LN 
(NDLN) of mice treated with TRI MP near the sensitization site, compared to sensitized mice 
(Figure 3-13A), we next wanted to see whether local treatment could generate systemic 
hyporesponsiveness to subsequent allergen exposure. Accordingly, we injected Blank MP or TRI 
MP at the abdomens of mice prior to sensitizing abdomens with DNFB, and then challenging 
ears (Figure 3-13B). Notably, TRI MP treatment at the sensitization site effectively suppressed 
the DTH response to challenge at a distal site (ears), as evidenced by a significant reduction in 
ear swelling (Figure 3-13C). 
 Finally, to demonstrate allergen-specificity of TRI MP-mediated DTH suppression, mice 
were treated with Blank MP or TRI MP near the site of sensitization to one allergen (OXA), and 
then sensitized to a second allergen (DNFB) at a different site and time (see timeline in Figure 
3-13D).  As with prior hapten-mediated ACD experiments (Figure 3-9 and Figure 3-10), ears 
were challenged 12 days after treatment with MPs.  Ear-swelling responses to DNFB challenge 
were comparable for both TRI MP- and Blank MP-treated mice (Figure 3-13E).  In contrast, TRI 
MP-treatment near the site of DNFB or OXA sensitization suppressed DTH responses to 
subsequent challenge with the same allergen (Figure 3-9B and Figure 3-10).  Collectively, these 
results suggest that TRI MP treatment suppresses DTH responses in an allergen-specific manner, 




Figure 3-13. TRI MP injected near sites of skin sensitization can suppress DTH responses to challenge at 
distal sites. (A) Four days after sensitization of ears with DNFB, ear-draining cervical LN (DLN, black) or non-
draining inguinal LN (NDLN, gray) were isolated and T-cell populations analyzed by flow cytometry (N≥7 for 
DLN, N≥20 for NDLN). TRI MP were injected either at the base of the ears or at the abdomen, a site “distal” to 
sensitization. Treg / Teff represents the ratio of CD4+ FoxP3+ Treg to CD4+ T-bet+ Th1 and CD8+ T-bet+ Tc1 
effector T cells (Teff). DNFB and DNFB + TRI MP DLN data are also presented in Figure 3-3B. (B) Experimental 
timeline for allergen challenge at a distal site to sensitization and treatment. (C) Increases in ear thickness (ear 
swelling) after DNFB challenge, relative to naïve (pre-challenge) thickness (N=10). (D) Experimental timeline to 
demonstrate allergen-specific DTH suppression. (E) Ear swelling after DNFB challenge (N=7-8) of mice sensitized 
to OXA and DNFB at different sites, according to the timeline in (D).  Mice were treated with Blank MP or TRI MP 
near the site of OXA sensitization only.  Significant differences are indicated by *p < 0.05 or **p < 0.001.  
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3.2.7 TRI MP travel to skin DLN after injection, but therapeutic efficacy does not depend 
on lymphotropic delivery. 
Given the requirement for local delivery of TRI factors, we sought to determine the importance 
of using small lymphotropic MPs that would travel to the skin DLN after injection.  Previous 
studies have demonstrated that subcutaneously injected nanoparticles (NPs), or small MPs, can 
travel passively through lymphatics to DLN [71, 159-162].  For example, small NPs (50-60 nm) 
coated with antigen, complement proteins, and/or tolerogenic ligands have been used as 
lymphotropic adjuvants or modulators of immune responses [71, 159, 160].  Larger 
chitosan/heparin particles (200-1000 nm) also arrived in DLN within 45 minutes of injection, 
which is faster than tissue-resident phagocytes could take up and carry them [161].  Another 
study found that larger NPs (500-2000 nm) were mostly associated with DCs from the injection 
site, while smaller (20-200 nm) NPs could associate with lymph node resident cells [162].   
Since TRI MPs are polydisperse in size, with diameters of approximately 1.7 ± 0.9 μm, 
we expected some to passively travel to skin DLN after injection, and some to be carried by 
phagocytic cells.  To test this hypothesis, fluorescently labeled MPs were injected at the bases of 
ears of mice, and DLN were isolated 90 minutes or 48 hours later, cryosectioned, and imaged.  
By 48 hours, MPs were observed in paracortical regions of DLN, often associated with CD11c+ 
cells (Figure 3-14), consistent with active transport by DCs at the injection site.  Some 
presumably smaller MPs also were observed in the subcapsular sinus of DLN within 90 minutes 
of injection (Figure 3-15A), consistent with passive trafficking through the lymphatics.  Notably, 




Figure 3-14. Some TRI MPs arrive in the local skin DLN after injection. Representative immunofluorescence 
images of paracortical regions of lymph nodes, with staining for nuclei (DAPI, blue), dendritic cells (CD11c, red), 
and MPs (FITC-labeled, green).  (A) Naïve cervical lymph node.  (B) Skin DLN 48 hours after local subcutaneous 
injection of FITC-labeled MPs.  Arrows indicate co-localization of FITC MPs and CD11c+ dendritic cells.  
 
To assess whether release of TRI factors from MPs within the DLN is necessary for 
efficient Treg-induction and therapeutic efficacy, treatment with the lymphotropic TRI MPs was 
compared to that with TRI MPs sequestered at the site of injection.  The latter was accomplished 
by suspending MPs in a 10% pNIPAM solution instead of PBS.  As a biologically inert 
thermoresponsive hydrogel, pNIPAM transitions from an injectable liquid at room temperature 
to a particle-retaining solid gel upon injection (lower critical solution temperature = 32°C [148]).  
Unlike TRITC-labeled MPs injected in PBS, those injected in pNIPAM did not appear in DLN at 
90 minutes (Figure 3-15A-B) or at 48 hours (not shown), confirming that pNIPAM sequestered 
MPs at the injection site.  Importantly, prior work from our lab also indicates that release of 
small molecule drugs from MPs is not affected by suspending MPs in pNIPAM hydrogel [163].  
Compared to prophylactic treatment with TRI MPs injected in PBS, treatment with TRI MPs 
sequestered in pNIPAM was equally effective at enhancing Treg populations, decreasing Th1 
and Tc1 effector T cell populations, and inhibiting DTH responses to DNFB challenge (Figure 
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3-15C-D).  Collectively, these data suggest that lymphotropic MPs are not essential for 
therapeutic efficacy.  Therefore, local injection of TRI MPs near allergen contact likely provides 
elevated concentrations of TRI factors in skin DLN due to sustained release at the injection site, 
which drains to that lymph node. 
 
 
Figure 3-15. TRI MPs do not need to travel to DLN for therapeutic efficacy. (A-B) Representative fluorescence 
images of TRITC-labeled MPs in the DLN of mice 90 minutes after injection in PBS (A), or 10% pNIPAM (B).  
Arrows indicate regions of the subcapsular sinus with large quantities of MPs.  For clarity, the DLN in (B) is 
outlined with a dotted line.  Scale bars are 500 μm.  (C) Relative frequencies of Tregs (CD4+ FoxP3+), Th1 (CD4+ T-
bet+), and Tc1 (CD8+ T-bet+) populations in DLN of mice 4 days after sensitization of ears with DNFB.  MPs were 
injected at the base of ears two days prior to sensitization.  (D) Increases in ear thickness (ear swelling) after DNFB 
challenge, relative to naïve (pre-challenge) thickness.  Ear swelling for mice treated with lymphotropic TRI MP (in 
PBS), or TRI MP sequestered at the injection site (in pNIPAM), are not significantly different (p > 0.05, N=5 mice 
per group).  
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3.2.8 In previously sensitized mice, TRI MPs administered at the time of allergen 
challenge suppress subsequent DTH responses. 
To determine whether TRI MPs could generate allergen tolerance in previously sensitized 
individuals, mice were exposed to DNFB twice at the abdomen prior to administration of TRI 
MP and challenge of left ears with DNFB. Mice were later re-challenged at the opposite ears 
according to the experimental timeline in Figure 3-16A. As with prophylactic treatment at the 
time of sensitization, TRI MP treatment of pre-sensitized mice at the time of allergen challenge 
significantly inhibited DTH responses, as indicated by a significant reduction in ear swelling 
relative to untreated mice (Figure 3-16B). Notably, TRI MP-induced tolerance persisted, 
resulting in suppressed DTH responses to a subsequent re-challenge (Figure 3-16C). TRI MP 
treatment remarkably improved ear skin histology post-challenge (Figure 3-16D) and re-
challenge (not shown). As with prophylactic treatment, treatment at the time of allergen 
challenge reduced acanthosis, hyperkeratosis, spongiosis, and cellular infiltrates (Figure 3-16E). 
Skin DLN from TRI MP treated mice also contained enhanced Treg populations and decreased 
Th1 and Tc1 populations, relative to untreated mice, contributing to an increase in Treg / Teff 
(FoxP3+ / T-bet+) ratios that is consistent with a more tolerogenic immune profile (Figure 3-16F). 
Finally, TRI MP treatment significantly reduced the influx of T-cells into the skin after allergen 





Figure 3-16. Treatment of previously sensitized mice with TRI MP at the time of allergen challenge reverses 
ongoing ACD and suppresses DTH responses to subsequent exposures. (A) Experimental timeline. (B-C) 
Increases in ear thickness (swelling) after (B) DNFB challenge and treatment (N=15) or (C) re-challenge (N=8), 
relative to naïve ear thickness. (D) Representative ear skin histology (H&E) from 4 days post-challenge. DNFB was 
applied to the dorsal side of ears (top of images). Scale bars are 100 μm. (E) Ratio of FoxP3+ Treg to T-bet+ Th1 and 
Tc1 effector T cells in DLN 4 days post-challenge. (F) Representative immunofluorescence images of ear skin from 
4 days post-challenge. (G) Quantification of T-cell infiltrates in skin 4 days after challenge or re-challenge, based on 
immunofluorescence (N=7-8). Significant differences are indicated by *p < 0.05 or **p < 0.001, relative to DNFB 
alone.  
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3.2.9 TRI MPs induce protein-specific Tregs and suppress protein-mediated ACD. 
While ACD typically involves polyclonal T-cell responses to hapten-autologous protein 
complexes, DTH responses to foreign protein antigens can develop when sensitizing exposure 
occurs through skin with barrier defects (e.g. from pre-existing dermatitis, physical damage, or 
chemical damage by detergents). To investigate whether TRI MP could generate protein antigen-
specific Tregs and suppress protein DTH responses, we used dissolvable microneedle arrays 
(MNAs) to deliver ovalbumin (OVA, model antigen) through the stratum corneum, into the 
epidermis and dermis [98]. In this application, MNAs serve as an alternative to tape-stripping 
and topical application of protein or intradermal injections of proteins, as others have reported 
for protein sensitization [81]. Adoptive transfer of CD45.2+ OVA-specific T cells (from OT-I 
and OT-II T-cell receptor transgenic mice) to congenic CD45.1 B6 mice enabled identification of 
OVA-specific T-cell responses to sensitization with OVA MNA and treatment with TRI MP 
(Figure 3-17A). OVA-sensitized mice (with Blank MP) generated strong DTH responses when 
challenged with OVA MNA, as indicated by ear swelling that peaked 48 hours post-challenge 
(Figure 3-17B). While TRI MPs alone were not able to suppress the ear swelling response (data 
not shown), likely due to the artificially high frequency of adoptively transferred OVA-specific T 
cells, treatment with TRI MP plus extra soluble factors (IL-2, TGF-β1, and rapamycin at the 
same time as TRI MP administration) significantly suppressed the OVA DTH response (Figure 
3-17B). Immunofluorescence stained ear tissue from 4 days post-challenge revealed a significant 
reduction in cutaneous CD3+ T-cell infiltrates (Figure 3-17C,D) with treatment, and a 
significantly greater proportion of FoxP3+ Tregs (Figure 3-17D). Finally, analysis of T-cell 
populations in ear skin DLN at 4 days post-sensitization revealed that Treg-inducing treatment 
significantly reduced OVA-specific T-cell expansion, as indicated by fewer CD45.2+ cells 
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(Figure 3-17E). Notably, increased frequencies of OVA-specific FoxP3+ Tregs were 
accompanied by significantly lower frequencies of OVA-specific T-bet+ Th1 and Tc1 effector T-
cell populations (Figure 3-17E).  Interestingly, we observed a substantial increase in a population 
of OVA-specific CD4+ CD25+ FoxP3- T-bet- T cells with potential suppressive capacity in an in 
vitro suppressive assay (Figure 3-17E and Figure 3-18).  As TRI MP treatment alone was unable 
to suppress the OVA DTH response, it was also unable to enhance Treg populations or reduce 
Th1 and Tc1 populations as well (Figure 3-17E). Notably, soluble factors alone had no 
significant effects on OVA-specific Treg, Th1, or Tc1 populations (Figure 3-17E), suggesting 
sustained delivery of the Treg-inducing factors is important. Collectively, these data demonstrate 
that TRI MP (along with extra soluble factors as a “burst” at the time of administration) can 
induce protein antigen-specific Tregs in vivo and suppress protein DTH responses. 
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Figure 3-17. Treatment with TRI MP prior to OVA sensitization suppresses a protein-specific DTH response. 
(A) Experimental timeline. OT-I & OT-II cells (CD45.2+) were transferred to congenic CD45.1+ B6 recipient mice. 
(B) Ear swelling after OVA challenge, represented as the difference in thickness between OVA MNA treated ears 
and contralateral Blank MNA treated ears (N=8). (C) Representative ear skin sections from 4 days post-challenge, 
stained for T cells (CD3, yellow) and counterstained with DAPI. Scale bars are 100 μm. (D) Quantification of 
cutaneous T cells per imaged field (as in C) and % Treg, based on similar IHC images with FoxP3 staining (N=5). 
(E) Frequencies of various OVA-specific (CD45.2+) T-cell subsets in skin DLN at 4 days post-sensitization (N≥5). 




Figure 3-18. TRI MP-induced CD25+ OT-II T cells suppress proliferation of naïve CD4+ CD25- conventional 
T cells (Tconv). Live CD45.2+ CD4+ CD25+ cells (CD25+ OT-II) were FACS sorted from DLN of CD45.1 B6 mice 
five days after adoptive transfer of 5x106 CD45.2+ OT-II cells, and four days after OVA sensitization and TRI MP 
treatment.  CFSE-labeled CD45.1+ Tconv (5x104 / well) were cultured with anti-CD3/anti-CD28 beads (5x104 / 
well) and CD25+ OT-II cells at the indicated ratios.  Unstimulated Tconv were cultured without anti-CD3/anti-CD28 
beads.  Based on flow cytometry analysis (Fig. 6E), the CD25+ OT-II population contains less than 12.5% FoxP3+ 
Tregs; therefore, a Tconv : CD25+ OT-II ratio of 8:1 corresponds to a Tconv : FoxP3+ OT-II ratio of at least 64:1.  
Representative CFSE-dilution histograms depict proliferation of Tconv, and gates indicate percent of cells 





As an alternative to the current symptomatic treatments for ACD, which use non-specific anti-
inflammatories (e.g. corticosteroids; see Chapter 1.1.2), our first therapeutic approach to promote 
allergen tolerance involved using the TRI MP delivery system to condition the local skin DLN 
microenvironment and expand Treg populations in vivo.  The overall therapeutic goal of 
expanding Treg populations (described in Chapter 1.2) stems from their ability to suppress 
aberrant immune responses in a variety of inflammatory and autoimmune diseases [14].  
Accordingly, in the present study, we demonstrated that sustained local release of TGF-β1, 
rapamycin, and IL-2 from TRI MPs injected near the site of cutaneous sensitization or challenge 
expanded allergen-specific Treg populations and suppressed pro-inflammatory Th1 and Tc1 
effector T-cell populations in skin DLN (Figure 3-3 and Figure 3-16E). Although an injection of 
un-encapsulated TRI factors 0 to 3 days after sensitization suppressed effector T cells, expansion 
of Treg populations required sustained release from TRI MPs (Figure 3-6A). This could be due 
to the fact that rapamycin, which can suppress effector T-cell proliferation, has a relatively long 
half-life of at least 6 hours in mice [164]. In contrast, IL-2 and TGF-β1, which are essential for 
Treg differentiation and proliferation [151], have very short in vivo half-lives of a few minutes 
[68, 165]. TRI MPs extend the presence of these immunomodulatory cytokines, presumably 
providing a tolerogenic microenvironment in which antigen presentation by skin-emigrating DCs 
occurs during the sensitization phase. Importantly, MP formulations directed toward 
conditioning the local antigen presentation microenvironment significantly reduce therapeutic 
doses of TRI factors. For example, TRI MP treatment translates to less than 100 ng/kg/day of 
cytokines and 0.15 mg/kg/day of rapamycin, doses which are orders of magnitude less than those 
typically used for systemic immunomodulation [166, 167]. These dose-sparing effects associated 
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with controlled release formulations are important because of adverse effects associated with 
high-dose cytokine and immunosuppressant therapies [64, 68]. Notably, while TRI MP do not 
appear to release sufficient amounts of factors to affect T-cell differentiation at distal sites 
(Figure 3-13A), local effects on Treg and effector T-cell populations can generate systemic 
tolerance and suppress DTH responses to subsequent allergen exposure at distal sites (Figure 
3-13B), presumably due to circulation of locally expanded Tregs and fewer circulating effector T 
cells. 
 In addition to increasing the ratio of anti-inflammatory, tissue-protective Tregs to pro-
inflammatory, tissue destructive effector T cells, TRI MP treatment during sensitization 
suppressed DTH responses to subsequent allergen exposures (Figure 3-9, Figure 3-5, Figure 
3-17). Hyporesponsiveness persisted through at least two allergen challenges 10 and 20 days 
after sensitization (Figure 3-9), and TRI MP reduced ear swelling to levels seen in un-sensitized 
mice when first exposed to DNFB (data not shown). In other words, ear swelling in TRI MP 
treated mice was comparable to that caused by the innate immune response to a hapten without 
T-cell involvement [45]. Furthermore, TRI MPs appeared to suppress DTH responses in an 
allergen-specific manner, with minimal non-specific or off-target immunosuppression. While 
TRI MPs may potentially expand some non-allergen-specific Tregs, the increased populations of 
OXA-specific Tregs and/or non-specific Tregs (Figure 3-5) failed to inhibit DTH responses to 
challenge with a second allergen (DNFB), for which sensitization occurred at a distal site and 
time, relative to TRI MP treatment (Figure 3-13E).  This allergen-specific suppression of ACD 
distinguishes TRI MP-treatment from traditional therapies involving anti-inflammatories (e.g. 
corticosteroids) applied topically after allergen challenge to reduce inflammation non-
specifically, regardless of the allergen.  Finally, TRI MPs were also able to reverse established 
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allergen-specific immune responses in previously sensitized mice and promote allergen 
tolerance, as evidenced by inhibited DTH responses to allergen challenge and re-challenge 
(Figure 3-16).  
Suppression of DTH responses appear to be mediated by the expanded Treg populations, 
as impairing Treg suppressive function via anti-GITR administration [157] reversed the 
beneficial effects of treatment with Treg-inducing MPs (Figure 3-9B). Previously, circulating 
Tregs were shown to suppress DTH responses by blocking influx of effector T cells into 
inflamed tissue. This process is mediated by contact-independent mechanisms, including 
production of cytokines and adenosine (by CD39), which inhibit effector T-cell adherence to 
vascular endothelial cells and subsequent extravasation [21, 49]. Immunohistochemical analysis 
of skin from TRI MP treated mice revealed a significant reduction in total T-cell infiltrates 
(Figure 3-9H, Figure 3-16F-G), and especially CD8+ effector T cells (Figure 3-9H). 
Interestingly, although there were fewer total FoxP3+ Tregs in skin tissue after TRI MP 
treatment, there was at least a two-fold increase in the ratio of FoxP3+ to CD8+ T cells (Figure 
3-9H). We observed a similar trend in the protein-mediated OVA DTH model, where total T-cell 
infiltrates were significantly reduced in TRI MP + Soluble TRI treated skin, and the frequency of 
FoxP3+ Tregs was enhanced (Figure 3-17C,D). In that model, we also observed increases in a 
population of CD25+ FoxP3- OT-II cells, which, given their apparent suppressive function 
(Figure 3-18) and lack of T-bet expression (Figure 3-17), may be an unstable population or a 
type of unconventional FoxP3- Treg reported previously in the setting of allergic disease [168, 
169]. Future studies will be needed to delineate the contributions of skin-resident and circulating 
Tregs toward suppressing the DTH responses, and to identify allergen-specific Tregs with 
resident-memory or central memory phenotypes at extended time-points. Additionally, future 
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studies will be needed to determine the maximum duration of tolerance induced by TRI MP 
under various conditions, including repeated allergen exposure or challenge more than three 
weeks after treatment. In the event that repeated allergen exposure eventually breaks tolerance 
induced by TRI MPs, a booster treatment and/or greater initial dose of TRI factors may be 
necessary. These longer-term studies will require the IL-2 and TGF-β1 release assays to be 
extended beyond three weeks, and if bioactive cytokines are detected at later time points, 
formulations may be modified to restrict release to one week.  This could involve increasing the 
overall PEG:PLGA ratio or blending the PEG-PLGA co-polymer with a lower molecular weight 
PLGA [170]. 
 In addition to demonstrating efficacy of Treg-inducing MPs in models of hapten-
mediated ACD, which involve polyclonal allergen-specific T-cell responses, we were also able 
to induce monoclonal protein-specific Tregs in a well-defined TCR transgenic adoptive transfer 
model. The fact that TRI MP alone did not expand OVA-specific FoxP3+ Tregs or suppress DTH 
responses in this model emphasizes that different amounts of Treg-inducing factors may be 
needed depending on the nature of the acute immune response to be modulated. In this particular 
case, adoptive transfer of a pool of clonal OVA-specific T cells from OT-II Rag2-/- mice 
significantly alters both the frequency and range of T-cell receptor binding affinities of available 
T-cell precursors. Consistent with this notion, difficulty in inducing OVA-specific Tregs also 
may be related to the dose of antigen delivered (up to 100 μg OVA per MNA). Dose-dependent 
responses to antigen have been reported, with maximal Treg proliferation observed at low 
antigen doses, and Th1 proliferation favored at high antigen doses in vitro [171]. Accordingly, 
protein-specific Treg induction in vivo may be further enhanced by optimizing the dose and 
concentration gradient of protein antigens delivered with MNAs. For previously sensitized 
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individuals, application of MHC-II-restricted peptides (e.g. OVA323-339, a CD4+ T cell epitope) 
instead of whole proteins, at the time of TRI MP treatment could prevent further expansion of 
class I restricted peptide-specific CD8+ effector T cells, while still allowing TRI MPs to induce 
and expand class II restricted peptide-specific Treg populations [81]. Ultimately, such 
considerations would be relevant to both inducing tolerance to protein allergens, as well as 
treating autoimmune diseases by loading MNAs with auto-antigenic peptides or proteins.  
 The current study focused on two distinct strategies for tolerance induction. The first 
involved administration of TRI MPs at the time of allergen sensitization, a prophylactic approach 
that would be clinically relevant for common and potent contact allergens, such as urushiol in 
poison ivy, which sensitizes an estimated 85% of the population. Alternatively, for less common 
and/or weakly sensitizing contact allergens, limiting treatment to patients with established ACD 
is more feasible. In this case, TRI MP treatment delivered in the context of a patch test defined 
allergen would need to expand Treg populations sufficiently to subdue the primed memory T-
cell response. This scenario may be more difficult than inducing tolerance with treatment at the 
time of sensitization, as memory T cells can be more resistant to Treg-mediated suppression than 
naïve T cells under some conditions [172]. Encouragingly, in the hapten-mediated ACD model, 
we found that treatment of previously sensitized mice with the same dose of TRI MPs at the time 
of allergen challenge was able to suppress the ensuing DTH response and prevent a subsequent 
DTH response to a re-challenge (Figure 3-16). Optimizing the dosing and/or ratios of TRI factors 
for prophylactic and curative therapies may enhance therapeutic efficacy even more. Further 
investigation will be necessary to determine whether TRI MPs can permanently reverse the 
allergen-specific memory T-cell response in previously sensitized subjects and induce persistent 
tolerance to protect against chronic, repeated allergen exposure. 
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 Finally, unlike other experimental approaches to Treg expansion, treatment with TRI 
MPs enables expansion of allergen-specific Tregs, regardless of whether the antigens are specific 
known proteins (e.g. OVA), or a broad array of unknown haptenated epidermal proteins. This is 
especially important for treatment of hapten-mediated ACD, since a single defined allergenic 
protein or peptide is unlikely to be available for therapy, and immunogenicity of the extensive, 
heterogeneous repertoire of hapten-protein conjugates differs among individuals. This approach 
may also be suitable for suppressing allograft rejection and graft vs. host disease, which involve 
T-cell responses against multiple unknown graft-associated or self-antigens. Ultimately, 
sustained local delivery of Treg-inducing factors from TRI MP may also be used to generate 
tolerance and halt the destructive inflammation responsible for a variety of other autoimmune 
diseases. In these scenarios, the patient’s tissue or allograft would serve as a source of 
unidentified antigens, and a Treg-inducing microenvironment for antigen presentation would be 
provided by TRI MP.   
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4.0  CO-DELIVERY OF ALLERGEN AND VITAMIN D3 ANALOG WITH 
MICRONEEDLE ARRAYS ENGINEERS THE SKIN MICROENVIRONMENT TO 
PROMOTE ALLERGEN TOLERANCE  
4.1 INTRODUCTION  
The cutaneous microenvironment, through which exposure to potential allergens occurs, dictates 
the nature of immune responses to proteins and chemical haptens.  Specifically, allergen 
sensitization is enhanced by pro-inflammatory microenvironments, while antigen exposure in the 
absence of pro-inflammatory “danger” signals, or combined with pro-tolerogenic signals, may 
promote antigen-specific hyporesponsiveness, or tolerance.  Pro-inflammatory cutaneous micro-
environment may exist prior to allergen exposure—as in individuals with atopic dermatitis 
[173]—or may result from innate immune responses to allergen exposure.  Some allergens evoke 
innate inflammatory responses directly by signaling through pattern recognitions receptors (e.g. 
TLR4 activation by nickel and cobalt [174, 175], or dust mite allergens Derp2 and Derf2 [176]).  
Alternatively, many contact allergens induce reactive oxygen species (ROS) and release of ATP 
and other damage-associated molecular patterns (DAMPs), such as low-molecular-weight 
hyaluronic acid, which signal through P2X7R and TLR2/4, respectively [177-179].  
Simultaneous exposure to a potential allergen and contact irritant (e.g. sodium lauryl sulfate 
 99 
[180]), multiple allergens [181-183], or allergen and adjuvant (e.g. TLR4 ligand 
lipopolysaccharide [184, 185]) may also enhance sensitization.  
 In contrast, exposure to potential allergens in the absence of pro-inflammatory “danger” 
signals, or with pro-tolerogenic context can lead to failed sensitization or even allergen tolerance.  
For example, structural analogs of haptens that fail to activate the inflammasome and induce pro-
inflammatory cytokines can induce tolerance to related allergens (e.g. dinitrothiocyanobenzene 
(DNTB), an analog of the strong sensitizers dinitrofluorobenzene (DNFB), dinitrochlorobenzene 
(DNCB), and trinitrochlorobenzene (TNCB) [77]).  Repeated cutaneous exposure to haptens at 
non-irritant, sub-sensitizing doses [78-80], or oral administration of allergens [186-193], also 
may promote tolerance rather than sensitization.  Unfortunately, non-immunogenic structural 
analogs are not available for most allergens, including more than 4350 known chemical haptens 
[2], and sub-threshold doses vary greatly among allergens and among individuals [194].  
Furthermore, oral tolerance induction is typically less effective and persistent after sensitization 
[195, 196], and may be associated with local and gastrointestinal side effects [197].  
 While the aforementioned approaches to tolerance induction involve modifying allergen 
chemical structure, dose, and/or site of introduction, the skin microenvironment also may be 
altered to provide pro-tolerogenic context for cutaneous introduction of unmodified allergens.  
For example, ultraviolet B (UVB) irradiation generates several immunosuppressive factors in the 
skin, including DNA photoproducts, oxidized membrane lipids and proteins, cis-urocanic acid, 
and 1,25-dihydroxyvitamin D3 [83].  These factors, as well as DNA damage, promote migration 
of Langerhans cells to skin draining lymph nodes (DLN) and sub-optimal presentation of antigen 
to T cells [198, 199].  Notably, application of proteins or haptens to UVB-irradiated skin results 
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in impaired priming of effector T-cell responses and enhanced induction of antigen-specific 
Tregs, which inhibit subsequent delayed-type hypersensitivity (DTH) responses [81-84].   
Since UVB-mediated tolerance induction is mediated—at least in part—by cutaneous 
synthesis of 1,25-dihydroxyvitamin D3 [83, 84], the immunosuppressive active form of vitamin 
D3 [200-202], topical application of 1,25-dihydroxyvitamin D3, or synthetic analogs (e.g. 
MC903), has been investigated as an alternative method to modulate the skin microenvironment 
and promote antigen-specific immune tolerance.  As with UVB-irradiation, topical application of 
1,25-dihydroxyvitamin D3 or MC903 promoted allergen-specific Treg-induction and inhibited 
effector T-cell priming, leading to allergen tolerance upon subsequent application of haptens or 
proteins to treated skin in murine models [84-86].  While this approach eliminates the acute 
burns, DNA damage, and increased risk of skin cancer associated with UVB-irradiation, the 
reported tolerance induction protocols are extensive and “messy.” Typically, epicutaneous 
allergen application follows treatment with 1,25-dihydroxyvitamin D3, or MC903, for 3-4 days, 
and optimal introduction of protein allergens requires barrier layer disruption (e.g. tape-
stripping) and occlusive dressings [84, 86].  Each of these components of the treatment regimen 
introduces potential sources of error, including inconsistent regions of application (e.g. allergen 
applied outside the pre-treated area could promote sensitization), variable per area dosing, and 
excessive or sub-optimal barrier disruption.   
To address some of these limitations, we used dissolvable microneedle arrays (MNAs) to 
simultaneously deliver allergen and MC903 into the skin, thereby engineering the skin 
microenvironment to promote allergen-specific tolerance.  Dissolvable MNAs are convenient 
off-the-shelf therapeutics that can efficiently deliver proteins and/or drugs into the epidermal and 
dermal layers of the skin, and enable reproducible treatment (i.e. consistent application area and 
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dose per area).  In this chapter, we describe allergen tolerance induction with Allergen + MC903 
MNA in murine models of ACD, and report effects of MC903 MNA on murine and human skin 
microenvironments and skin migratory cells.  
4.2 METHODS 
4.2.1 Mice 
Female C57BL/6 and congenic CD45.1 B6 (B6.SJL-Ptprca Pepcb/BoyJ) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME) and used at 8-12 weeks of age.  OVA TCR-
transgenic B6 Rag1-/- OT-I (B6.129S7-Rag1tm1Mom Tg(TcraTcrb)1100Mjb) and B6 Rag2-/- OT-II 
(B6.129S6-Rag2tm1Fwa Tg(TcraTcrb)425Cbn) mice were purchased from Taconic (Rensselaer, 
NY).  All mice were maintained under specific pathogen-free conditions at the University of 
Pittsburgh, and experiments were conducted in with the approval of the Institutional Animal 
Care and Use Committee and in accordance with NIH guidelines. 
4.2.2 Microneedle Array Fabrication  
Dissolvable microneedle arrays (MNAs) were fabricated using a previously reported spin-casting 
technique [98, 203].  Mastermolds were manufactured from a rigid polymer, poly(methyl 
methacrylate), via the micromilling technique described in [98], and used to create 
poly(dimethylsiloxane) (PDMS; Sylgard® 184; Dow Corning, Auburn, MI) production molds 
[98].  The PDMS molds were then used to spin-cast MNAs with the geometry and dimensions 
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depicted in Figure 4-1.  MNAs were tip-loaded with 100 μg ovalbumin containing endotoxin 
(OVAETX; grade V ovalbumin; Sigma Aldrich, St. Louis, MO), 100 μg EndoGrade® ovalbumin 
(OVA; endotoxin <0.1 EU/mg; Hyglos GmbH, Germany), 100 μg Alexa Fluor 647-labeled OVA 
(Thermo Fisher Scientific, Waltham, MA), 20 μg OVA323-339 peptide (OVAp; Anaspec, Fremont, 
CA), 1-5 μg calcipotriol (MC903; Cayman Chemical, Ann Arbor, MI), and/or 100 μg 2,4-
dinitrochlorobenzene (DNCB; Sigma Aldrich).  Unloaded Blank MNAs were fabricated for 
controls.  For OVA MNA formulations, protein or peptide was added to a 2% (w/v) solution of 
low-viscosity sodium carboxymethyl cellulose (CMC, Mw 90 kDa; Aldrich) in sterile-filtered 
cell-culture grade water (Sigma).  For MC903 and/or DNCB MNA formulations, the poorly 
water-soluble chemicals were first dissolved in N,N-dimethylformamide (DMF, Sigma Aldrich), 
and then added to the 2% CMC solution at a 1:1 ratio.  Given the total microneedle volume of 
2.3 μL per MNA, OVA and MC903 concentrations dictate total loading.  For example, 4.4 μg/μL 
MC903 in DMF plus 87 μg/μL OVA in 2% CMC yielded MNA with 5 μg MC903 and 100 μg 
OVA.  For tip-loading, 15 μL of the solution of bioactive agent(s) was dispensed onto each 
MNA production mold, followed by centrifugation in covered rotors for 1 min at 3500 rpm.  
Excess solution was removed, leaving ~ 2.3 μL per MNA in the obelisk-shaped cavities, and the 
molds were centrifuged uncovered for 30 min at 3500 rpm, with 20 L/min filtered airflow, 
leaving dry bioactive agent(s) in the tips of the microneedles.  After tip-loading, molds were 
loaded with 80 mg of 25 wt% hydrogel consisting of 3:2 CMC:trehalose (D-(+)-trehalose 
dihydrate; Sigma) to fill the remainder of the microneedle cavities and form the MNA backing.  
Molds were centrifuged in covered rotors for 15 min at 4500 rpm, followed by covered 
incubation for 15 min.  Rotor bucket covers were then removed, and molds centrifuged for 4 
hours and 3500 rpm, with 20 L/min filtered airflow, leaving dry MNAs.  All spin-casting steps 
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were carried out at room temperature (~22 °C) in a Sorvall Legend XTR centrifuge (TX-750 
rotor, rectangular buckets; Thermo Scientific).   
 
Figure 4-1. Microneedle Array (MNA) geometry and dimensions. (A) Schematic top-view of an MNA, which 
consists of an evenly distributed 10x10 matrix of microneedles.  (B) Dimensions of a single obelisk-shaped 
microneedle, with square cross-section, apex angle of 30°, and fillet radius of 15 μm.  The total volume of a single 
microneedle is 0.023 μL. 
4.2.3 MNA Characterization 
MNA geometry was evaluated by optical microscopy using a dissecting microscope (ZEISS 
Stemi 2000-C with an Olympus OM-D E-M5II camera).  MNAs were viewed at an angle of 45° 
with respect to the objective lens.  To obtain images with extended depth of field, several images 
captured at different focal planes were focus-stacked using the Photomerge and Auto Blend 
Layers functions in Adobe Photoshop CS6 (Adobe Systems, San Jose, CA).  Endotoxin content 
in MNAs was measured by chromogenic LAL assay.  Each MNA was dissolved in 1 mL reagent 
H2O and further diluted 1:10 for Blank and OVA MNAs, or 1:125 for OVAETX MNAs.  
Endotoxin concentrations in diluted samples were then measured with a chromogenic LAL 
endotoxin assay kit (ToxinSensor; GenScript, Piscataway, NJ). 
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4.2.4 Murine Models of OVA Delayed Type Hypersensitivity (DTH) 
Mice were sensitized to ovalbumin by transdermal application of an OVAETX MNA to the left 
side of shaved abdomens.  To elicit a DTH response, mice were challenged 5 days post-
sensitization (unless otherwise indicated) by applying an OVAETX MNA to the right ear.  For 
some experiments, OVA MNAs were used for sensitization and/or challenge.  A Blank MNA 
was applied to the left ear to control for any swelling caused by MNA application itself.  Ear 
thickness was measured using an engineer’s spring-loaded micrometer (Mitutoyo, Aurora, IL) 
prior to the OVAETX challenge and on days 1-4 post-challenge, and data are presented as 
differences between OVAETX MNA-treated and Blank MNA-treated ears.  Prophylactic 
tolerization to OVA involved application of the indicated MNA (e.g. OVA + 5 μg MC903) to the 
right side of the shaved abdomen 9, 6, and 3 days prior to sensitization with OVAETX MNA.  For 
tolerization of previously sensitized mice, mice were sensitized twice with an OVAETX MNA 
(days 0 and 5), followed by tolerization with OVA + MC903 MNA (days 10, 13, and 16), and 
challenge with OVAETX MNA (day 19).  To investigate OVA-specific T-cell responses to 
OVA±MC903 MNA formulations, OVA-specific CD8+ and CD4+ T cells were isolated from 
spleens of OT-I and OT-II mice (CD45.2+) and adoptively transferred to congenic CD45.1 B6 
mice by tail vein injection (5x106 OT-I and 5x106 OT-II cells per mouse) one day prior to MNA 
application. 
4.2.5 Evaluation of Skin Histology by H&E Staining 
Ears from mice were excised, flash frozen in OCT compound, and cryosectioned.  Skin sections 
(7 μm thick) were stained with hematoxylin and eosin (H&E).  Human skin explants were fixed 
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in 10% neutral buffered formalin for several days, dehydrated in 100% ethanol, cleared with 
xylene, and embedded in paraffin.  Paraffin blocks were sectioned (5 μm thick) and stained with 
H&E.  Stained tissue sections were imaged using a Nikon Eclipse E400 microscope with 
ProgRes C5 camera and ProgRes CapturePro v2.9 software (Jenoptik AG, Jena, Germany).   
4.2.6 Evaluation of Cellular Immune Responses by Flow Cytometry 
Ear-draining cervical lymph nodes and spleens were harvested, passed through 70 μm nylon cell 
strainer to create single cell suspensions.  Splenocyte suspensions were depleted of erythrocytes 
by hypotonic lysis with 0.83% (w/v) ammonium chloride buffer.  Ears were split along the 
central cartilage plate, and the dorsal sides chopped into small fragments and incubated in serum-
free IMDM (Gibco, Life Technologies, Carlsbad, CA), supplemented with 1 mg/mL DNase I 
(grade II, Roche, Sigma Aldrich) and 1 mg/mL Collagenase D (Roche, Sigma Aldrich) at 37 °C 
for 1 hour.  After passing twice through 70 μm cell strainers, cells were collected and washed 
with cold PBS before staining.  Cells were stained with fluorescently labeled antibodies 
purchased from BD Biosciences (San Jose, CA), eBioscience (San Diego, CA), or BioLegend 
(San Diego, CA).  To identify Treg, Th1, Th2, and Tc1 populations, cells were blocked with 
anti-CD16/32 (2.4G2; BD) and stained for CD4 (RM4-5; eBio), CD8b (H35-17.2; eBio), and 
CD25 (PC61; BD).  Transcription factor staining for FoxP3 (FJK-16s; eBio), T-bet (O4-46; BD), 
and GATA3 (L50-823; BD) was performed using the FoxP3 / Transcription Factor Staining 
Buffer Set (eBio).  Skin-resident leukocytes and adoptively transferred OVA-specific T cells 
were identified by staining for CD45.2 (104; BD).  Skin cell suspensions were also stained with a 
fixable viability dye (eBio) and antibodies for I-Ab (AF6-120.1; BD), CD11c (HL3; BD), CD11b 
(M1/70; BD), Ly6G (1A8; BD), F4/80 (BM8; BioLegend), and CD169 (3D6.112; BioLegend) 
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for some experiments.  Data were acquired with 5-laser BD LSR-II or BD LSRFortessa flow 
cytometers, and analyzed using FlowJo (Tree Star, Ashland, OR).  Population gates were set 
based on isotype, single-stain, and fluorescence minus one controls. 
4.2.7 Evaluation of Humoral Immune Responses by ELISA 
Blood was collected from anesthetized mice at the time of sacrifice (typically 4 days post-
challenge) by cardiac puncture, and transferred to serum separator BD Microtainer® serum 
separator tube.  After centrifugation (15 min at 16,000 xg), supernatant serum was collected and 
frozen for subsequent assessment.  OVA-specific IgG1 and IgG2c levels in serum were 
determined by indirect ELISAs.  High-binding 96-well plates (Costar EIA/RIA; Corning Inc., 
Corning, NY) were incubated overnight at 4 °C with Grade V OVA (100 μg/mL in 0.5 M 
carbonate-bicarbonate buffer, pH 9.6; Sigma).  Plates were washed (3x) with 0.05% Tween20 in 
PBS, and blocked with 1% goat serum in PBS for 1 hour at 37 °C.  Serum samples and standards 
(anti-OVA IgG1 from Cayman Chemical, Ann Arbor, MI; anti-OVA IgG2c from Chondrex, 
Redmond, WA) were diluted with 1% goat serum, added to plates, and incubated 2 hours at 37 
°C.  After washing (3x), plates were incubated for 1 hour at 37 °C with biotinylated secondary 
antibodies (goat anti-mouse IgG1 or IgG2c, 1:20,000 in 1% goat serum; Jackson 
ImmunoResearch, West Grove, PA).  Plates were then washed (3x) and incubated for 30 min 
with streptavidin-HRP (1:1000 in 1% goat serum; BD Pharmingen).  Plates were washed (3x) 
again and incubated at room temperature with 4,4’,5,5’-tetramethylbenzidine (TMB) peroxidase 
substrate (Sigma) for 2-3 minutes, and the reaction quenched with 1.0 M H2SO4.  OVA-specific 
IgE was quantified via sandwich ELISA using rat anti-mouse IgE capture antibody (R35-72, 4 
μg/mL in PBS; BD Biosciences) and biotinylated-OVA (4 μg/mL in PBS + 1% BSA; Nanocs, 
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New York, NY) for detection.  Serum samples and standards (anti-OVA IgE, Cayman Chemical) 
were diluted in 1% BSA in PBS.  For all ELISAs, absorbance at 450 nm (OD450) was read with 
a SpectraMax 340PC plate reader (Molecular Devices, Sunnyvale, CA), and serum 
concentrations calculated using standard curves known dilutions.   
4.2.8 Murine Skin Microenvironment Evaluation After Treatment with Topical MC903 
or MNAs Containing MC903 and/or DNCB 
Ears of mice were treated epicutaneously with 5 μg MC903 dissolved in ethanol or intradermally 
with MNAs containing 5 μg MC903.  Ethanol and Blank MNAs served as vehicle controls.  
Some mice were treated with MNAs containing MC903 and/or DNCB.  After 6, 24, or 48 hours, 
ears tissue was homogenized at 4 °C in TRI-reagent (Molecular Research Center, Cincinnati, 
OH) using a Bullet Blender Storm 24 with stainless steel beads in Navy RINO tubes (Next 
Advance, Averill Park, NY).  Total RNA was extracted according to the TRI-reagent 
manufacturer’s protocol, and quantified using a DeNovix DS-11 spectrophotometer 
(Wilmington, DE).  For each reverse transcriptase assay, 2 μg RNA was converted to cDNA 
using a QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA).  Quantitative real-time 
PCR was then performed using VeriQuest Probe qPCR Mastermix (Affymetrix, Santa Clara, 
CA), according to the manufacturer’s instructions, with 5’ nuclease PrimeTime qPCR assays 
(Applied Biosystems, Thermo Scientific) specific for IL-10 (Mm01288386_m1), IL-18 
(Mm00434226_m1), TSLP (Mm01157588_m1), IL-1B (Mm00434228_m1), TNF 
(Mm00443258_m1), NLRP3 (Mm00840904_m1), and β-glucuronidase (GUSB, endogenous 
control, Mm01197698_m1).  Duplex reactions (FAM-labeled target gene primer and VIC-
labeled GUSB primer) were run and analyzed on a StepOnePlus Real-Time PCR System 
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(Applied Biosystems, Carlsbad, CA).  Relative fold changes in expression were calculated and 
normalized based on the 2-ΔΔCt method, with naïve ear skin as the untreated control. 
4.2.9 Human Skin Explant Cultures with MC903 MNA  
Normal skin from healthy donors undergoing breast reduction surgery was acquired through the 
Magee-Women’s Hospital Tissue Bank with institutional review board approval, and used 
according to University of Pittsburgh Medical Center guidelines.  Tissue was rinsed in 70% 
ethanol and PBS, and skin explants (~ 1 mm thick) harvested with a Silver’s miniature skin graft 
knife (Padgett, Integra Miltex, Plainsboro, NJ).  Explants were cut into 2x2 cm squares, washed 
with 70% ethanol and twice with PBS, and placed epidermis up on wetted sterile filter paper on a 
silicone backing.  Explants were covered with thin plastic wrap, and MNAs (4 per explant) were 
applied through the plastic wrap into the skin.  Plastic wrap prevents MNA tips from starting to 
dissolve before penetrating the damp skin tissue.  MNAs were removed after 5 minutes, and two 
explants with the same MNA treatment were placed epidermis up on steel mesh (1 mm pores) in 
100 mm petri dishes (Falcon, Corning) with AIM-V serum-free media (Gibco, Life 
Technologies) supplemented with antibiotic antimycotic solution (Sigma Aldrich).  This 
arrangement maintains an air-epidermal interface, while the dermis is in contact with media.  
After culture for 48 hours at 37 °C in 5% CO2, explants were removed, cut into thin strips, and 
flash frozen for subsequent RNA isolation.  Non-adherent cells that migrated out of explants into 
the media were collected for analysis by flow cytometry and counted with a hemocytometer.  
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4.2.10 Human Skin Microenvironment Evaluation by qRT-PCR Array 
Skin was homogenized at 4 °C in TRI-reagent (Molecular Research Center, Cincinnati, OH) 
using a Bullet Blender Storm 24 with stainless steel beads in Navy RINO tubes (Next Advance, 
Averill Park, NY).  Total RNA was extracted according to the TRI-reagent manufacturer’s 
protocol, and quantified using a DeNovix DS-11 spectrophotometer (Wilmington, DE).  RNA 
quality was assessed with the Agilent TapeStation 4200 at the University of Pittsburgh HSCRF 
Genomics Research Core (Agilent Technologies, Santa Clara, CA).  For each reverse 
transcription assay, 1 μg RNA was converted to cDNA using an RT2 First Strand Kit (Qiagen, 
Germantown, MD).  Quantitative real-time PCR was then performed using a Human 
Inflammatory Response & Autoimmunity RT2 Profiler PCR Array (Qiagen), RT2 SYBR Green 
ROX qPCR Mastermix (Qiagen), and StepOnePlus Real-Time PCR System (Applied 
Biosystems, Foster City, CA).  Thresholds were set consistently for all plates.  Threshold cycles 
(CT) for target genes (i) and three reference genes (ActB, GAPDH, and HPRT1) were used to 
calculate fold change (FC) in gene expression, relative to untreated (naïve) skin, for each patient 
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4.2.11 Human Skin Migratory Cell Phenotype Analysis by Flow Cytometry 
Migratory cells were blocked with Human BD Fc Block™ (BD Biosciences) for 20 min at 4 °C, 
and then stained with fluorescently labeled antibodies for CD11c (3.9, BD), HLA-DR (L243, 
BioLegend, San Diego, CA), CD1a (HI149, BD), CD14 (M5E2, BD), CD207 (10E2, 
BioLegend), and CD163 (GHI/61, BD).  Cells were then analyzed by flow cytometry (BD 
LSRFortessa, FlowJo software).  Population gates were set based on isotype, single-stain, and 
fluorescence minus one controls. 
4.2.12 Statistical Analyses  
Statistical analyses were performed with GraphPad Prism v6 (San Diego, CA).  Data from 
experiments with multiple treatment groups were analyzed by one-way ANOVA, followed by 
Tukey’s or Sidak’s post-hoc testing.  For experiments with only two groups, two-tailed 
independent t-tests (with Welch’s correction as needed) were used.  Data that were not normally 
distributed were compared using non-parametric tests (Mann-Whitney test, or Kruskal-Wallis 
test followed by Dunn’s multiple comparisons).  Ear thickness measurements from multiple time 
points were analyzed by two-way mixed ANOVA, followed by post-hoc testing of treatment 
effect with a Sidak or Tukey correction.  Data represent mean ± SD, except for ear thickness 
measurements, which are mean ± SEM. 
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4.3 RESULTS 
4.3.1 Characterization of dissolvable tip-loaded MNAs  
The geometry of dissolvable MNAs was characterized by optical microscopy (Figure 4-2A-D). 
Each MNA consists of a 10x10 array of obelisk-shaped microneedles with sharp edges and tips 
and fillets at the base (Figure 4-2A-B), and detailed dimensions are provided in Figure 4-1.  All 
MNAs were tip-loaded with OVA and/or MC903, and use of Alexa Fluor 647-labeled OVA 
allowed protein in the microneedle to be visualized (Figure 4-2C).  The dark blue microneedle 
tip indicates the region containing most of the OVA, while the pale blue color toward the base of 
the pyramidal tip and top of the stem is consistent with less concentrated OVA (Figure 4-2C).  
MNAs were also examined before and after application to murine abdominal skin or human skin 
explants to confirm that the tip-loaded cargo had been deposited.  (Figure 4-2D-F).  Though a 
larger portion of microneedle stems remain after application to murine skin (Figure 4-2E), 
compared to human skin (Figure 4-2F), it appears that the tips, which contain most of the 
therapeutic payload (depicted in Figure 4-2C), have dissolved in both cases.  
In addition to geometry, endotoxin levels in various MNA formulations were measured 
since endotoxin is known to promote innate immune responses that can enhance sensitization 
and drive Th1-mediated hypersensitivity [204-206].  Total endotoxin content of Blank MNAs, or 
MNAs containing 100 μg of grade V OVA with endotoxin (OVAETX) or EndoGrade OVA 
(OVA), were quantified by chromogenic LAL assay.  Average endotoxin levels for Blank and 
OVA MNAs were less than 1 EU / MNA (Figure 4-3G).  As expected, OVAETX MNA contained 
substantially more endotoxin (65 ± 6 EU, Figure 4-3G).  These results suggest that minimal 
endotoxin is present in the bulk components of the MNAs (CMC and trehalose), or introduced by 
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Figure 4-2. MNA characterization.  (A) Optical microscopy image of a whole MNA, taken at low magnification 
with a dissecting microscope.  (B) High magnification image of a single microneedle from the MNA.  (C) Single 
microneedle from an MNA that was tip-loaded with 100 μg Alexa Fluor 647-labeled OVA (blue).  (D-E) MNAs 
before application (D) and after application to mouse abdominal skin (E), or a human skin explant (F).  (G) Total 
endotoxin content in MNAs, as determined by chromogenic LAL assay.  Bars are mean ± SD.  Each dot represents a 
single MNA, and different shapes within a given formulation indicate MNAs from distinct batches. 
4.3.2 Delayed-type hypersensitivity (DTH) responses to different OVA MNA formulations  
To characterize baseline responses to OVA sensitization and challenge with different OVA 
MNA formulations, ear thickness was measured before and after application of different MNAs 
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to ears of naïve or previously sensitized mice.  Application of Blank MNAs causes some ear 
swelling, which peaks within 24 hours and then decreases (Figure 4-3A).  To control for this 
antigen-independent tissue trauma response, measurements of DTH responses are presented as 
differences in thickness of ears treated with OVA MNA and contralateral ears treated with Blank 
MNA.  In naïve, unsensitized mice, OVAETX MNAs cause modest but significant increases in ear 
thickness at 1-2 days post-application, relative to Blank MNA (Figure 4-3B).  This may be due to 
an enhanced innate immune response to endotoxin in these MNAs, as OVA MNAs do not cause 
enhanced swelling beyond that attributed to Blank MNAs (Figure 4-3B).  Notably, mice 
sensitized with OVAETX MNA develop strong DTH responses to subsequent challenge with 
OVAETX MNA or OVA MNA, which peak around 2 days and last for at least 4 days (Figure 
4-3C).  Interestingly, mice sensitized with OVA MNA do not develop a strong ear-swelling 
response to challenge with OVA MNA, but do exhibit strong DTH responses to OVAETX MNA 
challenge (Figure 4-3C).  This suggests OVA MNA sensitize mice, but not to the same extent 
that OVAETX MNA do.  Based on these preliminary findings, subsequent tolerance induction and 
DTH suppression experiments involved mice that were sensitized and challenged with OVAETX 
MNA, the combination that yields the strongest DTH responses. 
 
Figure 4-3. Ear swelling responses to Blank, OVA, or OVAETX MNA in unsensitized and sensitized mice.  (A) 
Ear swelling response to Blank MNA application, presented as absolute ear thickness (N = 70).  (B) Ear swelling 
response to OVAETX or OVA MNA in unsensitized mice (N = 5).  Data represent differences in thickness between 
OVA MNA treated ears and contralateral Blank MNA treated ears.  Significantly ear swelling caused by OVA 
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MNAs, relative to Blank MNAs, is indicated by # p < 0.05 (one-sample t-tests).  (C) Ear swelling response to OVA 
challenge in previously sensitized mice (N = 5).  Mice were sensitized at the abdomen and challenged five days later 
at the right ear with the indicated OVA MNAs.  Significant differences relative to OVAETX sensitized and 
challenged mice are indicated by * p < 0.05 (two-way mixed ANOVA followed by Dunnett’s multiple 
comparisons).  
 
 To characterize cutaneous cellular infiltrates associated with the DTH response to OVA-
challenge, mice were sensitized with OVAETX MNA at the abdomen and then challenged with 
OVAETX MNA or Blank MNA at the ears 5 days later.  As expected, ear skin histology from 48 
and 96 hours post-challenge revealed substantial cellular infiltrates and edema in OVA-
challenged ears, compared to ears treated with Blank MNA (Figure 4-4A).  Consistent with ear 
thickness measurements (Figure 4-3C), OVA-challenged ears exhibited greater edema and 
overall thickness 48 hours post-challenge, compared to 96 hours post-challenge (Figure 4-4A).  
In order to characterize the composition of leukocytes infiltrating the skin, ear tissue from 48 or 
96 hours post-challenge was also enzymatically digested and the resulting cell suspensions 
analyzed by flow cytometry.  OVA-challenged ears contained 2-3 times more leukocytes (live 
CD45+ cells) than ears treated with Blank MNAs at both time points, and there were slightly, 
though not significantly, fewer total infiltrating cells 96 hours post-challenge (Figure 4-4B).  
Ly6G+ neutrophils (also CD11b+ I-Ab-) comprised approximately 40 percent of total leukocytes 
in both OVAETX and Blank MNA-treated skin 48 hours post-challenge, but only 18 percent or 6 
percent of total leukocytes in OVAETX and Blank MNA-treated skin at 96 hours (Figure 4-4B).  
F4/80+ cells, which include monocytes, macrophages, and eosinophils, comprised approximately 
35-40 percent of total leukocytes at 48 and 96 hours post-challenge with both types of MNAs 
(Figure 4-4B).  Compared to Blank MNAs, OVAETX MNAs induced greater infiltration of 
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monocytes and/or eosinophils (F4/80+ I-Ab- CD169-) and inflammatory macrophages (F4/80+ I-
Ab+ CD169-) 96 hours post-challenge, while tissue-resident dermal CD169+ macrophages 
(F4/80+ I-Ab+ CD169+ [207]) were found at similar levels in both OVAETX and Blank MNA-
treated skin (Figure 4-4C).  Finally, CD4+ and CD8+ T cells comprised a small percentage of 
total leukocytes, but T cells in the skin increased significantly over time in OVA-challenged, but 
not Blank MNA-treated, skin.  There were also more CD4+ T cells than CD8+ T cells at both 
time points (Figure 4-4B).   
 
Figure 4-4. Characterization of infiltrating leukocyte populations in skin following OVA challenge in 
sensitized, untolerized mice. (A) Representative ear skin histology (H & E) from 48 or 96 hours post-challenge.  
Mice were sensitized at the abdomen 5 days prior to challenge with OVAETX MNA or Blank MNA.  Scale bars are 
100 μm.  (B) Leukocytes in ear skin tissue were quantified by flow cytometry 48 or 96 hours post-challenge with 
OVAETX MNA (black) or Blank MNA (grey).  Data represent percent of total skin cells, and all cells in the indicated 
populations were live, as determined by viability staining (mean ± SD, N = 5 ears).  (C) Ears from 96 hours post-
challenge, analyzed individually in (B), were pooled and stained for additional markers: CD11b, MHC-II (I-Ab), and 
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CD169.  All F4/80+ cells were CD11bhi and were divided into three populations based on expression of I-Ab and 
CD169. 
4.3.3 Local and systemic T-cell responses to different OVA MNA formulations  
In addition to characterizing DTH responses to sensitization and challenge, we evaluated local 
and systemic T-cell responses to different OVA MNA formulations.  One day after adoptive 
transfer of OT-I and OT-II cells to expand the initial pool of OVA-specific T cells, different 
MNA formulations were applied to ears of mice.  T-cell responses were measured four days later 
by flow cytometry on lymphocytes from local skin draining lymph nodes (DLN) and 
splenocytes.  OVAETX MNAs substantially expanded CD4+ T-bet+ Th1 and CD8+ T-bet+ Tc1 
populations both locally (in DLN) and systemically (in spleen), relative to treatment with Blank 
MNA (Figure 4-5).  OVA MNA and OVAETX MNA enhanced Th1 populations locally and 
systemically to a similar extent, but OVA MNA only expanded Tc1 populations half as much as 
OVAETX MNA did (Figure 4-5).  Notably, OVA + MC903 MNAs did not significantly expand 
Th1 or Tc1 populations locally or systemically, compared to Blank MNAs (Figure 4-5). Mice 
treated with OVA ± MC903 MNAs, but not OVAETX MNAs, had greater frequencies of CD4+ 
FoxP3+ Tregs in local DLN, but not systemically; however, mice treated with each of OVA-
containing MNA formulations had reduced Treg frequencies among splenocytes, relative to 
Blank MNA-treated mice (Figure 4-5).  Finally, mice treated with class II MHC-restricted 
OVA323-339 peptide ± MC903 MNAs exhibited no increase in Tc1 populations, relative to Blank 




Figure 4-5. Local and systemic T-cell responses to MNAs in unsensitized mice.  To enhance the pool of naïve 
OVA-specific T cells, OT-I and OT-II T cells (5x106 of each) were adoptively transferred to wild-type mice one day 
prior to application of the indicated MNAs to each ear.  Ear skin DLN and spleens were isolated four days later, and 
T-cell subsets analyzed by flow cytometry.  (A) Frequencies of Treg, Th1, and Tc1 cells in DLN.  (B) Frequencies 
of Treg, Th1, and Tc1 in spleen.  Data represent mean ± SD (N = 4-5), and significant differences (p < 0.05) are 
indicated by different letters (ANOVA followed by Tukey’s multiple comparisons).  
4.3.4 Prophylactic tolerization with OVA + MC903 MNAs inhibits subsequent OVA 
sensitization 
To determine whether OVA + MC903 MNAs could generate tolerance to OVA and prevent 
subsequent sensitization, mice were treated (tolerized) with MNAs containing OVA and/or 
MC903 prior to sensitization and challenge with OVAETX MNAs (see experimental timeline in 
Figure 4-6A).  Tolerization with OVA + MC903 MNAs inhibited DTH responses to OVA 
challenge, relative to untolerized mice, with significantly reduced ear swelling from 1-4 days 
post-challenge (Figure 4-6B).  Interestingly, tolerization with OVA MNA did not affect early 
 118 
DTH responses (1 day post-challenge), but did reduce ear swelling 2-4 days post-challenge, 
relative to untolerized controls, though to a lesser extent than OVA + MC903 MNA treatment 
(Figure 4-6B).  Finally, pre-treatment with MC903 MNAs had only a modest reduction on ear 
swelling at 4 days post-challenge, relative to untolerized mice (Figure 4-6B). 
 Ear thickness measurements were corroborated by histology 4 days post-challenge, which 
qualitatively revealed substantially greater edema and cellular infiltrates in skin from untolerized 
mice, compared to OVA+MC903 tolerized mice (Figure 4-6C).  Cellular infiltrates were 
quantified by flow cytometry analysis of enzymatically digested ear tissue 4 days post-challenge.  
The frequency of total infiltrating leukocytes (live CD45+ cells) in OVA-challenged ear skin was 
approximately three times less in skin tissue from OVA + MC903 treated mice, compared to 
untolerized mice (Figure 4-6D).  Consistent with ear thickness measurements at 4 days post-
challenge, infiltrating leukocytes in ear skin from OVA, but not MC903, tolerized mice were 
also substantially reduced, relative to untolerized mice (Figure 4-6D).  Collectively, these results 
demonstrate that prophylactic treatment of naïve mice with OVA + MC903 MNA can prevent 
subsequent OVA sensitization and DTH responses.   
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Figure 4-6. Prophylactic tolerization with OVA + MC903 MNAs prevents OVA sensitization, inhibiting DTH 
responses to subsequent OVA challenge. (A) Experimental timeline.  Untolerized mice were not treated before 
sensitization.  (B) Ear swelling after OVA challenge, presented as the difference in thickness between OVAETX 
MNA treated ears and contralateral Blank MNA treated ears (mean ± SEM).  Significant differences relative to 
untolerized mice are indicated by * p < 0.05.  Significant differences between OVA ± MC903 tolerized groups are 
indicated by # p < 0.05 (two-way mixed ANOVA followed by Tukey’s multiple comparisons).  (C) Representative 
ear skin histology (H & E staining) from 4 days post-challenge with OVAETX MNA.  Scale bars are 100 μm.  (D) 
Representative flow cytometry plots of total cells from ear skin harvested 4 days post-challenge with OVAETX 
MNA.  Gates indicate total infiltrating leukocytes (live CD45+ cells).  (E) Frequency of infiltrating leukocytes (as in 
D) for all treatment groups.  Each dot represents OVA-challenged ears pooled from 3-5 mice. 
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4.3.5 Prophylactic tolerization alters cellular and humoral immune responses 
To determine whether prophylactic tolerization altered overall T-cell responses, frequencies of 
T-cell subsets in ear skin draining lymph nodes (DLN) were measured 4 days post-challenge by
flow cytometry.  Compared to untolerized mice, only tolerization with OVA + MC903 MNAs 
significantly increased the prevalence of CD4+ FoxP3+ Tregs and reduced CD8+ T-bet+ Tc1 
populations in the DLN (Figure 4-7).  Treatment with OVA ± MC903 MNAs led to diminished 
CD4+ T-bet+ Th1 populations and enhanced CD4+ GATA-3+ Th2 populations, contributing to 
significantly reduced Th1:Th2 ratios (Figure 4-7).  In contrast, MC903 MNAs had no detectable   
Figure 4-7. Prophylactic tolerization with OVA + MC903 MNAs shifts Th1 / Th2 and Treg / Teff ratios in 
DLN.  T-cell subsets in ear skin DLN were identified and quantified by flow cytometry 4 days post-challenge.  
Frequencies of Treg, Th1, Th2, and Tc1 cells are presented as the percent of total lymphocytes (mean ± SD; N = 9-
14 for Treg, Th1, and Tc1; N = 5-9 for Th2).  Mice were tolerized, sensitized, and challenged with MNAs according 
to the experimental timeline in Figure 4-6A.  Significant differences, relative to untolerized mice, are indicated by 
* p < 0.05 (ANOVA followed by Dunnett’s multiple comparisons).
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effect on T-cell populations, relative to untolerized mice (Figure 4-7).  Finally, concomitant 
changes in Treg, Th1, and Tc1 populations with OVA + MC903 MNA pre-treatment 
significantly increased the ratio of Tregs to type 1 effector T cells (Teff; Th1 and Tc1), which 
was not observed with other prophylactic treatments (Figure 4-7). 
 To evaluate the effects of prophylactic tolerization on humoral immunity, serum levels of 
OVA-specific Th1-associated (IgG2c) and Th2-associated (IgG1 and IgE) antibodies were 
measured by ELISAs.  Sensitization and challenge with OVAETX MNAs induced significant 
production of OVA-specific IgG1 and IgG2c (untolerized, Figure 4-8).  In contrast, serum from 
mice treated only with OVA + MC903 MNAs contained elevated levels of OVA-specific IgG1, 
but not IgG2c (Figure 4-8).  Tolerization with OVA ± MC903 MNAs prior to sensitization and 
challenge also led to significantly greater OVA-specific IgG1 serum levels post-challenge; 
however, no change in OVA-specific IgG2c production was detected (Figure 4-8).  Though pre-
treatment with MC903 MNAs had no influence on OVA-specific IgG1 levels, IgG2c serum 
concentrations were significantly greater post-challenge than in untolerized mice (Figure 4-8).  
This unexpected increase in IgG2c production was also observed in mice treated with OVAp + 
MC903 MNAs prior to sensitization (data not shown).  Interestingly, despite increasing Th2-
associated IgG1 levels, OVA ± MC903 MNA treatments did not enhance OVA-specific IgE 




Figure 4-8. Prophylactic tolerization alters humoral immune response to OVA.  Serum concentrations of OVA-
specific IgG1, IgG2c, and IgE (bars are geometric means).  Black circles represent mice from which serum was 
collected 4 days post-challenge, according to the experimental timeline in Figure 4-6A.  Grey circles represent mice 
that were not sensitized or challenged, and serum was collected 3 days after application of the third OVA + MC903 
MNA.  Open circles indicate levels below the detection limit (1.5 ng/mL for IgE).  Significant differences are 
indicated by * p < 0.05 (Kruskal-Wallis test followed by Dunn’s multiple comparisons to untolerized mice; 
independent t-test with Welch’s correction for naïve vs. OVA + MC903).  
4.3.6 Tolerization of previously sensitized mice suppresses subsequent DTH responses 
and alters cellular and humoral immune responses 
To determine whether allergen tolerance could be established in previously sensitized 
individuals, mice were sensitized with OVAETX MNAs twice prior to tolerization with OVA + 
MC903 MNAs (Figure 4-9A).  As with prophylactic tolerization, OVA + MC903 MNA 
treatment after sensitization inhibited DTH responses to a subsequent OVA challenge, as 
indicated by a significant reduction in ear swelling, relative to untolerized mice (Figure 4-9B).  
Reduced ear swelling in tolerized mice was supported by histological evaluation of ear tissue, 
which revealed substantially fewer cellular infiltrates and less dermal edema than in ears from 
untolerized mice (Figure 4-9C).   
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Figure 4-9. Tolerization of previously sensitized mice with OVA + MC903 MNAs suppresses subsequent DTH 
response.  (A) Experimental timeline.  Untolerized mice received no treatment between sensitization and challenge.  
(B) Ear swelling after OVA challenge, presented as the difference in thickness between OVAETX MNA treated ears 
and contralateral Blank MNA treated ears (N = 7).  (C) Representative ear skin histology (H & E staining) from 4 
days post-challenge. Scale bars are 100 μm.  Significant differences are indicated by * p < 0.05 (two-way mixed 
ANOVA followed by Sidak’s multiple comparisons). 
 
 As with prophylactic tolerization, OVA + MC903 MNA treatment after sensitization 
altered cellular and humoral immune responses.  Specifically, the frequency of CD4+ FoxP3+ 
Tregs in skin DLN after OVA challenge was significantly enhanced by tolerization; however, no 
differences in Th1 or Tc1 populations were detected in DLN or spleens (Figure 4-10A).  Though 
Th2 populations were not quantified in this experiment, OVA + MC903 tolerization did augment 
serum concentrations of OVA-specific Th2-type IgG1, but not IgE (Figure 4-10B).  Finally, as 
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with prophylactic tolerization, treatment of previously sensitized mice did not affect OVA-
specific Th1-type IgG2c levels (Figure 4-10B). 
 
Figure 4-10. Tolerization of previously sensitized mice with OVA + MC903 MNA influences cellular and 
humoral immune responses.  (A) Frequencies of T-cell subsets in skin DLN and spleen 4 days post-challenge, 
according to experimental timeline in Figure 4-9A.  Data are percent of total lymphocytes or splenocytes (mean ± 
SD, N = 7).  (B) Serum concentrations of OVA-specific IgG1, IgG2c, and IgE 4 days post-challenge (bars are 
geometric means).  Significant differences are indicated by * p < 0.05 (independent t-test with Welch’s correction as 
needed). 
4.3.7 MC903 applied topically or with MNAs alters the murine skin microenvironment 
To determine the influence of MC903 MNA on the murine skin microenvironment (for 
comparison to human skin responses), MC903 (5 μg) or Blank MNAs were applied to ears of 
naïve mice, and RNA was isolated from ear skin 24-48 hours later and analyzed by qRT-PCR.  
Consistent with results from human skin explants (Figure 4-13), cutaneous IL-10 expression was 
significantly enhanced and IL-18 expression significantly reduced by MC903 MNA (Figure 
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4-11A).  To determine the impact of MC903 delivery route on cutaneous cytokine responses, 
ears of naïve mice were treated with 5 μg MC903 either applied epicutaneously in ethanol, or 
intradermally via MNA.  Ethanol and Blank MNA served as vehicle controls.  We hypothesized 
that topical application of MC903 would have a greater effect on cytokines produced exclusively 
by epidermal keratinocytes (e.g. thymic stromal lymphopoietin, TSLP).  In contrast, MNAs that 
provide deeper delivery of MC903 to the dermal layer would have a greater effect on expression 
of cytokines also produced by immune cells in the dermis (e.g. IL-10) [208].  As expected, 
topical MC903 increased expression of TSLP significantly more than MC903 MNA did, while 
MC903 MNA enhanced IL-10 expression to a greater extent than topical MC903 (Figure 4-11B). 
 
Figure 4-11. Cutaneous cytokine expression in murine skin is altered by MC903 MNA and differentially 
regulated by epicutaneously applied MC903.  (A) MC903 (5 μg) MNA were applied to ears of naïve mice, and 
cytokine expression was quantified in ear tissue 24-48 hours later by qRT-PCR.  (B) MC903 (5 μg) was applied to 
ears of mice epicutaneously (dissolved in ethanol) or intradermally via MNA.  Cytokine expression was quantified 
in ear tissue 48 hours later by qRT-PCR.  Data represent mean ± SD fold change in expression (RQ = 2-ΔΔCt) relative 
to naïve tissue (N ≥ 4 for controls; N = 8 for MC903 treatments).  Significant differences indicated by * p < 0.05 
(ANOVA followed by Tukey’s multiple comparisons). 
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4.3.8 Co-delivery of allergen and MC903 via MNA inhibits allergen-induced expression of 
pro-inflammatory mediators in murine skin 
To evaluate the capacity for MC903 to counteract pro-inflammatory innate responses to contact 
allergens, MNAs were loaded with a model chemical allergen (DNCB) with or without MC903.  
DNCB ± MC903 MNAs were applied to ears of mice, and cutaneous expression of innate pro-
inflammatory mediators measured 6 and 24 hours post-application by qRT-PCR.  Co-delivery of 
DNCB with MC903 via MNA significantly inhibited expression of DNCB-induced pro-
inflammatory cytokines IL1B and TNF, as well as the NLRP3 inflammasome (Figure 4-12).  
Interestingly, although IL18 expression was reduced by MC903 MNA treatment (± DNCB), 
DNCB MNA did not enhance IL18 mRNA expression as expected.  Collectively, these results 
suggest that MC903 may block sensitization-promoting innate responses to chemical allergens.  
 
Figure 4-12. Co-delivery of allergen plus MC903 in MNAs inhibits innate response to allergen in murine skin. 
The indicated MNA formulations were applied to ears of naïve C57BL/6 mice, and was RNA isolated from ear 
tissue (A) 6 hours or (B) 24 hours later.  Cytokine expression was quantified by qRT-PCR, and data represent mean 
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± SD expression relative to naïve tissue (RQ = 2-ΔΔCt)  (N = 4-6 mice per group).  Significant differences indicated 
by * p < 0.05 (ANOVA followed by Sidak’s comparison of DNCB vs. DNCB + MC903). 
4.3.9 MC903 MNA alter human skin microenvironment 
To evaluate effects of MC903 MNAs on the human skin microenvironment, human skin explants 
were treated with MC903 MNAs (1 μg or 5 μg MC903 per MNA).  Controls included untreated 
skin and skin treated with Blank MNAs.  Explants were cultured for 48 hours, and then the skin 
microenvironment was assessed using qRT-PCR arrays.  Blank and MC903 MNAs consistently 
increased cutaneous expression of several CXC chemokines (CXCL1, 2, 3, 5, 6, 8, and 10), as 
well as IL-6, PTGS2 (COX-2), and some CC chemokines (CCL3 and CCL5) (Figure 4-13).  
MNAs also consistently decreased expression of CCL13, CCL2, and CCR3, relative to untreated 
skin (Figure 4-13).  MC903 MNAs further enhanced expression of several CXC chemokines, 
and further reduced expression of CCL13 (Figure 4-13).  Additionally, MC903 MNAs alone 
consistently upregulated expression of CD14, IL-10, IL-1RN, and FOS, and downregulated 






Figure 4-13. MC903 MNAs alter expression of inflammatory immune response genes in human skin explants.  
After 48 hours, RNA was isolated from human skin explants and expression of 84 genes (cytokines, chemokines, 
cytokine/chemokine receptors, pattern recognition receptors, and downstream signaling proteins) assayed by qRT-
PCR.  (A) Histology (H&E) of untreated human skin explant after 48 hours (100 μm scale bar).  (B) Heat map of 
average relative gene expression for skin explants treated with the indicated MNAs.  Red indicates increased 
expression and blue indicates decreased expression relative to untreated skin.  (C) Relative expression (as in B) 
showing variability among individual tissue donors.  Data represent average log2 fold changes in gene expression (N 
= 3, SD error bars) for each MNA treatment, relative to untreated skin.  Dotted lines correspond to two-fold changes 
in mRNA expression.  
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4.3.10 MC903 MNAs enhance migration of CD14+ dermal DCs from human skin 
In addition to evaluating effects of MC903 MNAs on the skin microenvironment, DCs migrating 
out of human skin explants in response to MNA application were analyzed by flow cytometry 48 
hours post-application.  Total migratory DCs in culture media were identified as SSCint/hi HLA-
DR+ CD11clo/hi (Figure 4-14A), and three subsets of skin migratory DCs were identified based 
on differential expression of CD1a, CD14, and CD207 (Langerin): epidermal Langerhans cells 
(LCs; CD1ahi CD14- CD207+), CD1a+ dermal DCs (CD1aint CD14- CD207-), and CD14+ dermal 
DCs (CD1alo/int CD14+ CD207-) (Figure 4-14B-C).  While MNAs did not significantly affect 
total numbers of migrating DCs, low and high dose MC903 MNAs selectively enhanced 
migration of CD14+ DDCs, and reduced migration of CD1a+ DDCs (Figure 4-14B, E).  Finally, 
approximately 25% of CD14+ migratory cells were CD163+ (Figure 4-14D), indicating the 
“CD14+ dermal DCs” are actually a heterogeneous population, including some M2 macrophage-




Figure 4-14. MC903 MNAs enhance migration of CD14+ dermal DCs (DDC) from human skin explants. (A) 
Flow cytometry gating strategy for skin migratory DCs (SSCint/high HLA-DR+ CD11c+/-).  Cells migrating out of 
human skin explants were obtained from media after 48 hours of culture.  (B) Migratory DCs were divided into 
three populations based on expression of CD1a and CD14: CD1ahigh CD14= Langerhans cells (LC, P1), CD1aint 
CD14- DCs (CD1a+ dermal DC, P2), and CD1aint/- CD14+ DCs (CD14+ dermal DC, P3).  (C) Selective expression of 
CD207 (Langerin) by CD1ahigh cells (P1).  (D) Expression of the scavenger receptor CD163, a monocyte- and 
macrophage-restricted marker [210, 211], by CD14+ cells (P3).  (E) Total migratory cells per 8 cm2 skin explant, and 
changes in % LC (P1), CD1a+ dermal DC (P2), and CD14+ dermal DC (P3) cells, relative to naïve untreated skin.  
Different symbols denote skin migratory DCs from three distinct patient samples.  Significant changes in 
frequencies of skin migratory DC populations are indicated by * p < 0.05 (one sample t-test). 
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4.4 DISCUSSION 
Though MNAs have been widely used for vaccination against pathogens (reviewed in [212-
214]), there are very few reports of MNAs being used to treat inflammation or induce immune 
tolerance [203, 215], and we are unaware of any that describe co-delivery of immunoregulatory 
agent(s) and antigens.  In the current study, dissolvable MNAs were used to induce allergen-
specific tolerance by co-delivering allergen (OVA or DNCB) with vitamin D3 analog (MC903) 
to the skin microenvironment.  In experiments with mice, treatment with OVA + MC903 MNA 
induced fewer Tc1 cells and suppressed expansion of Th1 populations both locally (skin DLN) 
and systemically (spleen), relative to treatments with OVAETX MNA or OVA MNA (Figure 4-5).  
This finding is consistent with a previous report that transcutaneous immunization through 
MC903-treated skin inhibits priming of Tc1 responses [86].  OVAETX MNA used for 
sensitization also yielded larger Tc1 populations than OVA MNA (Figure 4-5), likely due to 
adjuvant effects of endotoxin in OVAETX MNA (Figure 4-3G) [184, 185, 206].  In contrast to a 
previous report [86], however, OVA + MC903 MNA did not significantly increase Treg 
frequencies, relative to OVAETX MNA, in unsensitized mice (Figure 4-5).  Future experiments 
will be needed to determine whether this lack of OVA-specific Treg expansion is due to intrinsic 
properties of TCR-transgenic OT-II Rag2-/- T cells, compared to OT-II Rag2+/+ T cells used 
previously [86] or wild-type CD4+ T cells, subsets of which could be identified as OVA-specific 
by MHC-II tetramer staining.  Future studies will also investigate expansion of suppressive 
FoxP3- IL-10+ CD49b+ LAG-3+ Tr1 populations [16], which are reported to be induced by 
vitamin D3-treated dermal DCs, in contrast to FoxP3+ Tregs, which are induced by vitamin D3-
treated epidermal LCs [95].  As MNAs provide deeper delivery of MC903 and antigen, we may 
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expect to see greater expansion of Tr1 populations than with epicutaneous application of antigen 
and MC903.  
 Delayed-type hypersensitivity (DTH) responses to OVAETX MNA challenge in sensitized 
mice were characterized by considerable edema at 48 hours (Figure 4-4A) and prolonged 
infiltration of leukocytes observed 48 and 96 hours post-challenge (Figure 4-4).  This cellular 
response was characterized by a sustained influx of inflammatory monocytes, macrophages, and 
possibly eosinophils (Figure 4-4B-C), an early influx of neutrophils that decreased with time 
(Figure 4-4B), and an influx of CD4+ and CD8+ T cells that increased with time (Figure 4-4B) 
and included more CD4+ T cells, as expected for a response to extracellular protein antigen.  
Notably, prophylactic tolerization of naïve mice with OVA + MC903 MNA inhibited later 
sensitization with OVAETX MNA, as indicated by reduced DTH responses to subsequent OVA 
challenge (Figure 4-6).  In fact, ear swelling in tolerized mice 24-48 hours post-challenge (Figure 
4-6B) was reduced to levels seen in unsensitized mice (Figure 4-3B), suggesting that tolerization 
substantially inhibited the adaptive immune response.  Although pre-treatment with OVA MNA 
led to faster resolution of DTH responses, compared to sensitized, untolerized mice, it failed to 
prevent the early phase ear swelling response at 24 hours (Figure 4-6B).  Pre-treatment with 
MC903 MNA alone had minimal effect on OVA-specific DTH responses (Figure 4-6B), 
indicating that inhibition of OVA-sensitization by OVA + MC903 MNA is not merely a result of 
non-specific systemic immunosuppression by MC903.  The reduced ear swelling response in 
OVA + MC903 tolerized mice was supported by histology and flow cytometry on skin at 96 
hours, which both revealed substantial reductions in inflammatory infiltrates, compared to 
sensitized, untolerized controls (Figure 4-6C-D).  Future experiments will be needed to 
characterize the specific inflammatory infiltrates at earlier time points in tolerized mice.  
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 The therapeutic effects of prophylactic treatment with OVA + MC903 MNAs can be 
attributed to changes in cellular and humoral immune responses.  Specifically, OVA ± MC903 
MNAs reduced Th1 populations and enhanced Th2 populations, while OVA + MC903 MNA 
also reduced Tc1 populations and expanded Treg populations (measured post-challenge; Figure 
4-7).  Th2-skewing was also confirmed by analysis of humoral responses, which revealed higher 
serum levels of OVA-specific IgG1 in mice pre-treated with OVA ± MC903 MNA (Figure 4-8).  
In contrast, Th1-associated OVA-specific IgG2c levels were not affected by OVA ± MC903 
MNA, though elevated levels were unexpectedly observed in mice pre-treated with MC903 
MNA (Figure 4-8) or OVAp + MC903 MNA (data not shown).  Importantly, the Th2-biased 
humoral responses were not accompanied by increases in OVA-specific IgE, a second Th2-
associated isotype involved in type I hypersensitivities.  While Th2-associated cytokines (IL-4 
and IL-13) typically cause B cells to produce both IgG1 and IgE, the lack of IgE production is 
consistent with a prior report that intradermal injection of antigens promotes IgG1 production but 
diminishes IgE production [216].  These findings and literature precedent favor the use of MNAs 
for tolerance introduction, as IgE production and increased risk of type I hypersensitivity is more 
likely to be associated with epicutaneous introduction of protein antigens [216].  Ultimately, 
Th2-biasing by OVA ± MC903 MNA pre-treatment appears to contribute to faster resolution of 
DTH responses (Figure 4-6B), while OVA + MC903 MNA treatment also inhibits the early 
phase of the DTH response (Figure 4-6B), likely via enhanced Treg populations and further 
reduced Th1 and Tc1 populations (Figure 4-7).  Such conclusions are supported by prior reports 
that adoptive transfer of OVA-specific Th1, but not Th2, cells results in strong DTH responses to 
OVA challenge [217].  Furthermore, as Tregs can inhibit neutrophil survival, production of 
inflammatory mediators [218], and recruitment to the skin (by blocking CXCL1/2 expression 
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[23]), Treg populations enhanced by OVA + MC903 MNA pre-treatment may be suppressing the 
early influx of pro-inflammatory neutrophils (Figure 4-4B), which are essential for elicitation of 
DTH responses [219].  
In addition to preventing sensitization by prophylactic treatment with OVA + MC903 
MNA, tolerization of previously sensitized mice was capable of suppressing DTH responses to 
subsequent allergen challenge (Figure 4-9).  As with the prophylactic tolerization schedule, we 
observed both Th2-skewing, as indicated by an increase in serum anti-OVA IgG1 (Figure 
4-10B), and a significant increase in Treg frequency in skin DLN post-challenge (Figure 4-10A); 
however, there were no discernable differences in Th1 or Tc1 populations with OVA + MC903 
MNA treatment (Figure 4-10A).  Since total polyclonal T cell populations may mask changes in 
antigen-specific T cell subsets, future studies may use peptide-MHC tetramer staining to identify 
OVA-specific T cell populations.  Therapeutic tolerization, or hyposensitization, represents a 
more clinically relevant approach for individuals with pre-existing allergies, whereas 
prophylactic tolerization may be more suitable for strong sensitizing allergens that most people 
become allergic to upon contact (e.g. poison ivy), or for people with anticipated exposure to 
common occupational contact allergens (e.g. hairdressers exposed to p-phenylenediamine in hair 
dyes, or construction workers exposed to chromium in cement [220]).  Notably, while previous 
studies have shown that sensitization is inhibited by epicutaneous exposure to allergen through 
UVB- or MC903-treated skin [81, 82, 84, 86], our results indicate that Allergen + MC903 MNAs 
can both prevent subsequent sensitization (at a different site) and tolerize previously sensitized 
mice. 
Given the prophylactic and therapeutic effects of MC903 MNA in murine models of 
ACD, we investigated their effects on the skin microenvironment.  MC903 MNA promoted a 
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more tolerogenic microenvironment for allergen introduction in murine skin by enhancing 
expression of anti-inflammatory IL10 and reducing expression of pro-inflammatory IL18 (Figure 
4-11).  Notably, co-delivery of DNCB and MC903 with MNAs inhibited expression of allergen-
induced pro-inflammatory cytokines IL1B and TNF, as well as the NLRP3 inflammasome 
(Figure 4-12) [44].  While IL18 mRNA expression was reduced in DNCB + MC903 MNA-
treated skin, relative to naïve skin, DNCB MNA did not enhance IL18 expression (Figure 4-12), 
as was previously reported with topical application of contact allergens to skin of Balb/c mice 
[221].  However, DNCB MNA may still enhance secretion of active IL-18 in skin of C57BL/6 
mice by increasing post-translational procession of pro-IL-18 by the inflammasome [44].  
Accordingly, future measurements of IL-18 protein in skin after DNCB MNA application would 
be of interest.   
Experiments with human skin explants allowed us to extend these promising results in 
murine models to a human preclinical model.  Quantitative analysis of RNA isolated from 
human skin explants after application of Blank MNAs or MC903 MNAs revealed both MNA-
mediated effects (due to microtrauma from application) and MC903-mediated effects on human 
skin microenvironment.  In particular, MNA application induced expression of several neutrophil 
recruiting CXC chemokines (especially CXCL3/5 Figure 4-13), which correlates with the early 
influx of neutrophils seen in murine skin 48 hours after application of Blank MNAs (Figure 
4-4B).  MC903 MNAs increased expression of several anti-inflammatory molecules (e.g. IL10, 
IL1RN, FOS) and reduced expression of pro-inflammatory factors (e.g. CCL13, CCR2, TLR7, 
IL18, IL22) (Figure 4-13).  Increased expression of the suppressive cytokine IL-10 is a hallmark 
of vitamin D3-mediated immune responses [201, 222, 223], as are increased expression of the 
anti-inflammatory transcription factor FOS [224] and IL1RN, a gene encoding the IL-1 receptor 
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antagonist (a suppressor of pro-inflammatory IL-1 activity) [225].  Inhibited expression of 
CCL13, CCR2, TLRs, IL-18, and IL-22 have also been reported following treatment of skin 
and/or immune cells with vitamin D3, or related analogs [225-228].  Collectively, these MC903 
MNA-mediated effects on human skin are consistent with a more tolerogenic microenvironment 
for allergen introduction. 
In addition to altering the human skin microenvironment, MC903 MNAs selectively 
enhanced migration of CD14+ dermal DCs and reduced migration of CD1a+ dermal DCs from 
human skin explants, with no effects on migration of LCs (Figure 4-14).  These results are 
consistent with a prior report that intradermal injection of 1,25-dihydroxyvitamin D3 with insulin 
syringes selectively increased migration of CD14+ dermal DCs from human skin explants [229].  
Importantly, that study also demonstrated that Treg and Th1 induction by total migratory DCs 
were enhanced and inhibited, respectively, by intradermal vitamin D3 [229].  This finding is 
supported by several reports that describe CD14+ DCs as less mature and more tolerogenic than 
CD1a+ DCs, and capable of inducing Treg differentiation [229-233].  As cells migrating out of 
explants represent cells that would carry antigen to skin DLN in vivo, enhanced migration of 
more tolerogenic DCs could presumably promote Treg induction and allergen tolerance.  Since 
vitamin D3 has been reported to enhance expression of CD14 on dermal DCs, epidermal LCs, 
blood DCs, and monocytes [95, 226, 233, 234], enhanced migration of CD14+ DCs could be the 
result of increased expression of CD14 by CD1a+ DCs and/or selective enhancement of CD14+ 
DC migration and CD1a+ DC retention in the skin [229].  Future studies will be needed to further 
characterize human migratory DC populations following MC903 MNA application and 
distinguish between these two possible mechanisms; however, the substantial upregulation of 
CD14 mRNA observed in the skin microenvironment after MC903 MNA application (Figure 
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4-13) suggests that the enhanced frequency of CD14+ DCs among migratory cells is at least 
partially attributable to the first mechanism.  Changes in expression levels of co-stimulatory 
(CD80, CD83, CD86, CD40) and co-inhibitory (ILT3, ILT4, PD-L1) receptors in response to 
MC903 MNA treatment would also be of interest in future studies.   
Together with the promising data showing both prophylactic and therapeutic induction of 
allergen tolerance in mice, demonstration of a more tolerogenic cutaneous microenvironment and 
migration of more tolerogenic DCs from human skin explant experiments support the potential 
for clinical translation of this approach.  The ease of incorporating diverse types of allergens and 
prior FDA approval of MC903 for dermatological applications (plaque psoriasis) make this 
cutaneous microenvironment-modifying technology an exciting candidate for clinical translation.  
The path to clinical translation is also simplified by the fact that the MNAs are made of FDA-
designated “Generally Recognized As Safe” (GRAS) materials (sodium carboxymethyl cellulose 
and trehalose), and are being used to deliver doxorubicin in an ongoing phase I clinical trial for 
cutaneous T-cell lymphoma (NCT02192021).  
 In conclusion, by providing tolerogenic context for allergen introduction using a vitamin 
D3 analog—thereby mimicking natural synthesis of vitamin D3 in the skin—MC903 MNAs 
were able to induce allergen tolerance—mediated at least in part by increases in Treg/Teff and 
Th2/Th1 ratios—in both prophylactic and therapeutic murine models of ACD.  Experiments with 
human skin explants provide insight and correlation between the promising results in mice and 
humans and support the possibility for clinical translation.  Ultimately, as with the TRI MPs in 
Chapter 3, this approach to allergen-specific tolerance induction may be applicable to a variety 
of T-cell-mediated inflammatory diseases, autoimmune diseases, and allograft rejection.  
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5.0  FUTURE WORK 
The studies presented in Chapters 2-4 open a number of promising avenues for future 
exploration.  In addition to some of the future experiments identified in the discussion sections of 
those chapters, the following areas could merit further investigation: 
5.1 USING AGENT-POLYMER INTERACTIONS TO IMPROVE RATIONAL 
DESIGN OF CONTROLLED RELEASE SYSTEMS 
In the future, our findings regarding release of positively charged agents from negatively charged 
polymer matrices (Chapter 2 [144]), may be incorporated into existing mathematical models of 
controlled release [101, 102] to improve their predictive capacity.  Additionally, we expect this 
new understanding of how agent-polymer electrostatic interactions influence drug release 
kinetics will help to improve future rational design of controlled release formulations for a 
variety of therapeutic peptide, proteins, or charged small molecule drugs.  Finally, novel 
approaches to negate agent-polymer matrix interactions and different types of polymers could 
require further measurements of electrostatic interactions and new models of the influence of 
these interactions on release from different types of matrices.   
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5.2 IMPROVING TRI MP FOR CLINICAL TRANSLATION 
While TRI MPs described in Chapter 3 deliver bioactive factors and effectively suppress ACD in 
murine models [235], maximizing loading and reducing particle residence time (i.e. the time 
MPs remain in tissue after complete release) would be important for translational purposes.  
Greater loading and/or faster degrading MPs would allow the same amount of TRI factors to be 
delivered from a smaller and/or faster disappearing particle depot, and thereby minimize 
injection site irritation, facilitate scale-up for clinical translation [236], and make repeated 
injections easier if needed.  Microfluidic-based synthesis of MPs may facilitate increased loading 
and easier scale-up of fabrication, as microfluidic systems can be run in parallel with similar 
control parameters to achieve production of larger quantities of particles [237]. Compared to 
traditional particle fabrication using a homogenizer, microfluidic chips can reduce shear 
(improve bioactivity), increase loading, and decrease particle polydispersity, eliminating MPs at 
the low end of the size distribution, which may make up a sizable fraction of total mass with very 
little drug encapsulation [238-240].  Alternatively, TRI factor loading could be increased in MPs 
fabricated with the single or double emulsion solvent evaporation methods used in Chapters 2 
and 3 [93, 121, 144, 235] by increasing the amount of factor and/or reducing the total mass of 
polymer per batch.  To achieve faster particle degradation, lower molecular weight PLGA and/or 
PEG-PLGA polymers could be used [99, 102, 144].  Since lower molecular weight polymers 
have greater densities of end-groups, ester-capped PLGA would be used, especially for TGF-β1 
MPs, to reduce the negative charge density shown in Chapter 2 to impede release of positively 
charged proteins, like TGF-β1 [144]. 
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5.3 EVALUATING TRI MP EFFICACY IN CHRONIC MODELS OF ACD 
In Chapter 3, we demonstrated that TRI MPs provide sufficient tolerogenic context during 
allergen exposure to enhance Treg / Teff ratios and suppress subsequent DTH responses in an 
allergen-specific manner [235].  Given these promising results in acute models of hapten- and 
protein-mediated ACD, future studies may investigate the therapeutic potential TRI MPs in 
chronic hypersensitivity models, which more closely reflect the clinical presentation of ACD.  
Since ACD often involves repeated exposure to contact allergens over extended periods of time, 
determining the duration and durability of TRI MP-induced allergen tolerance would be 
advantageous for future clinical translation of this approach, and could be investigated in long-
term and repeated-exposure models (summarized in Figure 5-1).  Since long-term tolerance 
depends on enduring allergen-specific memory Tregs, persistence and stability of TRI MP-
induced Tregs could be evaluated using congenic T cell adoptive transfer models and transgenic 
Foxp3 fate-mapping reporter mice [241, 242].  To identify and track allergen-specific Tregs at 
extended time points, wild-type (CD45.2+) conventional (FoxP3-) T cells could be adoptively 
transferred to congenic (CD45.1+) recipients prior to TRI MP and hapten sensitization.  At 
extended time points, hapten-specific (CD45.2+) peripherally induced pTregs could be identified 
and quantified in skin and lymphatic tissues.  Since reports have suggested that peripherally 
induced Tregs (e.g. those generated by TRI MP treatment) may retain some degree of plasticity 
[243, 244], stability of allergen-specific Tregs induced by TRI MP treatment could be evaluated 
using FoxP3 fate-mapping reporter mice [242].  Finally, for long-term studies, release assays for 
IL-2 and TGF-β1 (as in Figure 3-1) would need to be extended beyond three weeks, and particles 
may need to be reformulated if bioactive cytokines are released after three weeks.   Increasing 
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the overall PEG:PLGA ratio or blending the PEG-PLGA co-polymer with a lower molecular 
weight PLGA would help to achieve complete release within the first week [245]. 
 
Figure 5-1. Timelines for future experiments to evaluate (A) duration and (B) durability of TRI MP-induced 
tolerance. Mice would be sensitized and challenge with the same allergen (e.g. DNFB) at the indicated times.  In 
(A), “T” represents the time to first challenge, which would be greater than 10 days (prior studies from Chapter 3).  
As in acute models, DTH responses would be evaluated by ear swelling, cutaneous histology, and flow cytometry.   
5.4 TESTING MC903 MNA IN MURINE MODELS OF HAPTEN-MEDIATED ACD 
Since sensitization to haptens requires innate inflammatory responses [44], and co-delivery of 
DNCB and MC903 with MNAs inhibited cutaneous expression of DNCB-induced inflammatory 
cytokines and inflammasome (Figure 4-12), future studies should determine whether DNCB + 
MC903 MNA can tolerize mice to DNCB.  Experiments involving prophylactic tolerization of 
naïve mice and therapeutic tolerization of previously sensitized mice would be similar to those 
with OVA + MC903 MNA, described in Chapter 4.  Evaluating induction of tolerance to 
different types of chemical allergens would also help to demonstrate broad translational potential 
for thousands of potential chemical allergens [2], or alternatively, identify subsets of allergens 
that may be more or less compatible with this therapeutic approach.  In particular, DNCB, nickel, 
and urushiol represent three different types of contact allergens that induce innate inflammatory 
responses through similar yet distinct mechanisms.  DNCB induces production of damage 
associated molecular patterns (DAMPs) that activate TLR2 and TLR4, and release of ATP that 
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promotes inflammasome activation [44].  Metal allergens like nickel directly bind to and activate 
human TLR4 [174], while urushiol, a mixture of allergenic lipids in poison ivy, signals through 
the CD1a receptor on cutaneous APCs [246].  Accordingly, tolerization with Nickel + MC903 
MNA, or Urushiol + MC903 MNA, could be tested in human TLR4 transgenic mice [174], or 
human CD1a transgenic mice [246], respectively. 
5.5 EVALUATING HUMAN SKIN MICROENVIRONMENT RESPONSES TO 
ALLERGEN + MC903 MNA 
The absence of pro-inflammatory stimuli (i.e. allergen) is a potential limitation of the 
experiments with human skin explants presented in Chapter 4.  Changes to the cutaneous 
microenvironment in response to MC903 MNA were reported relative to untreated skin (Figure 
4-13), with very low baseline expression of many pro-inflammatory cytokines or chemokines, 
which means that even 10-fold increases in expression may not be physiologically significant.  
Thus, future studies could examine human skin responses to MNAs containing allergen (e.g. 
DNCB, nickel, and/or urushiol) with or without MC903, as allergens alone should induce 
sufficient expression of pro-inflammatory factors to generate physiological responses.  As in 
Chapter 4, RNA isolated from human skin explants would be analyzed by qRT-PCR arrays.  
Alternatively, analysis of additional target genes (e.g. expression of 249 inflammation-related 
genes by NanoString nCounter Gene Expression Assays), or whole transcriptome analysis by 
RNA-Seq could be used to further characterize cutaneous microenvironment responses to 
treatments.  In addition to microenvironment evaluation, migrating cells would be harvested 
from human skin explants treated with Allergen ± MC903 MNAs, and flow cytometry used to 
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assess subsets and inflammatory / tolerogenic phenotypes.  The stimulatory capacity of 
migratory DCs could also be evaluated by allogeneic mixed leukocyte reactions (co-cultures of 
migratory DCs with naïve allogeneic T cells).  Finally, assessment of differential responses to 
Allergen + MC903 MNA in explants from allergic and nonallergic individuals would be relevant 
to future clinical translation for prophylactic or therapeutic tolerization. 
5.6 INVESTIGATING RESPONSES TO DIFFERENT MODES OF CUTANEOUS 
DELIVERY OF DIFFERENT TYPES OF ALLERGENS 
Since allergens and MC903 have traditionally been introduced epicutaneously, and MNAs 
provide deeper delivery to epidermal and dermal layers of the skin, future studies are needed to 
investigate the influence of these distinct delivery routes on the subsets of skin-resident DCs 
targeted and modulation of their phenotype.  Preliminary data suggest that MNAs deliver OVA 
protein to epidermal Langerhans cells (LCs), CD11b+ dermal DCs, and CD103+ dermal DCs 
(Figure 5-2).  Furthermore, most OVA+ cells in DLN were CD11b+ dermal DCs, and few non-
migratory lymphoid-resident CD8a+ DCs contained OVA (Figure 5-2).  To compare delivery 
with MNAs to epicutaneous application, OVA-AF647 would be applied topically to tape-
stripped skin and covered with an occlusive dressing.  To extend these results to other types of 
allergens, fluorescent peptide or FITC (a model hapten) could be delivered with tip-loaded 
MNAs or applied epicutaneously.  Compared to epicutaneous application, MNAs would be 
expected to provide greater delivery of proteins and peptides to dermal DCs; however, since low 
molecular weight haptens easily penetrate the skin, both modes of delivery for haptens may 
ultimately target similar populations of DCs.  Finally, to determine the influence of cutaneous 
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microenvironment and antigen introduction method (i.e. epicutaneous vs. MNA) on the 
phenotype of DCs that access allergen, OVA-AF647 ± MC903 MNAs could be applied to 
murine or human skin, and the phenotype of OVA+ migratory DCs assessed by flow cytometry.   
 
 
Figure 5-2. MNAs deliver OVA protein to different subsets of skin migratory DCs. (A) Flow cytometry 
analysis of DC subsets in skin DLN 24 hours after application of (B) tip-loaded Alexa Fluor 647-labeled OVA 




6.0  CONCLUSIONS AND BROADER IMPLICATIONS 
TRI MPs and MC903 MNAs effectively modify the skin and draining lymph node (DLN) 
microenvironments associated with allergen uptake by APCs and presentation to T cells, 
respectively.  In doing so, these delivery systems mimic some of the natural mechanisms the 
body uses to induce differentiation of Tregs.  Specifically, TRI MPs mimic the secretion of IL-2 
and TGF-β1 by tolerogenic DCs and other cells in the body, which provide key signals to naïve 
T cells, causing them to differentiate into Tregs [40, 88, 89].  Alternatively, delivery of MC903 
into the skin with MNAs mimics cutaneous synthesis of 1,25-dihydroxyvitamin D3 in response 
to sunlight (UV), which helps maintain immunological homeostasis and peripheral tolerance to 
benign foreign and self antigens [90, 91]. By providing key signals with appropriate 
temporospatial context, these biomimetic delivery systems convey instructions that can be 
interpreted by the immune system [87], and result in allergen-specific tolerogenic responses, 
characterized by enhanced Treg induction and reduced differentiation of effector T cells.   
 Notably, our approaches to promote Treg differentiation and allergen tolerance using TRI 
MPs (Chapter 3) or MC903 MNAs (Chapter 4) may be broadly applicable to a variety of 
autoimmune diseases, inflammatory diseases, or transplant rejection.  In many of these 
conditions, much like ACD, tissue destruction is mediated by pro-inflammatory effector T cells 
that recognize self antigens or alloantigens instead of allergens.  Furthermore, as in ACD, Tregs 
are known to efficiently regulate such aberrant inflammation, and enhancing Treg populations 
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has been a common therapeutic goal in numerous murine and human studies [19, 247-251].  
Accordingly, in our lab, Treg-inducing TRI MP are currently being used to restore immune 
homeostasis in murine models of dry eye disease, periodontal disease, type I diabetes, and 
vascularized composite allotransplantation (unpublished data).  Finally, we also envision using 
MC903 MNA to treat autoimmune diseases, or prevent allograft rejection, by incorporating 
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